Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
602493fc521a8402f63ace9abcb94c6735d6bedcb247a728a2a80ac92ecd2f48.png
simple
<table><tr><td>Patient </td><td>Age</td><td>Clinical stage</td><td>Histologic type</td><td>Tumor size </td><td>Estrogen receptor (ER)</td><td>Progesterone receptor (PR)</td><td>Her2 status</td><td>Molecular classification</td></tr><tr><td>A</td><td>50 yr</td><td>T2N1M0 (grading: IIB)</td><td>Ductal infiltrating</td><td>3 cm</td><td>(&#8722;)</td><td>(&#8722;)</td><td>(+)</td><td>Her2+</td></tr><tr><td>B</td><td>59 yr</td><td>T3N0M0 (grading: IIB)</td><td>Ductal infiltrating</td><td>5 cm</td><td>(+)</td><td>(+)</td><td>(+)</td><td>Luminal B</td></tr><tr><td>C</td><td>41 yr</td><td>T2N1M0 (grading: IIB)</td><td>Ductal infiltrating</td><td>4 cm</td><td>(+)</td><td>(+)</td><td>(&#8722;)</td><td>Luminal A</td></tr></table>
a8ab1217879b6b6a3ab54ed8958ed0d41307f0dce98b3ff9ccec17c67169b4c0.png
complex
<table><tr><td>MiRs</td><td>Expression levels</td><td>mRNA targets</td><td>Cell types</td><td>Refs</td><td>miR classification</td></tr><tr><td colspan="5">Diabetic retinopathy</td><td></td></tr><tr><td>miR-146a</td><td>Down</td><td>Fibronectin</td><td>HUVECs</td><td>[103]</td><td>I, A, O</td></tr><tr><td>miR-146b-3p</td><td>Down</td><td>ADA2</td><td>Vitreous of diabetes patients, macrophages</td><td>[79]</td><td>O</td></tr><tr><td>miR-200b</td><td>Down</td><td>VEGF</td><td>HUVEC</td><td>[104]</td><td>O, A</td></tr><tr><td>miR-195</td><td>Up</td><td>SIRT1</td><td>HRECs, HMECs</td><td>[105]</td><td>A, O</td></tr><tr><td colspan="5">Diabetic nephropathy</td><td></td></tr><tr><td>miR-192</td><td>Up</td><td>ZEB 1/2</td><td>Glomeruli from renal biopsies</td><td>[106]</td><td>O</td></tr><tr><td>miR-377</td><td>Up</td><td>Pak1, Sod1/2</td><td>NHMCs</td><td>[107]</td><td>O, A</td></tr><tr><td>miR-29a/b/c</td><td>Down</td><td>Col1, Col4</td><td>h. conditionally immortalized podocyte</td><td>[108]</td><td>O</td></tr><tr><td>miR-21</td><td>Up</td><td>PTEN, RAS40</td><td>hMCs</td><td>[91]</td><td>O, I, A</td></tr><tr><td></td><td>Up</td><td>TIMP3</td><td>human kidney biopsy</td><td>[92]</td><td></td></tr><tr><td>miR-155</td><td>Up</td><td></td><td>h. kidney biopsy, HRGECs</td><td>[109]</td><td>I, O, A</td></tr><tr><td>miR-146a</td><td>Up</td><td></td><td>h. kidney biopsy, HRGECs</td><td>[109]</td><td>I, A, O</td></tr><tr><td>miR-215</td><td>Down</td><td>SIP1/ZEB2</td><td>h. conditionally immortalized podocytes</td><td>[110]</td><td>O</td></tr><tr><td>miR-135a</td><td>Up</td><td>TRPC1</td><td>kidney tissues, HMC</td><td>[111]</td><td>O</td></tr><tr><td colspan="5">Macrovascular diabetic complications</td><td></td></tr><tr><td>miR-16</td><td>Down</td><td>Cox-2</td><td>THP-1 monocytes</td><td>[112]</td><td>O</td></tr><tr><td>miR-503</td><td>Up</td><td>Ccne1-Cdc25A</td><td>HUVEC, HMVEC</td><td>[102]</td><td>O, A</td></tr><tr><td>miR-133</td><td>Down</td><td>Rho-A, Cdc42</td><td>h. embryos/fetuses cardiac cells</td><td>[113]</td><td>I, A</td></tr><tr><td>miR-223</td><td>Up</td><td>Glut4</td><td>Left ventricular biopsies</td><td>[114]</td><td>I, O, A</td></tr><tr><td>miR-221</td><td>Up</td><td>C-kit</td><td>HUVEC</td><td>[115]</td><td>O, A</td></tr><tr><td>miR-492</td><td>Down</td><td>Resistin</td><td>HUVEC</td><td>[116]</td><td>O, A</td></tr></table>
bb80dcc6e41abe1b2398cdf1ba078a4d6e9dec224637df90492633408df4ec16.png
complex
<table><tr><td></td><td>Total, <i>n</i></td><td>Proactive care, <i>n</i> (%)<sup>*</sup> or mean (SD)</td><td>Usual care, <i>n</i> (%) or mean (SD)</td><td>p value</td></tr><tr><td>All participants</td><td>1077</td><td>525</td><td>552</td><td>&#8211;</td></tr><tr><td colspan="5">Demographic characteristics:</td></tr><tr><td> Age (years)</td><td>57.4 (10.5)</td><td>57.2 (10.3)</td><td>57.6 (10.8)</td><td>0.47</td></tr><tr><td> Race</td><td colspan="4"></td></tr><tr><td>White</td><td>572 (58.4)</td><td>260 (55.0)</td><td>312 (61.6)</td><td rowspan="4">0.20</td></tr><tr><td>Black</td><td>340 (29.0)</td><td>178 (31.2)</td><td>162 (27.1)</td></tr><tr><td>Hispanic</td><td>85 (5.8)</td><td>43 (6.2)</td><td>42 (5.4)</td></tr><tr><td>Other</td><td>80 (6.8)</td><td>44 (7.7)</td><td>36 (5.9)</td></tr><tr><td> Gender</td><td colspan="4"></td></tr><tr><td>Male</td><td>1017 (94.1)</td><td>504 (95.7)</td><td>513 (92.6)</td><td>0.045</td></tr><tr><td> Marital status</td><td colspan="4"></td></tr><tr><td>Married</td><td>521 (50.0)</td><td>250 (50.0)</td><td>271 (50.1)</td><td>0.98</td></tr><tr><td colspan="5">Socioeconomic status:</td></tr><tr><td> Income ($)</td><td colspan="4"></td></tr><tr><td>&lt; 10,000</td><td>203 (18.9)</td><td>98 (19.0)</td><td>105 (18.9)</td><td rowspan="4">0.91</td></tr><tr><td>10,000&#8211;20,000</td><td>334 (32.4)</td><td>170 (33.4)</td><td>164 (31.6)</td></tr><tr><td>20,001&#8211;40,000</td><td>311 (31.3)</td><td>146 (31.2)</td><td>165 (31.4)</td></tr><tr><td>&#8805; 40,001</td><td>172 (17.4)</td><td>81 (16.5)</td><td>91 (18.1)</td></tr><tr><td colspan="5">Social and environmental pressures:</td></tr><tr><td> Home smoking rules</td><td colspan="4"></td></tr><tr><td>Not allowed anywhere</td><td>473 (48.6)</td><td>227 (48.3)</td><td>246 (48.9)</td><td rowspan="3">0.58</td></tr><tr><td>Allowed some places/times</td><td>241 (22.3)</td><td>113 (21.7)</td><td>128 (23.7)</td></tr><tr><td>Allowed anywhere</td><td>295 (28.7)</td><td>151 (30.1)</td><td>144 (27.4)</td></tr><tr><td> Friends who smoke</td><td colspan="4"></td></tr><tr><td>None</td><td>167 (16.5)</td><td>85 (16.7)</td><td>82 (16.3)</td><td rowspan="5">0.96</td></tr><tr><td>&lt; half</td><td>328 (32.7)</td><td>149 (31.5)</td><td>179 (33.7)</td></tr><tr><td>About half</td><td>213 (21.7)</td><td>104 (22.0)</td><td>109 (21.5)</td></tr><tr><td>&gt; half</td><td>179 (18.0)</td><td>92 (18.8)</td><td>87 (17.3)</td></tr><tr><td>All</td><td>119 (11.2)</td><td>59 (11.1)</td><td>60 (11.2)</td></tr><tr><td colspan="5"> People important to me want me to quit smoking</td></tr><tr><td>Strongly disagree to neutral</td><td>125 (13.2)</td><td>47 (10.1)</td><td>78 (16.0)</td><td rowspan="3">0.031</td></tr><tr><td>Somewhat agree</td><td>198 (19.3)</td><td>99 (19.7)</td><td>99 (18.9)</td></tr><tr><td>Strongly agree</td><td>671 (67.5)</td><td>332 (70.3)</td><td>339 (65.1)</td></tr><tr><td colspan="5">Smoking behaviors:</td></tr><tr><td> Cigarettes per day</td><td colspan="4"></td></tr><tr><td>&#8804; 10</td><td>517 (46.7)</td><td>244 (45.3)</td><td>273 (48.0)</td><td rowspan="3">0.67</td></tr><tr><td>11&#8211;20</td><td>398 (38.9)</td><td>201 (40.4)</td><td>197 (37.7)</td></tr><tr><td>&#8805; 21</td><td>138 (14.4)</td><td>67 (14.4)</td><td>71 (14.4)</td></tr><tr><td> Time to first cigarette, min</td><td colspan="4"></td></tr><tr><td>&#8805; 31</td><td>375 (33.6)</td><td>172 (32.5)</td><td>203 (34.5)</td><td rowspan="3">0.75</td></tr><tr><td>6&#8211;30</td><td>518 (50.1)</td><td>259 (50.5)</td><td>259 (49.8)</td></tr><tr><td>&lt; 5</td><td>172 (16.3)</td><td>88 (17.0)</td><td>84 (15.7)</td></tr><tr><td> Quit in past 12 months</td><td colspan="4"></td></tr><tr><td>Yes</td><td>866 (80.6)</td><td>414 (80.0)</td><td>452 (81.1)</td><td>0.66</td></tr><tr><td> Longest quit length</td><td colspan="4"></td></tr><tr><td>Never quit</td><td>55 (4.7)</td><td>30 (5.5)</td><td>25 (4.1)</td><td rowspan="4">0.11</td></tr><tr><td>&lt; 1 month</td><td>260 (24.2)</td><td>140 (26.4)</td><td>120 (22.2)</td></tr><tr><td>1&#8211;6 months</td><td>313 (28.9)</td><td>155 (29.8)</td><td>158 (28.2)</td></tr><tr><td>&gt; 6 months</td><td>441 (42.2)</td><td>194 (38.4)</td><td>247 (45.6)</td></tr></table>
99cd950e6520960608171e196e117034db85ee7414e008d97219b64a8fcbe334.png
complex
<table><tr><td rowspan="2">Altitude</td><td colspan="2">1st Hb (g/dL)</td><td colspan="2">2nd Hb (g/dL)</td><td colspan="2">GA 1st Hb (weeks)</td><td colspan="2">GA 2nd Hb (weeks)</td><td colspan="2">Gestational age (weeks)</td><td colspan="2">Birthweight (g)</td></tr><tr><td colspan="2">X &#177; SD</td><td colspan="2">X &#177; SD</td><td colspan="2">X &#177; SD</td><td colspan="2">X &#177; SD</td><td colspan="2">X &#177; SD</td><td colspan="2">X &#177; SD</td></tr><tr><td>Low</td><td>12.1</td><td>0.80</td><td>11.4</td><td>1.34</td><td>17.2</td><td>8.2</td><td>36</td><td>11.6</td><td>38.9</td><td>1.76</td><td>3262</td><td>512</td></tr><tr><td>Moderate</td><td>12.7</td><td>0.90</td><td>12.5</td><td>1.43</td><td>19.4</td><td>8.36</td><td>36.7</td><td>4.6</td><td>38.8</td><td>2.07</td><td>3123</td><td>529</td></tr><tr><td>High</td><td>13.0</td><td>0.88</td><td>12.9</td><td>1.40</td><td>20.6</td><td>8.3</td><td>37.3</td><td>3.9</td><td>38.8</td><td>1.89</td><td>3095</td><td>489</td></tr><tr><td><i>P</i></td><td colspan="2">&lt;0.05</td><td colspan="2">&lt;0.05</td><td colspan="2">&lt;0.05</td><td colspan="2">&lt;0.05</td><td></td><td></td><td colspan="2">&lt;0.05</td></tr><tr><td>Total</td><td>12.4</td><td>0.91</td><td>11.9</td><td>1.52</td><td>18.3</td><td>8.4</td><td>36</td><td>4.5</td><td>38.9</td><td>1.83</td><td>3206</td><td>515</td></tr></table>
88e7d4011fc60bb59bea68487c94b1dc560f1a2898bdcee422a5eeb4bbf47133.png
complex
<table><tr><td></td><td colspan="3">Reference Subjects</td><td colspan="3">Test Subjects</td><td></td></tr><tr><td>RTP</td><td>W1</td><td>W2</td><td>L</td><td>W1</td><td>W2</td><td>L</td><td>LSD</td></tr><tr><td>M1</td><td>15.0</td><td>24.8</td><td>14.3</td><td>14.7</td><td>25.3</td><td>14.4</td><td>0.59</td></tr><tr><td>M2</td><td>15.0</td><td>24.8</td><td>14.3</td><td>15.6</td><td>24.9</td><td>14.4</td><td>0.62</td></tr><tr><td>M3</td><td>15.0</td><td>24.8</td><td>14.3</td><td>15.2</td><td>25.2</td><td>14.6</td><td>0.54</td></tr><tr><td>M4</td><td>15.0</td><td>24.8</td><td>14.3</td><td>15.3</td><td>25.0</td><td>14.0</td><td>0.47</td></tr><tr><td>M5</td><td>15.0</td><td>24.8</td><td>14.3</td><td>14.6</td><td>24.9</td><td>13.8</td><td>0.65</td></tr><tr><td>M6</td><td>15.1</td><td>27.2</td><td>16.5</td><td>15.3</td><td>27</td><td>15.6</td><td>0.94</td></tr><tr><td>M7</td><td>15.1</td><td>27.2</td><td>16.5</td><td>14.1</td><td>26.7</td><td>16.2</td><td>1.16</td></tr><tr><td>F1</td><td>14.6</td><td>24.9</td><td>13.8</td><td>15.1</td><td>24.1</td><td>13.9</td><td>0.95</td></tr><tr><td>F2</td><td>14.6</td><td>24.9</td><td>13.8</td><td>14.7</td><td>25.3</td><td>14.4</td><td>0.73</td></tr><tr><td>F3</td><td>14.6</td><td>24.9</td><td>13.8</td><td>14.9</td><td>24.0</td><td>13.5</td><td>0.99</td></tr><tr><td>F4</td><td>14</td><td>26.1</td><td>16</td><td>14.1</td><td>26.7</td><td>16.2</td><td>0.64</td></tr><tr><td>F5</td><td>14</td><td>26.1</td><td>16</td><td>14.7</td><td>26</td><td>16.2</td><td>0.73</td></tr><tr><td>F6</td><td>14</td><td>26.1</td><td>16</td><td>14.3</td><td>26.9</td><td>15.3</td><td>1.10</td></tr><tr><td>F7</td><td>15.1</td><td>27.2</td><td>16.5</td><td>15.8</td><td>26.8</td><td>16.9</td><td>0.90</td></tr><tr><td>F8</td><td>15.1</td><td>27.2</td><td>16.5</td><td>15</td><td>27.2</td><td>15.7</td><td>0.81</td></tr></table>
11f58a6d3b4d74ae45a4d4eb38542bb7f980ec4ad79f4208ec0a99bf6d08490a.png
complex
<table><tr><td></td><td>Measure</td><td colspan="3">A. Single-task</td><td colspan="3">B. Dual-task</td><td colspan="3">C. Dual-task cost</td></tr><tr><td></td><td></td><td><i>r</i></td><td><i>F</i></td><td><i>p</i></td><td><i>r</i></td><td><i>F</i></td><td><i>p</i></td><td><i>r</i></td><td><i>F</i></td><td><i>p</i></td></tr><tr><td>I. Monthly means</td><td><i>MD</i></td><td>&#8722;0.34</td><td>2.41</td><td>0.138</td><td>&#8722;0.32</td><td>2.11</td><td>0.163</td><td>0.02</td><td>0.01</td><td>0.931</td></tr><tr><td></td><td><i>MV</i></td><td>0.04</td><td>0.03</td><td>0.870</td><td>0.06</td><td>0.07</td><td>0.799</td><td>&#8722;0.05</td><td>0.05</td><td>0.824</td></tr><tr><td></td><td><i>AREA</i></td><td>&#8722;0.27</td><td>0.55</td><td>0.468</td><td>&#8722;0.18</td><td>0.57</td><td>0.460</td><td>&#8722;0.06</td><td>0.06</td><td>0.813</td></tr><tr><td></td><td><i>fC</i></td><td>0.43</td><td>4.17</td><td>0.056</td><td>0.29</td><td>1.59</td><td>0.223</td><td>&#8722;0.18</td><td>0.58</td><td>0.457</td></tr><tr><td></td><td><i>FD</i></td><td>&#8722;0.05</td><td>0.05</td><td>0.827</td><td>&#8722;0.12</td><td>0.24</td><td>0.629</td><td>&#8722;0.12</td><td>0.24</td><td>0.631</td></tr><tr><td>II. Day-to-day variability</td><td><i>MD</i></td><td>&#8722;0.48</td><td>5.51</td><td>0.031</td><td>&#8722;0.45</td><td>4.47</td><td>0.049</td><td>0.08</td><td>0.13</td><td>0.723</td></tr><tr><td></td><td><i>MV</i></td><td>0.18</td><td>0.61</td><td>0.446</td><td>0.16</td><td>0.50</td><td>0.491</td><td>&#8722;0.17</td><td>0.51</td><td>0.485</td></tr><tr><td></td><td><i>AREA</i></td><td>&#8722;0.25</td><td>1.15</td><td>0.297</td><td>&#8722;0.47</td><td>5.03</td><td>0.038</td><td>&#8722;0.06</td><td>0.06</td><td>0.804</td></tr><tr><td></td><td><i>fC</i></td><td>0.46</td><td>4.91</td><td>0.040</td><td>0.26</td><td>1.33</td><td>0.265</td><td>&#8722;0.27</td><td>1.40</td><td>0.252</td></tr><tr><td></td><td><i>FD</i></td><td>0.21</td><td>0.84</td><td>0.371</td><td>0.05</td><td>0.04</td><td>0.842</td><td>0.00</td><td>0.00</td><td>0.992</td></tr></table>
44f68b977f30e2d864b282a42874e30a978fb9c7877b881c3c9a6a6ebbe9e095.png
complex
<table><tr><td colspan="4">I. Site 1 (n = 4 writers with 10 letters each)</td></tr><tr><td>Item</td><td>GP</td><td>Specialist</td><td>p</td></tr><tr><td>History</td><td>4.04 &#177; 1.0</td><td>4.16 &#177; 0.95</td><td>NS</td></tr><tr><td>Physical Examination</td><td>4.34 &#177; 0.90</td><td>4.23 &#177; 0.98</td><td>NS</td></tr><tr><td>Impression</td><td>4.12 &#177; 0.90</td><td>4.14 &#177; 1.0</td><td>NS</td></tr><tr><td>Plan</td><td>4.21 &#177; 0.85</td><td>4.21 &#177; 0.99</td><td>NS</td></tr><tr><td>Brevity</td><td>3.87 &#177; 0.94</td><td>4.25 &#177; 0.87</td><td>0.003</td></tr><tr><td>Clarity</td><td>4.00 &#177; 1.1</td><td>4.14 &#177; 1.0</td><td>NS</td></tr><tr><td>Format</td><td>3.98 &#177; 1.1</td><td>4.01 &#177; 1.0</td><td>NS</td></tr><tr><td>Educational Value</td><td>4.02 &#177; 0.95</td><td>3.90 &#177; 0.90</td><td>NS</td></tr><tr><td>Global rating</td><td>4.04 &#177; 0.96</td><td>3.92 &#177; 0.97</td><td>NS</td></tr><tr><td>Overall score</td><td>36.45 &#177; 7.36</td><td>36.97 &#177; 7.85</td><td>NS</td></tr><tr><td colspan="4">II Site 2 (n = 5 writers with 10 letters each)</td></tr><tr><td>Item</td><td>GP</td><td>Specialist</td><td>p</td></tr><tr><td>History</td><td>3.88 &#177; 1.1</td><td>4.40 &#177; 0.72</td><td>0.0001</td></tr><tr><td>Physical Examination</td><td>3.90 &#177; 0.97</td><td>4.45 &#177; 0.71</td><td>&lt;0.0001</td></tr><tr><td>Impression</td><td>4.00 &#177; 1.0</td><td>4.08 &#177; 0.96</td><td>NS</td></tr><tr><td>Plan</td><td>4.14 &#177; 0.90</td><td>4.18 &#177; 0.87</td><td>NS</td></tr><tr><td>Brevity</td><td>3.64 &#177; 1.2</td><td>3.83 &#177; 0.90</td><td>NS</td></tr><tr><td>Clarity</td><td>3.931 &#177; .0</td><td>4.03 &#177; 0.91</td><td>NS</td></tr><tr><td>Format</td><td>3.63 &#177; 1.1</td><td>3.68 &#177; 0.67</td><td>NS</td></tr><tr><td>Educational Value</td><td>4.00 &#177; 1.0</td><td>3.38 &#177; 1.1</td><td>&lt;0.0001</td></tr><tr><td>Global rating</td><td>3.88 &#177; 0.93</td><td>3.74 &#177; 0.91</td><td>NS</td></tr><tr><td>Overall score</td><td>34.97 &#177; 7.70</td><td>35.79 &#177; 5.19</td><td>NS</td></tr></table>
31dca9ef299e0bf2263e01110398ccb744e624957a28dc0d7352308b7a3101ef.png
simple
<table><tr><td>Putative gene</td><td>SNP (bp)</td><td>Nucleotides</td><td>AA residual</td></tr><tr><td><i>Lp1-SST</i></td><td>871</td><td>TCA&#8594;GCA</td><td>Y/D</td></tr><tr><td></td><td>1,087</td><td>GCC&#8594;TCC</td><td>A/S</td></tr><tr><td></td><td>1,091</td><td>GTC&#8594;GCC</td><td>V/A</td></tr><tr><td></td><td>1,116</td><td>GAC&#8594;GAG</td><td>D/E</td></tr><tr><td></td><td>1,124</td><td>CTG&#8594;CCG</td><td>L/P</td></tr><tr><td><i>Lp6G-FFT</i></td><td>835</td><td>GTC&#8594;ATC</td><td>V/I</td></tr><tr><td></td><td>938</td><td>TAC&#8594;TTC</td><td>Y/F</td></tr><tr><td><i>LpCAT</i></td><td>1,093</td><td>GTG&#8594;ATG</td><td>V/M</td></tr><tr><td><i>LpACO1</i></td><td>469</td><td>CCG&#8594;TCG</td><td>P/S</td></tr></table>
38eabeb403a054d8a62783b36ea96db33c3ba25cc8dffccc4f67cd6c8c4bb5c9.png
complex
<table><tr><td></td><td colspan="2">CRC</td><td colspan="2">CRC (interaction)</td><td colspan="2">BC</td><td colspan="2">BC (interaction)</td></tr><tr><td></td><td>coeff</td><td>pval</td><td>coeff</td><td>pval</td><td>coeff</td><td>pval</td><td>coeff</td><td>pval</td></tr><tr><td>Person level</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Age &lt; 50 (reference 50&#8211;64)</td><td>0.306</td><td>0.000</td><td>0.306</td><td>0.000</td><td>0.040</td><td>0.000</td><td>0.040</td><td>0.000</td></tr><tr><td>Age 65&#8211;74</td><td>&#8722;0.105</td><td>0.000</td><td>&#8722;0.105</td><td>0.000</td><td>&#8722;0.255</td><td>0.000</td><td>&#8722;0.255</td><td>0.000</td></tr><tr><td>Age 75+</td><td>&#8722;0.051</td><td>0.000</td><td>&#8722;0.051</td><td>0.000</td><td>&#8722;0.139</td><td>0.000</td><td>&#8722;0.139</td><td>0.000</td></tr><tr><td>Female (reference male)</td><td>0.040</td><td>0.000</td><td>0.040</td><td>0.000</td><td>.</td><td>.</td><td>.</td><td>.</td></tr><tr><td>Black (reference white)</td><td>0.079</td><td>0.000</td><td>0.079</td><td>0.000</td><td>0.386</td><td>0.000</td><td>0.386</td><td>0.000</td></tr><tr><td>Race all other (reference white)</td><td>0.008</td><td>0.363</td><td>0.008</td><td>0.399</td><td>0.136</td><td>0.000</td><td>0.136</td><td>0.000</td></tr><tr><td>County level</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Percentage of population &lt; age 65, with no health insurance</td><td>0.005</td><td>0.000</td><td>0.007</td><td>0.016</td><td>0.003</td><td>0.002</td><td>0.005</td><td>0.031</td></tr><tr><td>Average distance traveled by Medicare beneficiary to cancer screening provider</td><td>0.002</td><td>0.037</td><td>0.002</td><td>0.041</td><td>0.000</td><td>0.532</td><td>0.000</td><td>0.519</td></tr><tr><td>Screening rate (percent of area FFS Medicare population utilizing screening)</td><td>&#8722;0.036</td><td>0.000</td><td>&#8722;0.037</td><td>0.000</td><td>&#8722;0.027</td><td>0.000</td><td>&#8722;0.027</td><td>0.000</td></tr><tr><td>Managed care penetration (percentage of area insured population in managed care plans)</td><td>0.101</td><td>0.033</td><td>0.103</td><td>0.039</td><td>&#8722;0.284</td><td>0.000</td><td>&#8722;0.285</td><td>0.000</td></tr><tr><td>State level</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>State Policy (1 = yes, 0 = no) `Direct Access Specialist'</td><td>&#8722;0.055</td><td>0.004</td><td>&#8722;0.271</td><td>0.000</td><td>&#8722;0.053</td><td>0.001</td><td>&#8722;0.009</td><td>0.841</td></tr><tr><td>Cross level interaction</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&lt; 65 Pop uninsured * state policy interaction</td><td>.</td><td>.</td><td>0.013</td><td>0.000</td><td>.</td><td>.</td><td>&#8722;0.003</td><td>0.288</td></tr><tr><td>Variance Components</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Level 1 * (individual)</td><td colspan="2">3.2899</td><td colspan="2">3.2899</td><td colspan="2">3.2899</td><td colspan="2">3.2899</td></tr><tr><td>Level 2 (county)</td><td colspan="2">0.02497</td><td colspan="2">0.02484</td><td colspan="2">0.01450</td><td colspan="2">0.01447</td></tr><tr><td>Level 3 (state)</td><td colspan="2">0.00074</td><td colspan="2">0.00065</td><td colspan="2">0.00018</td><td colspan="2">0.00017</td></tr></table>
df3a33dd2e47fb545a261f556e7538b186155833275d87b07dc61aae2e969929.png
complex
<table><tr><td></td><td colspan="5">Good perceived health status</td><td colspan="5">Poor perceived health status</td></tr><tr><td>Variables</td><td>n</td><td>Prev.</td><td>Bivar OR</td><td>Mvar OR</td><td>95% CI</td><td>n</td><td>Prev.</td><td>Bivar OR</td><td>Mvar OR</td><td>95% CI</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 15-34</td><td>64</td><td>11.2</td><td>1</td><td>1</td><td></td><td>13</td><td>29.3</td><td>1</td><td>1</td><td></td></tr><tr><td> 35-54</td><td>86</td><td>14.9</td><td>1.4</td><td>1.41</td><td>0.94-2.11</td><td>42</td><td>32.2</td><td>1.14</td><td>1.11</td><td>0.43-2.87</td></tr><tr><td> 55-64</td><td>47</td><td>26.6</td><td>*2.89</td><td>2.84</td><td>1.69-4.77</td><td>50</td><td>40.5</td><td>1.64</td><td>1.87</td><td>0.70-4.97</td></tr><tr><td> &gt; = 65</td><td>91</td><td>36.6</td><td>*4.62</td><td>3.42</td><td>1.81-6.46</td><td>183</td><td>51.1</td><td>*2.51</td><td>3.13</td><td>1.13-8.63</td></tr><tr><td> Total</td><td>288</td><td>18.3</td><td></td><td></td><td></td><td>288</td><td>43.9</td><td></td><td></td><td></td></tr><tr><td>Social class</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> I-II</td><td>58</td><td>17.6</td><td>1</td><td>1</td><td></td><td>22</td><td>50.4</td><td>1</td><td>1</td><td></td></tr><tr><td> III</td><td>86</td><td>18.5</td><td>1.06</td><td>0.94</td><td>0.64-1.38</td><td>52</td><td>44.3</td><td>*0.78</td><td>0.67</td><td>0.32-1.39</td></tr><tr><td> IV-V</td><td>121</td><td>16.8</td><td>0.94</td><td>0.93</td><td>0.63-1.37</td><td>188</td><td>42.2</td><td>*0.71</td><td>0.65</td><td>0.33-1.27</td></tr><tr><td>Employment status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Salaried employees</td><td>107</td><td>15.2</td><td>1</td><td>1</td><td></td><td>42</td><td>48.1</td><td>1</td><td>1</td><td></td></tr><tr><td> Housewifes</td><td>81</td><td>13.2</td><td>0.85</td><td>0.90</td><td>0.59-1.38</td><td>133</td><td>38.1</td><td>*0.66</td><td>1.10</td><td>0.63-1.91</td></tr><tr><td> Unemployed women</td><td>19</td><td>18.4</td><td>*1.26</td><td>1.44</td><td>0.80-2.56</td><td>3</td><td>20.0</td><td>*0.27</td><td>0.52</td><td>0.14-1.85</td></tr><tr><td> Retired women</td><td>57</td><td>26.4</td><td>*2.06</td><td>1.63</td><td>0.88-3.04</td><td>88</td><td>56.1</td><td>*1.37</td><td>0.99</td><td>0.51-1.93</td></tr><tr><td> Students</td><td>21</td><td>27.1</td><td>*2.07</td><td>0.85</td><td>0.48-1.52</td><td>4</td><td>66.7</td><td>*2.15</td><td>1.59</td><td>0.37-6.87</td></tr><tr><td>Type of PHC</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> PCR 1984-93</td><td>50</td><td>18.2</td><td>1</td><td>1</td><td></td><td>73</td><td>49.4</td><td>1</td><td>1</td><td></td></tr><tr><td> PCR 1994-98</td><td>53</td><td>13.6</td><td>*0.71</td><td>0.76</td><td>0.48-1.20</td><td>61</td><td>42.4</td><td>*0.75</td><td>0.74</td><td>0.45-1.22</td></tr><tr><td> No PCR</td><td>101</td><td>20.3</td><td>1.14</td><td>1.22</td><td>0.81-1.83</td><td>110</td><td>42.3</td><td>*0.74</td><td>0.85</td><td>0.54-1.32</td></tr><tr><td> Mutual or private</td><td>53</td><td>16.6</td><td>0.89</td><td>0.80</td><td>0.49-1.30</td><td>32</td><td>43.7</td><td>*0.79</td><td>0.69</td><td>0.36-1.31</td></tr><tr><td> No usual PHC</td><td>29</td><td>15.5</td><td>*0.82</td><td>0.81</td><td>0.47-1.41</td><td>8</td><td>26.9</td><td>*0.37</td><td>0.44</td><td>0.15-1.27</td></tr></table>
661bf657655da2ce5538345ea352fd0ace907f31060255dc9e1879491bfdda62.png
complex
<table><tr><td>Variable</td><td>n (%)</td></tr><tr><td colspan="2">Quality of provider (n = 285)</td></tr><tr><td> Licensed pharmacist</td><td>16 (5.6)</td></tr><tr><td> Pharmacist assistant</td><td>36 (12.6)</td></tr><tr><td> Auxiliary</td><td>233 (81.8)</td></tr><tr><td colspan="2">Sex (n = 285)</td></tr><tr><td> Females</td><td>216 (75.8)</td></tr><tr><td> Males</td><td>69 (24.2)</td></tr><tr><td>Years of experience (n = 285)</td><td></td></tr><tr><td> &#8804;2</td><td>66 (23.2)</td></tr><tr><td> 2&#8211;5</td><td>115 (40.4)</td></tr><tr><td> 5&#8211;10</td><td>58 (20.3)</td></tr><tr><td> &gt;10</td><td>46 (16.1)</td></tr></table>
6cb2395952b83e7fb72f2334a30fd20adc7a7367c5c5c082bb25eaf78c34dd5a.png
simple
<table><tr><td>Variable</td><td>Total</td><td>N</td><td>%</td></tr><tr><td>Mode of spread of HIV/AIDS*</td><td> </td><td> </td><td> </td></tr><tr><td> Sexual intercourse</td><td>206</td><td>203</td><td>98.5</td></tr><tr><td> Blood transfusion</td><td>206</td><td>188</td><td>91.3</td></tr><tr><td> Unsterile instrument</td><td>206</td><td>199</td><td>96.6</td></tr><tr><td> MTCT</td><td>206</td><td>179</td><td>87.7</td></tr><tr><td> Other (spiritual)</td><td>206</td><td>33</td><td>15.0</td></tr><tr><td>Mother to child transmission</td><td> </td><td> </td><td> </td></tr><tr><td> Possible</td><td>206</td><td>190</td><td>92.2</td></tr><tr><td> Not possible</td><td>206</td><td>1</td><td>0.5</td></tr><tr><td> Don&#8217;t know</td><td>206</td><td>15</td><td>7.3</td></tr><tr><td>Mode of mother &#8211;to-child transmission*</td><td> </td><td> </td><td> </td></tr><tr><td> In the womb (intrauterine)</td><td>190</td><td>179</td><td>94.2</td></tr><tr><td> During delivery</td><td>190</td><td>154</td><td>81.1</td></tr><tr><td> Through breastfeeding</td><td>190</td><td>187</td><td>98.4</td></tr><tr><td>MTCT preventable?</td><td> </td><td> </td><td> </td></tr><tr><td> Preventable</td><td>206</td><td>182</td><td>88.3</td></tr><tr><td> Not preventable</td><td>206</td><td>8</td><td>3.8</td></tr><tr><td> Don&#8217;t know</td><td>206</td><td>15</td><td>7.2</td></tr><tr><td>Means of PMTCT*</td><td> </td><td> </td><td> </td></tr><tr><td> Giving ART</td><td>182</td><td>176</td><td>96.7</td></tr><tr><td> Avoiding breastfeeding</td><td>182</td><td>162</td><td>89.0</td></tr><tr><td> C/S delivery</td><td>182</td><td>69</td><td>37.9</td></tr><tr><td>Antiretrovials*</td><td> </td><td> </td><td> </td></tr><tr><td> Drug to prevent transmission to baby</td><td>206</td><td>58</td><td>28.2</td></tr><tr><td> Drug to cure HIV</td><td>206</td><td>78</td><td>37.9</td></tr><tr><td> Drug to prevent death from HIV/AIDS</td><td>206</td><td>147</td><td>71.4</td></tr><tr><td> Drug to prolong lives</td><td>206</td><td>184</td><td>89.3</td></tr><tr><td> Works effectively with optimal adherence</td><td>206</td><td>200</td><td>97.6</td></tr></table>
69464b16b771d181a901161127f7f6e0431dde0c8902585bd04ed881ef9c0518.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Non-syndromic Robin sequence (ns-RS)</td><td colspan="2">Non-syndromic cleft palate (ns-CP)</td><td>Chi-square Test (two-sided)</td></tr><tr><td><i>N</i></td><td>%</td><td><i>N</i></td><td>%</td><td><i>P</i></td></tr><tr><td>Total number of patients</td><td>115</td><td>100</td><td>191</td><td>100</td><td></td></tr><tr><td> Males/females</td><td>49/66</td><td>42.6/57.4</td><td>86/105</td><td>45.0/55.0</td><td></td></tr><tr><td>Tooth agenesis (excl. 3rd molars)</td><td>55</td><td>47.8</td><td>57</td><td>29.8</td><td>&lt; 0.001</td></tr><tr><td> Maxilla</td><td>28</td><td>24.3</td><td>31</td><td>16.2</td><td>0.082</td></tr><tr><td> Mandibula<sup>a</sup></td><td>45</td><td>39.1</td><td>39</td><td>20.4</td><td>&lt; 0.001</td></tr><tr><td> Right dental quadrants (q1, q4)</td><td>42</td><td>36.5</td><td>43</td><td>22.5</td><td>0.008</td></tr><tr><td> Left dental quadrants (q2, q3)</td><td>50</td><td>43.4</td><td>42</td><td>22.0</td><td>&lt; 0.001</td></tr><tr><td> In males</td><td>18/49</td><td>36.7</td><td>28/86</td><td>32.6</td><td>0.622</td></tr><tr><td> In females<sup>b</sup></td><td>37/66</td><td>56.0</td><td>30/105</td><td>28.6</td><td>&lt; 0.001</td></tr></table>
e571f64236d0bbb3a30c221d0695d74f137ba87af74754d2b04b6fb1e6955139.png
complex
<table><tr><td></td><td>Never smokers <i>N</i> = 25</td><td>COPDGene <i>N</i> = 2098</td><td>SPIROMICS <i>N</i> = 1117</td><td>p-value (SPIROMICS vs COPDGene) (current and former smokers)</td></tr><tr><td>Age (years)</td><td>57.5 (7)</td><td>65.8 (8.9)</td><td>62.7 (9)</td><td>&lt; 10<sup>&#8722;04</sup></td></tr><tr><td>Gender Male</td><td>36.0%</td><td>50.9%</td><td>51.9%</td><td>0.6931</td></tr><tr><td colspan="5">Race</td></tr><tr><td> White</td><td>100.0%</td><td>71.2%</td><td>74.9%</td><td></td></tr><tr><td> Black</td><td>0.0%</td><td>28.4%</td><td>20.8%</td><td></td></tr><tr><td> Other</td><td>0.0%</td><td>0.0%</td><td>4.3%</td><td></td></tr><tr><td>Current Smoker</td><td>0%</td><td>34.7%</td><td>40.5%</td><td>0.0009</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.7 (4.2)</td><td>28.8 (6.3)</td><td>28.2 (5.4)</td><td>0.0028</td></tr><tr><td>ATS Smoking, pack-years</td><td>0 (0)</td><td>45.1 (24)</td><td>47.6 (24.7)</td><td>0.0054</td></tr><tr><td>FEV<sub>1</sub> (% predicted)</td><td>105.5 (12)</td><td>76.1 (25.6)</td><td>76.1 (28.7)</td><td>0.9906</td></tr><tr><td>FEV<sub>1</sub>/FVC</td><td>0.8 (0)</td><td>0.7 (0.2)</td><td>0.6 (0.2)</td><td>&lt; 10<sup>&#8722;04</sup></td></tr><tr><td>BODE Index</td><td>0.2 (0.4)</td><td>1.3 (1.7)</td><td>1.5 (2)</td><td>0.0084</td></tr><tr><td>SGRQ</td><td>2.7 (3.5)</td><td>23.6 (21.1)</td><td>32 (21.2)</td><td>&lt; 10<sup>&#8722;04</sup></td></tr><tr><td>Emphysema (% LAA &lt; &#8722;950 HU)</td><td>1 (1.3)</td><td>6.5 (10.2)</td><td>7.3 (10.4)</td><td>0.0386</td></tr><tr><td>Chronic Bronchitis (%)</td><td>4%</td><td>15.2%</td><td>20.9%</td><td>&lt; 10<sup>&#8722;04</sup></td></tr><tr><td>Duration of participation in study (years)</td><td>NA</td><td>6.7 (1.2)</td><td>2.2 (0.9)</td><td>&lt; 10<sup>&#8722;04</sup></td></tr><tr><td>Decline in FEV<sub>1</sub> (ml/year)</td><td>NA</td><td>&#8722;38.1 (53.4)</td><td>&#8722;48.5 (144.1)</td><td>0.0416</td></tr><tr><td>Exacerbations (#/year)</td><td>0 (0)</td><td>0.3 (0.8)</td><td>0.5 (1.0)</td><td>&lt; 10<sup>&#8722;04</sup></td></tr><tr><td>Never Smoker</td><td>100%</td><td>0%</td><td>0%</td><td></td></tr><tr><td colspan="5">Spirometry category</td></tr><tr><td> PRISm</td><td>0%</td><td>10.4%</td><td>0%</td><td></td></tr><tr><td> Control Smoker</td><td>0%</td><td>41.5%</td><td>49.3%</td><td></td></tr><tr><td> GOLD 1</td><td>0%</td><td>9.3%</td><td>7.9%</td><td></td></tr><tr><td> GOLD 2</td><td>0%</td><td>20.4%</td><td>17.5%</td><td></td></tr><tr><td> GOLD 3</td><td>0%</td><td>12.2%</td><td>18.1%</td><td></td></tr><tr><td> GOLD 4</td><td>0%</td><td>5.8%</td><td>7.1%</td><td></td></tr></table>
646947d9c3ab903fb5512d9bfa83117241120c261a9b868868afcb07014eb4f7.png
simple
<table><tr><td>Beads Type</td><td>Beads Size (&#956;m; n = 50)</td><td>Encapsulation yield (%; n = 15)</td><td>Viability (log CFU/mL, n = 4)</td></tr><tr><td>I + 5% GT</td><td>344.19 &#177; 1</td><td>37.14 &#177; 0.4</td><td>9.28 &#177; 0.3</td></tr><tr><td>I + 10% GT</td><td>339.1.6 &#177; 1</td><td>35.33 &#177; 0.7</td><td>9.36 &#177; 0.2</td></tr><tr><td>B + 5% GT</td><td>329.36 &#177; 1</td><td>37.18 &#177; 0.4</td><td>9.39 &#177; 0.3</td></tr><tr><td>B +10% GT</td><td>331.25 &#177; 1</td><td>36.15 &#177; 0.7</td><td>9.43 &#177; 0.4</td></tr><tr><td>I</td><td>325.14 &#177; 0.5</td><td>38.24 &#177;0.5</td><td>9.34 &#177; 0.3</td></tr><tr><td>B</td><td>321.08 &#177; 0.9</td><td>37.24 &#177;0.8</td><td>9.24 &#177; 0.4</td></tr><tr><td>10% GT</td><td>318.23 &#177; 1</td><td> </td><td> </td></tr></table>
5283ff49663e41e54b0dcab1e4677e85180c1b03d8f5c7ea42a8064f52b201c4.png
complex
<table><tr><td>Variables</td><td>Total</td><td colspan="2">Fasting triglycerides</td><td>P-value</td></tr><tr><td> </td><td> </td><td>&lt;1.2 mmol/L (N = 103)</td><td>&#8805;2 mmol/L (N = 226)</td><td> </td></tr><tr><td>Biochemical markers</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>hs-CRP (mg/L)</td><td>3.2 &#177; 4.1</td><td>3.5 &#177; 4.5</td><td>3.1 &#177; 3.9</td><td>0.440</td></tr><tr><td>Leucocyte count (10<sup>9</sup>/L)</td><td>6.5 &#177; 1.6</td><td>6.2 &#177; 1.5</td><td>6.6 &#177; 1.6</td><td>0.048</td></tr><tr><td>Neutrophil count (10<sup>9</sup>/L)</td><td>3.8 &#177; 1.2</td><td>3.6 &#177; 1.1</td><td>3.9 &#177; 1.2</td><td>0.041</td></tr><tr><td>Neutrophil/lymphocyte ratio</td><td>2.2 &#177; 1.1</td><td>2.1 &#177; 1.0</td><td>2.2 &#177; 1.1</td><td>0.530</td></tr><tr><td>Fasting blood glucose (mmol/L)</td><td>6.1 &#177; 2.2</td><td>5.7 &#177; 1.9</td><td>6.3 &#177; 2.3</td><td>0.025</td></tr><tr><td>Hemoglobin A1C (%)</td><td>6.9 &#177; 1.4</td><td>6.7 &#177; 1.3</td><td>6.9 &#177; 1.4</td><td>0.149</td></tr><tr><td>D-dimer (ug/mL)</td><td>0.4 &#177; 0.5</td><td>0.4 &#177; 0.6</td><td>0.4 &#177; 0.4</td><td>0.252</td></tr><tr><td>Fibrinogen (g/L)</td><td>3.1 &#177; 0.8</td><td>3.1 &#177; 0.8</td><td>3.1 &#177; 0.9</td><td>0.644</td></tr><tr><td>Endothelin-1 (fmol/ml)</td><td>0.6 &#177; 0.3</td><td>0.6 &#177; 0.3</td><td>0.6 &#177; 0.3</td><td>0.587</td></tr><tr><td>Alkaline phosphatase (IU/L)</td><td>63.5 &#177; 18.6</td><td>62.0 &#177; 20.1</td><td>64.2 &#177; 17.9</td><td>0.318</td></tr><tr><td>Uric acid (mmol/L)</td><td>338.3 &#177; 78.9</td><td>314.9 &#177; 75.9</td><td>348.9 &#177; 78.1</td><td>0.000</td></tr><tr><td>Creatinine (umol/L)</td><td>76.3 &#177; 15.6</td><td>74. 4 &#177; 14.0</td><td>77.2 &#177; 16.2</td><td>0.138</td></tr><tr><td>Lipid profile</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Total cholesterol (mmol/L)</td><td>4.0 &#177; 1.0</td><td>3.5 &#177; 0.8</td><td>4.2 &#177; 1.1</td><td>0.000</td></tr><tr><td>LDL-C (mmol/L)</td><td>2.4 &#177; 0.9</td><td>2.1 &#177; 0.7</td><td>2.5 &#177; 0.9</td><td>0.000</td></tr><tr><td>HDL-C (mmol/L)</td><td>1.1 &#177; 0.3</td><td>1.1 &#177; 0.3</td><td>1.0 &#177; 0.3</td><td>0.002</td></tr><tr><td>Lipoprotein (a) (mg/L)</td><td>244.4 &#177; 244.5</td><td>267.9 &#177; 218.9</td><td>233.6 &#177; 254.9</td><td>0.237</td></tr><tr><td>apoA(g/L)</td><td>1.4 &#177; 0.3</td><td>1.4 &#177; 0.3</td><td>1.4 &#177; 0.3</td><td>0.477</td></tr><tr><td>apoB(g/L)</td><td>1.0 &#177; 0.3</td><td>0.9 &#177; 0.2</td><td>1.1 &#177; 0.3</td><td>0.000</td></tr><tr><td>TG/HDL-C index</td><td>1.7 &#177; 1.3</td><td>0.8 &#177; 0.3</td><td>2.2 &#177; 1.3</td><td>0.000</td></tr><tr><td>Non-HDL-C (mmol/L)</td><td>2.9 &#177; 0.9</td><td>2.4 &#177; 0.7</td><td>3.1 &#177; 0.9</td><td>0.000</td></tr><tr><td>LDL-C/HDL-C ratio</td><td>2.3 &#177; 0.8</td><td>1.9 &#177; 0.7</td><td>2.4 &#177; 0.8</td><td>0.000</td></tr></table>
a2bc4adb50f4a660719721b13c2b8593a8fed3d03e3d26dc5eeebcaf77f4e0fe.png
simple
<table><tr><td>Parameters</td><td>Control group (<i>n</i> = 61) <i>n</i> (%)</td><td>Patient group (<i>n</i> = 66) <i>n</i> (%)</td><td><i>P</i></td></tr><tr><td>Fatigue</td><td>36 (59)</td><td>59 (92.4)</td><td>&lt;0.001</td></tr><tr><td>Presence of RBD</td><td>3 (4.9)</td><td>8 (12.1)</td><td>0.001</td></tr><tr><td>PSQI</td><td>35 (57.4)</td><td>46 (69.7)</td><td>&gt;0.05</td></tr><tr><td>Depression</td><td>25 (41)</td><td>62 (93.9)</td><td>&lt;0.001</td></tr><tr><td>Presence of RLS</td><td>10 (16.4)</td><td>45 (68.1)</td><td>&lt;0.001</td></tr></table>
833eb7d03e2ce769d049ffbcee2338251102a0973c1e550f7abf9c2a18e589e4.png
simple
<table><tr><td></td><td>SKM</td><td>CSM</td></tr><tr><td></td><td>Concentration (nmol/g SKM protein)</td><td>Concentration (nmol/g CSM protein)</td></tr><tr><td>Laminin</td><td>2.20 &#177; 0.22</td><td>N/A</td></tr><tr><td>&#945;-Dystroglycan</td><td>89.72 &#177; 15.04</td><td>692.67 &#177; 57.39</td></tr><tr><td>Dystrophin</td><td>2.20 &#177; 0.07</td><td>16.11 &#177; 0.69</td></tr><tr><td>Ratio</td><td>Lam : &#945;DG : Dys = 1 : 41 : 1</td><td>&#945;DG : Dys = 43 : 1</td></tr></table>
3deb36615f2b08abfaf569dc311055ba12b82d144353041dad8cbfdccd9e3617.png
complex
<table><tr><td>Frailty status</td><td>Overall</td><td>Not frail (CFS 1&#8211;4)</td><td>Frail (CFS 5&#8211;9)</td><td><i>p</i>-value</td></tr><tr><td>Number of admissions</td><td>308 (100%)</td><td>143 (46.4%)</td><td>165 (53.6%)</td><td></td></tr><tr><td>Age</td><td>84 [82&#8211;87]</td><td>82 [81&#8211;86]</td><td>85 [82&#8211;88]</td><td>&lt; 0.001</td></tr><tr><td>Male</td><td>164 (50%)</td><td>79 (55.2%)</td><td>75 (45.5%)</td><td>0.09</td></tr><tr><td>APACHE II</td><td>18 [12&#8211;26]</td><td>15 [12&#8211;25]</td><td>19 [12&#8211;26]</td><td>0.18</td></tr><tr><td>SAPS II</td><td>39 [29.5&#8211;51]</td><td>37 [29&#8211;48]</td><td>42 [30&#8211;55]</td><td>0.17</td></tr><tr><td>SOFA Score</td><td>6 [3&#8211;10]</td><td>6 [3&#8211;9]</td><td>7 [4&#8211;10]</td><td>0.016</td></tr><tr><td colspan="5">Cause of admission</td></tr><tr><td> Acute medical</td><td>162 (52.6%)</td><td>58 (40.6%)</td><td>104 (63%)</td><td>&lt; 0.001</td></tr><tr><td> Acute surgery</td><td>16 (5.2%)</td><td>8 (5.6%)</td><td>8 (4.8%)</td><td>0.77</td></tr><tr><td> Trauma</td><td>33 (10.7%)</td><td>14 (9.8%)</td><td>19 (11.5%)</td><td>0.63</td></tr><tr><td> Elective surgery</td><td>97 (31.5%)</td><td>63 (44.1%)</td><td>34 (20.6%)</td><td>&lt; 0.001</td></tr><tr><td>ICU length of stay (days)</td><td>3.1 [1.1&#8211;8.1]</td><td>2.9 [1&#8211;7]</td><td>3.4 [1.4&#8211;9.5]</td><td>0.21</td></tr><tr><td colspan="5">Use of life sustaining treatments</td></tr><tr><td> Non-invasive ventilation</td><td>104 (33.8%)</td><td>48 (33.6%)</td><td>56 (33.9%)</td><td>0.95</td></tr><tr><td> Mechanical ventilation</td><td>141 (45.8%)</td><td>59 (41.3%)</td><td>82 (49.7%)</td><td>0.14</td></tr><tr><td> Vasoactive drugs</td><td>189 (61.4%)</td><td>82 (57.3%)</td><td>107 (64.8%)</td><td>0.18</td></tr><tr><td> Renal replacement therapy</td><td>59 (19.2%)</td><td>26 (18.2%)</td><td>33 (20%)</td><td>0.69</td></tr><tr><td>Treatment withheld</td><td>41 (13.3%)</td><td>11 (7.7%)</td><td>30 (18.2%)</td><td>0.01</td></tr><tr><td>Treatment withdrawn</td><td>36 (11.7%)</td><td>10 (7%)</td><td>26 (15.8%)</td><td>0.02</td></tr><tr><td>ICU mortality</td><td>53 (17.3%)</td><td>16 (11.3%)</td><td>37 (22.4%)</td><td>0.01</td></tr><tr><td>30-day mortality</td><td>84 (31.2%)</td><td>23 (18.4%)</td><td>61 (42.4%)</td><td>&lt; 0.001</td></tr></table>
de701ab6492b518ea846c509f13018b8008482cae5e8d9f6dc0860220581a35d.png
simple
<table><tr><td></td><td></td><td>Group 1</td><td>Group 2</td><td>Group 3</td><td>Group 4</td><td>TOTAL</td></tr><tr><td>Number of animals</td><td></td><td>6</td><td>7</td><td>7</td><td>7</td><td>27</td></tr><tr><td>Number of tumours</td><td></td><td>12</td><td>14</td><td>14</td><td>14</td><td>54</td></tr><tr><td>Weight (g)</td><td>Mean</td><td>30</td><td>29</td><td>29</td><td>29</td><td>29</td></tr><tr><td></td><td>Range</td><td>28&#8211;33</td><td>27&#8211;32</td><td>28&#8211;31</td><td>28&#8211;31</td><td>27&#8211;33</td></tr><tr><td>Tumour size (mm<sup>3</sup>)</td><td>Mean</td><td>100</td><td>95</td><td>97</td><td>96</td><td>97</td></tr><tr><td></td><td>Range</td><td>26&#8211;181</td><td>25&#8211;165</td><td>40&#8211;271</td><td>39&#8211;182</td><td>25&#8211;271</td></tr><tr><td>Treatment given</td><td></td><td>vehicle</td><td>5Gy + vehicle</td><td>FGFR inhibitor</td><td>FGFR inhibitor + 5 Gy</td><td></td></tr></table>
dbe34a41b3ff4532e238b713ab9adf57aa703c8a13097904e2b27a343301c1cb.png
simple
<table><tr><td>LPS</td><td>IL1A</td><td>IL1<i>&#946;</i></td><td>IL6</td><td>IL8</td><td>iNOS</td></tr><tr><td>ng/mL</td><td>Expression, a.u.</td><td>Expression, a.u.</td><td>Expression, a.u.</td><td>Expression, a.u.</td><td>Expression, a.u.</td></tr><tr><td>0</td><td>1 &#177; 3.25</td><td>1 &#177; 1.82</td><td>1 &#177; 1.54</td><td>1 &#177; 1.41</td><td>1 &#177; 3.14</td></tr><tr><td>50</td><td>194 &#177; 2.77*</td><td>317 &#177; 1.63*</td><td>99 &#177; 1.48*</td><td>26 &#177; 1.8*</td><td>882 &#177; 2.46*</td></tr><tr><td>100</td><td>265 &#177; 2.33*</td><td>465 &#177; 1.78*</td><td>155 &#177; 1.4*</td><td>46 &#177; 1.36*</td><td>1128 &#177; 2.3*</td></tr><tr><td>500</td><td>315 &#177; 2.35*</td><td>755 &#177; 1.68*</td><td>47 &#177; 2.67*</td><td>18 &#177; 1.98*</td><td>1596 &#177; 2.46*</td></tr><tr><td>1000</td><td>247 &#177; 2.38*</td><td>498 &#177; 1.78*</td><td>98 &#177; 1.6*</td><td>11 &#177; 1.61*</td><td>1489 &#177; 2.37*</td></tr><tr><td>2500</td><td>338 &#177; 2.35*</td><td>729 &#177; 1.57*</td><td>224 &#177; 2.32*</td><td>20 &#177; 3.33*</td><td>1438 &#177; 2.25*</td></tr></table>
687bff7bd83a5861a018350270ce652d79922657ea980e1ecbff8c6ab50dbdcb.png
simple
<table><tr><td></td><td>PGM-High</td><td>PGM-Low</td></tr><tr><td>MiSeq-High</td><td>2864925</td><td>44534</td></tr><tr><td>MiSeq-Low</td><td>394</td><td>115</td></tr></table>
20961f47a6d9c11cab69a0cd719d1640995e13083e6e9d6e7c62d606b0de9ce7.png
simple
<table><tr><td>Special stain/IHC</td><td>Squamous cell carcinoma</td><td>Adenocarcinoma</td></tr><tr><td>CK7</td><td>&#8722;/+</td><td>+</td></tr><tr><td>p63</td><td>+</td><td>&#8722;</td></tr><tr><td>CK5/6</td><td>+</td><td>&#8722;</td></tr><tr><td>TTF-1</td><td>&#8722;</td><td>+/&#8722;</td></tr></table>
9f70e63ab2ce52a0c49a6c624866fad81e756d0049355d59b37368cfd2a86d98.png
simple
<table><tr><td>Height for age</td><td>Male No %</td><td>Female No %</td></tr><tr><td>Stunted</td><td>38 (7.9)</td><td>14 (2.9)</td></tr><tr><td>Normal</td><td>443 (92.1)</td><td>465 (97.1)</td></tr><tr><td>Total</td><td>481 (100)</td><td>479 (100)</td></tr></table>
a3272acbbbb00091e78bb13ddedcc084b54094691f9e624dc940d6fcbecf5650.png
complex
<table><tr><td></td><td></td><td></td><td>t-TATI(f*i)</td><td></td><td></td><td>s-TATI(&#956;g/L)</td><td></td></tr><tr><td></td><td></td><td>Pre RT</td><td></td><td>After RT(OP)</td><td>Before RT</td><td></td><td>After RT</td></tr><tr><td colspan="2">Age at OP</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>R</td><td></td><td>-0,007</td><td></td><td>0,114</td><td>0,586</td><td></td><td>0,453</td></tr><tr><td>p</td><td></td><td>0,970</td><td></td><td>0,474</td><td>&lt; 0,001*</td><td></td><td>0,001*</td></tr><tr><td>n</td><td></td><td>33</td><td></td><td>42</td><td>56</td><td></td><td>51</td></tr><tr><td colspan="2">Gender</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>R</td><td></td><td>-0,214</td><td></td><td>-0,406</td><td>0,011</td><td></td><td>-0,167</td></tr><tr><td>p</td><td></td><td>0,232</td><td></td><td>0,008*</td><td>0,94</td><td></td><td>0,241</td></tr><tr><td>n</td><td></td><td>33</td><td></td><td>42</td><td>52</td><td></td><td>51</td></tr><tr><td colspan="2">Disease stage</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>R</td><td></td><td>0,066</td><td></td><td>0,330</td><td>0,057</td><td></td><td>0,338</td></tr><tr><td>p</td><td></td><td>0,720</td><td></td><td>0,033*</td><td>0,703</td><td></td><td>0,021*</td></tr><tr><td>n</td><td></td><td>31</td><td></td><td>42</td><td>47</td><td></td><td>46</td></tr><tr><td colspan="2">Vascular invasion</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>R</td><td></td><td>0,204</td><td></td><td>-0,062</td><td>-0,165</td><td></td><td>-0,053</td></tr><tr><td>p</td><td></td><td>0,262</td><td></td><td>0,695</td><td>0,268</td><td></td><td>0,725</td></tr><tr><td>n</td><td></td><td>32</td><td></td><td>42</td><td>47</td><td></td><td>36</td></tr><tr><td colspan="2">s-kreatinin drafted preOP</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>R</td><td></td><td>0,170</td><td></td><td>0,038</td><td>0,369</td><td></td><td>0,302</td></tr><tr><td>p</td><td></td><td>0,346</td><td></td><td>0,812</td><td>0,011*</td><td></td><td>0,041*</td></tr><tr><td>n</td><td></td><td>33</td><td></td><td>41</td><td>47</td><td></td><td>46</td></tr></table>
8edf4229f480ff06f2bcc02b0bdf85f0a89183f2aaada5bcba17cd869beaffa4.png
simple
<table><tr><td>Risk factor</td><td>Odds ratio</td><td>95 % CI</td><td><i>P</i> value</td></tr><tr><td>&#8722;1SD of BMI</td><td>1.2</td><td>0.6&#8211;2.3</td><td>0.562</td></tr><tr><td>+1SD of age</td><td>4.5</td><td>1.9&#8211;13.0</td><td>0.001</td></tr><tr><td>+1SD of NTX</td><td>1.9</td><td>0.9&#8211;4.1</td><td>0.073</td></tr><tr><td>+1SD of BAP</td><td>0.7</td><td>0.3&#8211;1.4</td><td>0.442</td></tr><tr><td>&#8722;1SD of L2&#8211;4 BMD</td><td>8.2</td><td>2.9&#8211;34.4</td><td>&lt;0.001</td></tr><tr><td>&#8722;1SD of total BMD</td><td>4.5</td><td>2.0&#8211;13.3</td><td>0.001</td></tr><tr><td>&#8722;1SD of neck BMD</td><td>7.2</td><td>2.6&#8211;28.8</td><td>&lt;0.001</td></tr><tr><td>&#8722;1SD of troch BMD</td><td>9.6</td><td>3.0&#8211;51.2</td><td>0.001</td></tr></table>
0e88b489808f8b55308fec60f3b2e10981d0431cf3a5cc0d7f91764ac292959d.png
simple
<table><tr><td>Control</td><td>MT</td><td>Cell 1</td><td>Cell 2</td><td>MT-Diff</td><td>Diff-Cell1</td><td>Diff-Cell2</td></tr><tr><td>CGC</td><td>13.33</td><td>8.5</td><td>8.66</td><td>6.33</td><td>4.66</td><td>6.5</td></tr><tr><td>GO</td><td>72.33</td><td>33.66</td><td>41.5</td><td>47.66</td><td>43.16</td><td>29.5</td></tr><tr><td>Oncogenic</td><td>7.66</td><td>3</td><td>3.33</td><td>10.33</td><td>10.33</td><td>4.83</td></tr><tr><td>Breast &amp; Prostate</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CGC</td><td>14.66</td><td>8.33</td><td>10</td><td>2.66</td><td>3.33</td><td>1.83</td></tr><tr><td>GO</td><td>77.5</td><td>70.66</td><td>64.83</td><td>18.16</td><td>25.66</td><td>18.33</td></tr><tr><td>Oncogenic</td><td>8.66</td><td>4.33</td><td>5.16</td><td>2.66</td><td>2.5</td><td>2.5</td></tr><tr><td>Prostate</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CGC</td><td>15</td><td>10.16</td><td>10.33</td><td>3.33</td><td>2.33</td><td>3.83</td></tr><tr><td>GO</td><td>82.33</td><td>85.83</td><td>88.66</td><td>23</td><td>26.83</td><td>18.5</td></tr><tr><td>Oncogenic</td><td>11</td><td>8.33</td><td>7.66</td><td>3</td><td>4.5</td><td>3.16</td></tr></table>
98ed348a3758d1bc7bf6fe346b2c3c6b2c82719e8a6c64fde7fa7f65bf2187c9.png
complex
<table><tr><td colspan="7">THE BPRS SCALE Assessment of each item: EMOTION</td></tr><tr><td></td><td>GROUP</td><td></td><td></td><td>CONTOL</td><td></td><td></td></tr><tr><td></td><td>T0</td><td>T4</td><td><i>Diff</i>.</td><td>T0</td><td>T4</td><td><i>Diff</i>,</td></tr><tr><td>Thought disorganization</td><td>2,56</td><td>2,00</td><td><i>-0,56</i></td><td>2,34</td><td>2,18</td><td><i>-0,16</i></td></tr><tr><td>Emotional flattening</td><td>3,24</td><td>2,24</td><td><i>-7,00</i></td><td>2,80</td><td>2,61</td><td><i>-0,79</i></td></tr><tr><td>Emotional withdrawal</td><td>3,37</td><td>2,34</td><td><i>-7,03</i></td><td>3,18</td><td>2,80</td><td><i>-0,38</i></td></tr><tr><td>Delayed motor skills</td><td>2,53</td><td>1,42</td><td><i>-1,11</i></td><td>2,13</td><td>1,85</td><td><i>-0,28</i></td></tr><tr><td>Tension</td><td>3,48</td><td>2,16</td><td><i>-1.32</i></td><td>3,10</td><td>2,55</td><td><i>-0,55</i></td></tr><tr><td>Lack of compliance</td><td>2,11</td><td>1,29</td><td><i>-0,82</i></td><td>1,98</td><td>1,56</td><td><i>-0,42</i></td></tr><tr><td>Excitement</td><td>1,63</td><td>1,11</td><td><i>-0,52</i></td><td>1,99</td><td>1,44</td><td><i>-0,55</i></td></tr><tr><td>Distractibility</td><td>2,38</td><td>1,40</td><td><i>-0.98</i></td><td>2,30</td><td>1,80</td><td><i>-0,50</i></td></tr><tr><td>Motor skill hyperactivity</td><td>1,59</td><td>1,06</td><td><i>-0,53</i></td><td>1,76</td><td>1,32</td><td><i>-0,44</i></td></tr><tr><td>Artificial behavior</td><td>1,89</td><td>1,24</td><td><i>-0,65</i></td><td>1,92</td><td>1,67</td><td><i>-0,25</i></td></tr><tr><td>TOTAL Assessment</td><td>24,80</td><td>16,27</td><td><i>-8,53</i></td><td>23,47</td><td>19,77</td><td><i>-3,70</i></td></tr></table>
6517210802141c162fb55d683a356ae4b43346e40cd6f86863b19466d75cc524.png
simple
<table><tr><td>Tumor samples</td><td><i>IRX1</i></td><td><i>NOL4</i></td><td>Age (years)</td><td>Gender</td><td>Race</td><td>Smoking</td><td>Alcohol</td><td>Tumor anatomic site</td><td>Overall stage</td></tr><tr><td>1</td><td>N</td><td>N</td><td>67</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Nasal floor</td><td>2</td></tr><tr><td>2</td><td>Y</td><td>Y</td><td>57</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Larynx</td><td>2</td></tr><tr><td>3</td><td>N</td><td>N</td><td>61</td><td>M</td><td>C</td><td>No</td><td>No</td><td>Neck</td><td>3</td></tr><tr><td>4</td><td>Y</td><td>Y</td><td>60</td><td>F</td><td>C</td><td>Yes</td><td>Yes</td><td>Larynx</td><td>4</td></tr><tr><td>5</td><td>Y</td><td>Y</td><td>55</td><td>M</td><td>A</td><td>Yes</td><td>Yes</td><td>Larynx</td><td>2</td></tr><tr><td>6</td><td>Y</td><td>Y</td><td>54</td><td>M</td><td>C</td><td>No</td><td>Yes</td><td>Oropharynx</td><td>4</td></tr><tr><td>7</td><td>Y</td><td>N</td><td>64</td><td>M</td><td>A</td><td>Yes</td><td>Yes</td><td>Hypopharynx</td><td>3</td></tr><tr><td>8</td><td>Y</td><td>Y</td><td>55</td><td>F</td><td>A</td><td>Yes</td><td>No</td><td>Oral cavity</td><td>1</td></tr><tr><td>9</td><td>N</td><td>Y</td><td>80</td><td>M</td><td>C</td><td>Yes</td><td>No</td><td>Oral cavity</td><td>NA</td></tr><tr><td>10</td><td>Y</td><td>Y</td><td>54</td><td>F</td><td>C</td><td>No</td><td>Oral</td><td>cavity</td><td>4</td></tr><tr><td>11</td><td>Y</td><td>Y</td><td>62</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Oropharynx</td><td>4</td></tr><tr><td>12</td><td>Y</td><td>Y</td><td>72</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Hypopharynx</td><td>3</td></tr><tr><td>13</td><td>Y</td><td>Y</td><td>42</td><td>M</td><td>C</td><td>Yes</td><td>No</td><td>Larynx</td><td>2</td></tr><tr><td>14</td><td>Y</td><td>Y</td><td>66</td><td>M</td><td>C</td><td>Yes</td><td>No</td><td>Oropharynx</td><td>4</td></tr><tr><td>15</td><td>Y</td><td>Y</td><td>74</td><td>M</td><td>C</td><td>Yes</td><td>Larynx</td><td>2</td><td></td></tr><tr><td>16</td><td>Y</td><td>Y</td><td>58</td><td>M</td><td>A</td><td>Yes</td><td>Yes</td><td>Oropharynx</td><td>4</td></tr><tr><td>17</td><td>Y</td><td>Y</td><td>56</td><td>F</td><td>C</td><td>Yes</td><td>Yes</td><td>Oral cavity</td><td>2</td></tr><tr><td>18</td><td>Y</td><td>Y</td><td>43</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Oropharynx</td><td>4</td></tr><tr><td>19</td><td>Y</td><td>Y</td><td>68</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Oropharynx</td><td>4</td></tr><tr><td>20</td><td>Y</td><td>Y</td><td>63</td><td>M</td><td>A</td><td>Yes</td><td></td><td>Oral cavity</td><td>NA</td></tr><tr><td>21</td><td>Y</td><td>Y</td><td>64</td><td>F</td><td>C</td><td>No</td><td>Yes</td><td>Oral cavity</td><td>3</td></tr><tr><td>22</td><td>N</td><td>Y</td><td>88</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Oral cavity</td><td>NA</td></tr><tr><td>23</td><td>Y</td><td>Y</td><td>42</td><td>M</td><td>C</td><td>Yes</td><td>No</td><td>Oral cavity</td><td>3</td></tr><tr><td>24</td><td>Y</td><td>Y</td><td>51</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Larynx</td><td>4</td></tr><tr><td>25</td><td>Y</td><td>Y</td><td>80</td><td>M</td><td>C</td><td>No</td><td>Yes</td><td>Neck</td><td>NA</td></tr><tr><td>26</td><td>Y</td><td>Y</td><td>58</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Larynx</td><td>3</td></tr><tr><td>27</td><td>Y</td><td>Y</td><td>71</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Neck</td><td>NA</td></tr><tr><td>28</td><td>Y</td><td>Y</td><td>48</td><td>M</td><td>C</td><td>Yes</td><td>Yes</td><td>Oropharynx</td><td>4</td></tr><tr><td>29</td><td>Y</td><td>Y</td><td>61</td><td>M</td><td>C</td><td>Yes</td><td>No</td><td>Maxillary sinus</td><td>1</td></tr><tr><td>30</td><td>Y</td><td>Y</td><td>77</td><td>M</td><td>C</td><td>No</td><td>No</td><td>Salivary gland</td><td>NA</td></tr><tr><td>31</td><td>Y</td><td>Y</td><td>67</td><td>M</td><td>C</td><td>Larynx</td><td>3</td><td></td><td></td></tr><tr><td>32</td><td>Y</td><td>Y</td><td>36</td><td>M</td><td>C</td><td>Yes</td><td>No</td><td>Oral cavity</td><td>4</td></tr><tr><td>33</td><td>Y</td><td>Y</td><td>74</td><td>F</td><td>C</td><td>No</td><td>Yes</td><td>Maxillary sinus</td><td>4</td></tr></table>
d769fb57e912e200a49f1ab8004751049e2a42ccb15b830ad1c6770071e701c0.png
complex
<table><tr><td></td><td colspan="3">Year</td></tr><tr><td>Indicator</td><td>1995</td><td>2000</td><td>2005</td></tr><tr><td>Received any prenatal care ***</td><td>42.4</td><td>54.1</td><td>71.4</td></tr><tr><td>CI by Education</td><td>0.41 (0.396 0.424)</td><td>0.39 (0.378 0.402)</td><td>0.41 (0.402 0.418)</td></tr><tr><td>CI by Wealth index</td><td>0.50 (0.486 0.514)</td><td>0.37 (0.358 382)</td><td>0.45 (0.442 0.458)</td></tr><tr><td>Received regular prenatal care (4+ visits)***</td><td>31.0</td><td>40.7</td><td>61.3</td></tr><tr><td>CI by Education</td><td>0.49 (0.474 0.506)</td><td>0.44 (0.426 0.454)</td><td>0.39 (0.382 0.398)</td></tr><tr><td>CI by Wealth index</td><td>0.60 (0.584 0.616)</td><td>0.42 (0.404 0.436)</td><td>0.49 (0.482 0.498)</td></tr><tr><td>Received tetanus injection before birth***</td><td>73.1</td><td>78.0</td><td>80.7</td></tr><tr><td>CI by Education</td><td>-0.15 (-0.162 -0.138)</td><td>-0.14 (-0.148 -0.132)</td><td>-0.21 (-0.216 -0.204)</td></tr><tr><td>CI by Wealth index</td><td>-0.22 (-0.234 -0.206)</td><td>-0.23 (-0.240 -0.220)</td><td>-0.36 (-0.368 -0.352)</td></tr><tr><td>Told about pregnancy complications***</td><td>-</td><td>26.0</td><td>36.7</td></tr><tr><td>CI by Education</td><td>-</td><td>0.11 (0.083 0.137)</td><td>0.12 (0.104 0.136)</td></tr><tr><td>CI by Wealth index</td><td>-</td><td>0.07 (0.041 0.099)</td><td>0.15 (0.132 0.168)</td></tr><tr><td>Given iron supplement during pregnancy***</td><td>-</td><td>43.6</td><td>64.7</td></tr><tr><td>CI by Education</td><td>-</td><td>0.23 (0.212 0.248)</td><td>0.17 (0.162 0.178)</td></tr><tr><td>CI by Wealth index</td><td>-</td><td>0.23 (0.212 0.248)</td><td>0.22 (0.200 0.240)</td></tr></table>
0130dbebfcc267979b0db01000aca2d2c66ae9d0acc3883daff2aa8f0684d634.png
complex
<table><tr><td rowspan="2">Independent variables</td><td colspan="2">Adjusted</td></tr><tr><td>OR (95 % CI)</td><td><i>P</i>-value</td></tr><tr><td colspan="3">Sex</td></tr><tr><td> Male</td><td>1.08 (0.68 &#8211; 1.72)</td><td>0.73</td></tr><tr><td> Female (Ref.)</td><td></td><td></td></tr><tr><td colspan="3">Age</td></tr><tr><td> &#8804;35 years</td><td>2.71 (1.14 &#8211; 6.46)</td><td>0.024</td></tr><tr><td> &#8805;36 years (Ref.)</td><td></td><td></td></tr><tr><td colspan="3">Nationality</td></tr><tr><td> Yemeni</td><td>0.69 (0.35 &#8211; 1.35)</td><td>0.28</td></tr><tr><td> Foreign (Ref.)</td><td></td><td></td></tr><tr><td colspan="3">University</td></tr><tr><td> Yemeni</td><td>0.71 (0.33 &#8211; 1.52)</td><td>0.39</td></tr><tr><td> Foreign (Ref.)</td><td></td><td></td></tr><tr><td colspan="3">Referral</td></tr><tr><td> Yes</td><td>0.78 (0.41 &#8211; 1.50)</td><td>0.47</td></tr><tr><td> No (Ref.)</td><td></td><td></td></tr></table>
25438deadaf4a5b9c24eb92096606f5dada43b4f86e3fbd738942c7ab14caa96.png
simple
<table><tr><td>Participant</td><td>Age</td><td>Sex</td><td>Diagnosis</td><td>CARS</td></tr><tr><td>1</td><td>14</td><td>Male</td><td>ASD</td><td>42</td></tr><tr><td>2</td><td>14</td><td>Male</td><td>ASD</td><td>33</td></tr><tr><td>3</td><td>13</td><td>Male</td><td>ASD</td><td>43.5</td></tr><tr><td>4</td><td>16</td><td>Male</td><td>ASD</td><td>39</td></tr><tr><td>5</td><td>20</td><td>Male</td><td>ASD</td><td>36</td></tr><tr><td>6</td><td>13</td><td>Male</td><td>ASD</td><td>38</td></tr></table>
759ae3ddfa9b68b795b2222a448405d96e04db88aaf6bac24793a211e5c5a107.png
simple
<table><tr><td></td><td>Study patients</td><td>n</td><td>Children</td><td>Adults</td><td>HLA DQ2/DQ8</td><td>IgA-tTG/EMA</td><td>Atrophy grade at diagnosis (Marsh criteria)</td></tr><tr><td>Celiac patients</td><td>aCD-patient</td><td>2</td><td>1</td><td>1</td><td>+</td><td>+</td><td>II-III</td></tr><tr><td></td><td>GFD-patient </td><td>2</td><td>1</td><td>1</td><td>+</td><td>+</td><td>II-III</td></tr><tr><td>Non-Celiac patients</td><td>GP-patient</td><td>2</td><td>1</td><td>1</td><td>+/-</td><td> - (*)</td><td>M.M</td></tr></table>
29861df2e25e86d83514e76dccd0404c8a6d61fbe07ba1a02d42b9c0d4a1edd1.png
complex
<table><tr><td>Type of data</td><td>Data source</td><td>Detail of data to be collected</td><td>Time point(s)</td></tr><tr><td>Non-participant observation of training sessions</td><td>Observation, training sessions</td><td rowspan="2">&#8226;Observation of the training and care home-based sessions will allow recording of content and delivery of training, length of sessions, number of attendees. Also, identification of possible issues for follow-up in semi-structured interviews in the case study care homes</td><td>Each session</td></tr><tr><td>Non-participant observation of care home-based sessions</td><td>Observation, care home-based sessions</td><td>A selected number of sessions throughout the programme (approximately 30% of the total)</td></tr><tr><td>Documentary analysis</td><td>Patient Safety Collaborative Programme Board</td><td>&#8226;All documents relating to the programme will be analysed to provide information about programme planning, content and delivery</td><td>Throughout the programme</td></tr><tr><td>Focus groups</td><td>Care home staff participating in the programme (2 groups of 6&#8211;8 staff at each time point)</td><td>&#8226;What has been learned by participation in the programme, how learning has been applied to individuals&#8217; practice, barriers and facilitators to implementing change in the care home, perceptions of best/worst features of the programme, suggestions for improvement</td><td>6, 12 and 18 months</td></tr><tr><td>Semi-structured interviews</td><td>CCG managers and programme facilitators (<i>n</i> = 6)</td><td>&#8226;Experience of running the programme, perceived barriers to safety-related change in care homes, best/worst features of the programme, suggestions for improvement</td><td>Months 6, 12 and 24</td></tr><tr><td>Semi-structured interviews in four case study care homes</td><td>Staff and care home managers (participants and non-participants in the programme) (<i>n</i> = 6 to 8 in each of the four case study sites at each time point)</td><td>&#8226;What has been learned, how learning has been applied to individuals&#8217; practice, barriers and facilitators to implementing change in the care home, changes made to safety-related processes at the care home level, extent and type of collaboration across care homes</td><td>12 and 24 months</td></tr></table>
c53d2cdd7b0dbca4bd9af8e272412b91d0fe1bbaf7c13660f83f1446a3af71f0.png
simple
<table><tr><td></td><td>Controls</td><td>PD patients</td><td>AR</td><td>TD</td></tr><tr><td><i>n</i></td><td>20</td><td>20</td><td>10</td><td>10</td></tr><tr><td>Mean age (SD; range)</td><td>66.0 (9.1; 43&#8211;85)</td><td>66.25 (9.0; 42&#8211;84)</td><td>66.3 (5.9; 58&#8211;79)</td><td>66.2 (11.7; 42&#8211;84)</td></tr><tr><td>Gender ratio: male/female</td><td>10/10</td><td>11/9</td><td>5/5</td><td>6/4</td></tr><tr><td>Time symptom onset in years (SD)</td><td></td><td>6.27 (4.4)</td><td>6.75 (5.0)</td><td>5.78 (3.8)</td></tr><tr><td>Unified Parkinson Disease Rating Scale (UPDRS)</td><td></td><td>34.6 (17.4)</td><td>30.4 (13.2)</td><td>38.8 (20.6)</td></tr><tr><td>Subtype ratio</td><td></td><td>1.1 (0.7)</td><td>0.5 (0.2)**</td><td>1.7 (0.6)**</td></tr><tr><td>Addenbrooke's Cognitive Examination-Revised (ACE-R)</td><td></td><td>88.4 (15.0)</td><td>91.3 (7.5)</td><td>85.6 (20.1)</td></tr><tr><td>Barratt Impulsiveness Scale (BIS)</td><td></td><td>0.5 (0.1)</td><td>0.5 (0.1)</td><td>0.5 (0.1)</td></tr><tr><td>l-dopa equivalence units</td><td></td><td>393.8 (339.0)</td><td>375.4 (268.2)</td><td>412.2 (412.2)</td></tr><tr><td>Whole brain volume in mm3 (SD)</td><td>1235.3 (146.2)</td><td>1230.4 (102.1)</td><td>1193.3 (101.1)</td><td>1267.4 (93.5)</td></tr><tr><td>Intracranial volume mm<sup>3</sup> (SD)</td><td>1647.7 (201.5)</td><td>1705.1 (140.6)</td><td>1678.1 (153.8)</td><td>1732.0 (128.4)</td></tr><tr><td>Whole brain MT (SD)</td><td>0.833 (0.14)</td><td>0.848 (0.09)</td><td>0.835 (0.08)</td><td>0.861 (0.09)</td></tr><tr><td>Whole brain R2* (SD)</td><td>22.4 (0.9)</td><td>22.9 (2.0)</td><td>23.1 (2.5)</td><td>22.8 (1.6)</td></tr></table>
41a119d3adc88961d64481cb37201f16bd123397bafba4f15be6f2bdd9872417.png
complex
<table><tr><td>Original version</td><td>Translated version</td></tr><tr><td><i>Is there a view of the outside from corridors? (include internal courtyard)</i></td><td rowspan="2"><i>Are there external views from different parts of the circulation space? (including internal courtyard)</i></td></tr><tr><td><i>Are there external views from different parts of the circulation space?</i></td></tr></table>
2a83a271ab547f8697187efb3f956b625f8b910ac68e9e8d5f4ed2ff132575d8.png
simple
<table><tr><td>Water (mL)</td><td>Starch (g)</td><td>Urea (g)</td><td>Borate (g)</td><td>Reaction temp. (&#176;C)</td><td>Stirring rate (rpm)</td></tr><tr><td>1000</td><td>50 </td><td>15</td><td>2.5 </td><td>80</td><td>600 &#177; 5</td></tr><tr><td>1000</td><td>50</td><td>15 </td><td>3.5 </td><td>80</td><td>600 &#177; 5</td></tr><tr><td>1000</td><td>50 </td><td>15 </td><td>4.5 </td><td>80</td><td>600 &#177; 5</td></tr></table>
2ac220c14b53f14fd84b6575948274bd33f03bae3e87d8d45d42b91694f3425a.png
simple
<table><tr><td></td><td>Growth Medium</td><td>2,4-D (mg/L)</td><td>NAA (mg/L)</td><td>Kinetin (mg/L)</td></tr><tr><td>Alfalfa (<i>M. sativa </i>ssp. Varia A2)</td><td>MS</td><td>1</td><td>-</td><td>0.2</td></tr><tr><td>Arabidopsis (<i>A. thaliana </i>ecotype Columbia)</td><td>MS</td><td>-</td><td>0.5</td><td>0.05</td></tr><tr><td>Grape (<i>V. berlandieri </i>&#215; <i>V. rupestris </i>cv. 'Richter 110')</td><td>MS</td><td>-</td><td>1</td><td>0.2</td></tr><tr><td>Maize (<i>Z. mays</i>, cv. H1233)</td><td>N6 M (LP40)</td><td>0.5</td><td>-</td><td>-</td></tr><tr><td>Rice (<i>O. sativa </i>ssp. japonica cv. 'Unggi 9'</td><td>G1</td><td>1</td><td>-</td><td>-</td></tr><tr><td>Tobacco (<i>N. tabacum </i>cv. Petit Havana SR1)</td><td>MS</td><td>-</td><td>1</td><td>0.2</td></tr></table>
ae58a1e6a3b0b28595172071d93578afe06b9dcb57cf7d4c849bb00d68d7f860.png
complex
<table><tr><td></td><td></td><td></td><td colspan="4">Calculated peak sizes<sup>#</sup></td></tr><tr><td>Dye</td><td>Oligonucleotide</td><td>Fragment length</td><td>Mean</td><td>StdDev</td><td>Min</td><td>Max</td></tr><tr><td>TET</td><td>PRNP_154R</td><td>92 bp</td><td>89.16</td><td>0.12</td><td>88.91</td><td>89.70</td></tr><tr><td></td><td>PRNP_154H</td><td>96 bp</td><td>92.13</td><td>0.09</td><td>91.98</td><td>92.45</td></tr><tr><td></td><td>PRNP_171Q</td><td>146 bp</td><td>142.91</td><td>0.12</td><td>142.67</td><td>143.48</td></tr><tr><td></td><td>PRNP_171R</td><td>150 bp</td><td>148.05</td><td>0.18</td><td>146.72</td><td>148.42</td></tr><tr><td></td><td>PRNP_171H</td><td>154 bp</td><td>153.13</td><td>0.72</td><td>152.31</td><td>153.74</td></tr><tr><td>FAM</td><td>PRNP_154R</td><td>92 bp</td><td>89.56</td><td>0.13</td><td>89.36</td><td>89.84</td></tr><tr><td></td><td>PRNP_154H</td><td>96 bp</td><td>np</td><td>np</td><td>np</td><td>np</td></tr><tr><td></td><td>PRNP_171Q</td><td>146 bp</td><td>143.29</td><td>0.11</td><td>143.13</td><td>143.48</td></tr><tr><td></td><td>PRNP_171R</td><td>150 bp</td><td>np</td><td>np</td><td>np</td><td>np</td></tr><tr><td></td><td>PRNP_171H</td><td>154 bp</td><td>np</td><td>np</td><td>np</td><td>np</td></tr></table>
c0e567e6d1abb85437cc544d6f5740a1460db2801e19b08c1e733fd58221207f.png
simple
<table><tr><td> </td><td>Total cells</td><td>Eosinophils</td><td>Neutrophils</td><td>Lymphocytes</td><td>Macrophages</td></tr><tr><td>Control</td><td>8.91 &#177; 1.17</td><td>0.00 &#177; 0.00</td><td>0.05 &#177; 0.00</td><td>0.19 &#177; 0.01</td><td>8.37 &#177; 1.57</td></tr><tr><td>OVA</td><td>74.64 &#177; 12.60 *</td><td>9.08 &#177; 2.20 *</td><td>2.12 &#177; 0.52 *</td><td>4.51 &#177; 1.43 *</td><td>58.41 &#177; 10.05 *</td></tr><tr><td>OVA + OVA<sub>323-339</sub></td><td>63.64 &#177; 8.07 #</td><td>4.58 &#177; 0.86 #</td><td>1.03 &#177; 0.15</td><td>3.06 &#177; 0.52</td><td>55.59 &#177; 9.91</td></tr><tr><td>OVA + MAPs</td><td>43.32 &#177; 5.64 &#167;</td><td>1.02 &#177; 0.16 &#167;</td><td>0.92 &#177; 0.16</td><td>0.86 &#177; 0.11 &#167;</td><td>40.24 &#177; 6.29</td></tr></table>
0f7a1008558aca5c9f9d23df95d379cb46069644e4b6a5e422a3d289149e8eb7.png
complex
<table><tr><td colspan="7">Chromosome - RNA</td></tr><tr><td></td><td colspan="3">Positive</td><td colspan="3">Negative</td></tr><tr><td>Dataset</td><td>Overlap</td><td>Enrichment</td><td>p-value</td><td>Overlap</td><td>Enrichment</td><td>p-value</td></tr><tr><td>GO Process</td><td>238</td><td>1.50</td><td>2.76E-12</td><td>393</td><td>1.66</td><td>9.55E-29</td></tr><tr><td>SGD Phenotype</td><td>59</td><td>2.73</td><td>8.45E-12</td><td>135</td><td>4.19</td><td>9.35E-44</td></tr><tr><td>Positive Genetic</td><td>20</td><td>23.82</td><td>7.29E-21</td><td>3</td><td>2.39</td><td>0.13</td></tr><tr><td>Synthetic Sick</td><td>2</td><td>1.30</td><td>0.67</td><td>49</td><td>21.35</td><td>1.44E-46</td></tr><tr><td colspan="7">Chromosome - Signalling</td></tr><tr><td></td><td></td><td>Positive</td><td></td><td></td><td>Negative</td><td></td></tr><tr><td>Dataset</td><td>Overlap</td><td>Enrichment</td><td>p-value</td><td>Overlap</td><td>Enrichment</td><td>p-value</td></tr><tr><td>GO Process</td><td>56</td><td>1.39</td><td>5.98E-03</td><td>121</td><td>1.30</td><td>1.12E-03</td></tr><tr><td>SGD Phenotype</td><td>10</td><td>1.40</td><td>2.50E-01</td><td>67</td><td>4.07</td><td>2.13E-22</td></tr><tr><td>Positive Genetic</td><td>3</td><td>13.48</td><td>1.56E-03</td><td>2</td><td>3.90</td><td>0.09</td></tr><tr><td>Synthetic Sick</td><td>0</td><td>0.00</td><td>1.00</td><td>24</td><td>19.98</td><td>3.06E-23</td></tr><tr><td colspan="7">RNA - Signalling</td></tr><tr><td></td><td></td><td>Positive</td><td></td><td></td><td>Negative</td><td></td></tr><tr><td>Dataset</td><td>Overlap</td><td>Enrichment</td><td>p-value</td><td>Overlap</td><td>Enrichment</td><td>p-value</td></tr><tr><td>GO Process</td><td>65</td><td>2.03</td><td>5.97E-09</td><td>162</td><td>2.25</td><td>7.63E-26</td></tr><tr><td>SGD Phenotype</td><td>33</td><td>5.07</td><td>1.87E-14</td><td>88</td><td>6.02</td><td>7.13E-42</td></tr><tr><td>Positive Genetic</td><td>16</td><td>71.81</td><td>1.19E-24</td><td>2</td><td>4.00</td><td>0.09</td></tr><tr><td>Synthetic Sick</td><td>1</td><td>2.40</td><td>0.34</td><td>54</td><td>57.77</td><td>1.98E-74</td></tr></table>
4ed200c0bbf3a138cb05f489184a0451da345eb6258ad2bf748c6bfaa6418159.png
simple
<table><tr><td>Handle</td><td>Functionality</td><td>Comfort</td><td>Freedom of movement</td></tr><tr><td>Scissors handle A</td><td>4.4 &#177; 1.8</td><td>3.8 &#177; 1.7</td><td>4.1 &#177; 1.5</td></tr><tr><td>Scissors handle B</td><td>5.0 &#177; 1.4</td><td>4.6 &#177; 1.4</td><td>4.9 &#177; 1.3</td></tr><tr><td>In-line handle</td><td>4.0 &#177; 1.6</td><td>4.6 &#177; 1.5</td><td>4.7 &#177; 1.6</td></tr><tr><td>Pistol grip A</td><td>5.3 &#177; 1.4</td><td>5.3 &#177; 1.4</td><td>5.0 &#177; 1.3</td></tr><tr><td>Pistol grip B</td><td>4.5 &#177; 1.8</td><td>4.6 &#177; 1.7</td><td>4.4 + 1.6</td></tr></table>
ad7aef8e0563c219e28462689a962a5f982480a10e20b37f6a3a0aa66e48e4a1.png
simple
<table><tr><td>Variation</td><td>Purpose of the variation and ideas for the debriefing discussions</td></tr><tr><td>Include observers.</td><td>&#8226; Include an outside view on the processes during the conduct into the debriefing. What does such an outside view contribute to the analysis of the conduct of <i>Hand-it-on</i>?&#8226; Prepare participants for the observer role during scenarios and debriefings. What is helpful feedback to colleagues after a simulation scenario?</td></tr><tr><td>Vary the objects.</td><td>&#8226; Use objects where there is something at stake for those who handle them. When handling a full glass of water there is a different &#8220;risk&#8221; for the person handling the water than when handing on a pen. Where are own risks during the care for patients? How do they impact the actions of those involved?&#8226; Use objects that are difficult to manipulate (e.g., a thin thread). They can be used to focus on technical skills and psychomotoric challenges in combination with keeping an overview of parallel tasks. How does the requirement to concentrate on handling this object impact the overview of the situation?</td></tr><tr><td>Vary the direction in which the objects should be passed and/or include more tasks.</td><td>&#8226; This variation can challenge improvement plans between two rounds of <i>Hand-it-on</i>. How are the intentions to implement changes (work as imagined) impacted by the practicalities of the work system (work as done)?&#8226; Discuss the impact of work procedures and personal preferences on their implementation. How do changes in procedures impact the patient care?</td></tr><tr><td>Separate one or more participants while giving the details of the instruction. Let the first few rounds run without them and include those participants only then.</td><td>&#8226; Discuss the integration of new colleagues into a department. How are they introduced to the tasks they are supposed to do? How are they welcomed on a social and emotional level? What influences their integration (think about time pressure, work-load, or structured introduction programs)? Are there differences in the introduction between the two departments in the variation for large groups (See Fig. 1b)?&#8226; Discuss the importance of knowing about the history of discussions in a department. How do people understand a situation if they know only parts of its development and did not have any prior practice of the task?&#8226; Discuss working with people who might not have been part of forming the current routines, norms, values and beliefs. How does the shared understanding of those impact the task and social level? How does it feel to accept the features of the work system if you were not a part in forming them?</td></tr><tr><td>Include &#8220;hidden&#8221; instructions for briefed role players. You could ask them to frequently &#8220;drop&#8221; objects or to not concentrate on the process, causing delays. Remember to reveal the hidden instructions during the debriefing to protect your role player. They would not like to come across as &#8220;obstructive&#8221; or &#8220;unable&#8221; in reality.</td><td>&#8226; Discuss how the group reacted to such a &#8220;low&#8221; performer. How can a work team or an organization deal with a worker who does not perform to standards? How would a team identify such a person in the first place? What would impact the reaction to such a worker? Is there a difference in how you treat people who you like vs. those you do not get along with? How does it feel to observe this person? How does it feel to be this person? What do patients think about the low performer?</td></tr><tr><td>Include &#8220;stressors&#8221; such as loud music, noise, or the threat of moving the organization to a different country.</td><td>&#8226; Discuss the impact of such disturbances and ask participants to draw connections to real life. How do different operation room settings with their lighting, temperature or noise conditions impact performance?&#8226; Explore the differences in the experience and in handling of such stressors between the individuals involved. Who is disturbed by such external factors, who can deal with them easily? What are the coping strategies?</td></tr></table>
6200422a6817f09391dcb4f437ffa6adaaf243631a4bb09ae3b863d0893be53f.png
simple
<table><tr><td></td><td>PG group</td><td>Control group</td><td>95% CI</td><td>p-value</td></tr><tr><td>Wound closure )</td><td>n = 32</td><td>n = 41</td><td></td><td></td></tr><tr><td> Second day postoperatively</td><td>0</td><td>0</td><td></td><td>&#8211;</td></tr><tr><td> Third day postoperatively</td><td>7</td><td>6</td><td>7% (&#8211;11% to 25%)</td><td>0.5</td></tr><tr><td> Fourth day postoperatively</td><td>7</td><td>13</td><td>&#8211;9% (&#8211;30% to 10%)</td><td>0.4</td></tr><tr><td>Wound closure</td><td>n = 36</td><td>n = 46</td><td></td><td></td></tr><tr><td> 2 weeks postoperatively</td><td>4</td><td>16</td><td>&#8211;24% (&#8211;41% to 7%)</td><td>0.02</td></tr><tr><td>Drop in Hb, mean (SD)</td><td>n = 50</td><td>n = 52</td><td></td><td></td></tr><tr><td> mmol/L</td><td>&#8211;1.58 (0.63)</td><td>&#8211;1.75 (0.58)</td><td>0.16 (&#8211;0.07 to 0.4)</td><td>0.2</td></tr><tr><td>Pain at rest, median (range)</td><td>n = 50</td><td>n = 52</td><td></td><td></td></tr><tr><td> At inclusion</td><td>3 (1&#8211;5)</td><td>3 (1&#8211;5)</td><td></td><td>0.8</td></tr><tr><td> 6 weeks</td><td>2 (1&#8211;5)</td><td>2 (1&#8211;5)</td><td></td><td>0.08</td></tr><tr><td> 3 months</td><td>2 (1&#8211;5)</td><td>2 (1&#8211;5)</td><td></td><td>0.8</td></tr><tr><td>Pain during walking, median (range)</td><td>n = 50</td><td>n = 52</td><td></td><td></td></tr><tr><td> At inclusion</td><td>4 (1&#8211;5)</td><td>4 (1&#8211;5)</td><td></td><td>0.4</td></tr><tr><td> 6 weeks</td><td>2 (1&#8211;5)</td><td>2 (1&#8211;5)</td><td></td><td>0.07</td></tr><tr><td> 3 months</td><td>2 (1&#8211;5)</td><td>2 (1&#8211;5)</td><td></td><td>0.9</td></tr><tr><td>Use of pain medication, median (range)</td><td>n = 50</td><td>n = 52</td><td></td><td></td></tr><tr><td> At inclusion</td><td>2 (1&#8211;5)</td><td>2 (1&#8211;5)</td><td></td><td>0.5</td></tr><tr><td> 6 weeks</td><td>2 (1&#8211;5)</td><td>2 (1&#8211;5)</td><td></td><td>0.9</td></tr><tr><td> 3 months</td><td>2 (1&#8211;5)</td><td>2 (1&#8211;5)</td><td></td><td>0.1</td></tr><tr><td>WOMAC score, mean (range)</td><td>n = 50</td><td>n = 52</td><td></td><td></td></tr><tr><td> At inclusion</td><td>45 (8&#8211;76)</td><td>44 (14&#8211;74)</td><td></td><td></td></tr><tr><td> 6 weeks</td><td>26 (3&#8211;76)</td><td>24 (0&#8211;65)</td><td>0 (&#8211;8 to 8)</td><td>0.7</td></tr><tr><td> 3 months</td><td>25 (0&#8211;76)</td><td>21 (0&#8211;66)</td><td>&#8211;3 (&#8211;6 to 1)</td><td>0.4</td></tr><tr><td>ROM, mean (SD)</td><td>n = 32</td><td>n = 36</td><td></td><td></td></tr><tr><td> Second day postoperatively</td><td>53 (14)</td><td>50 (17)</td><td></td><td></td></tr><tr><td> Third day postoperatively</td><td>68 (13)</td><td>65 (16)</td><td></td><td></td></tr><tr><td> Fourth day postoperatively</td><td>72 (13)</td><td>73 (14)</td><td></td><td>0.7</td></tr><tr><td>ROM, mean (SD)</td><td>n = 34</td><td>n = 45</td><td></td><td></td></tr><tr><td> 2 weeks postoperatively</td><td>91 (13)</td><td>89 (13)</td><td></td><td></td></tr><tr><td> 6 weeks postoperatively</td><td>99 (11)</td><td>100 (13)</td><td></td><td></td></tr><tr><td> 3 months postoperatively</td><td>102 (12)</td><td>101 (12)</td><td></td><td>0.9</td></tr></table>
80010ddd6c07c8cadc44ec90a65301610836c7e601615411cb65181715e5b113.png
complex
<table><tr><td></td><td colspan="8">CLSI Guidelines</td><td colspan="8">EUCAST Guidelines</td></tr><tr><td></td><td>Disk content (&#956;g)</td><td>2006</td><td>2007</td><td>2008</td><td colspan="2">2010</td><td>2011</td><td>2012</td><td>Disk content (&#956;g)</td><td colspan="4">2013</td><td colspan="3">2014</td></tr><tr><td></td><td></td><td>11/8</td><td>23/8</td><td>6/8</td><td>5/5</td><td>14/12</td><td>22/4</td><td>10/4</td><td></td><td>26/3</td><td>6/6</td><td>30/9</td><td>20/12</td><td>23/1</td><td>23/1<sup>a</sup></td><td>11/9<sup>a</sup></td></tr><tr><td>Drug</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Ofloxacin</td><td>5</td><td>S</td><td>S</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>0</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td></tr><tr><td> Pipercillin/ Tazobactum</td><td>100/10</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>36</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td> Ceftazidime</td><td>30</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>10</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td></tr><tr><td> Tobramycin</td><td>10</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>10</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td></tr><tr><td> Ciprofloxacin</td><td>5</td><td>NT</td><td>S</td><td>NT</td><td>S</td><td>S</td><td>S</td><td>S</td><td>5</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td></tr><tr><td> Amikacin</td><td>30</td><td>NT</td><td>S</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>30</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td></tr><tr><td> Aztreoman</td><td>30</td><td>NT</td><td>S</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>S</td><td>30</td><td>S</td><td>I</td><td>I</td><td>I</td><td>I</td><td>I</td><td>I</td></tr><tr><td> Colistin (E-Test)</td><td>10</td><td>NT</td><td>S</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>10</td><td>NT</td><td>NT</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td></tr><tr><td> Imipenem</td><td>10</td><td>NT</td><td>S</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>10</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td></tr><tr><td> Meropenem</td><td>10</td><td>NT</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>10</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td></tr></table>
5be539c09c397c20589ce96563f111e6a2e6f87129ebfbca221d0d8dce004d9e.png
simple
<table><tr><td>Enterobacteria phage</td><td>Accession no.</td><td>Genome size (bp)</td><td>Coverage (&#215;)</td><td>No. of CDSs<sup><i>a</i></sup></td><td>No. of tRNAs</td></tr><tr><td>RB3</td><td>KM606994</td><td>168,402</td><td>2,831</td><td>273</td><td>10</td></tr><tr><td>RB5</td><td>KM606995</td><td>168,394</td><td>3,449</td><td>271</td><td>10</td></tr><tr><td>RB6</td><td>KM606996</td><td>168,394</td><td>1,474</td><td>271</td><td>10</td></tr><tr><td>RB7</td><td>KM606997</td><td>168,395</td><td>6,985</td><td>272</td><td>10</td></tr><tr><td>RB9</td><td>KM606998</td><td>168,395</td><td>2,826</td><td>272</td><td>10</td></tr><tr><td>RB10</td><td>KM606999</td><td>168,401</td><td>2,798</td><td>272</td><td>10</td></tr><tr><td>RB27</td><td>KM607000</td><td>165,179</td><td>2,966</td><td>271</td><td>10</td></tr><tr><td>RB33</td><td>KM607001</td><td>166,007</td><td>3,355</td><td>274</td><td>8</td></tr><tr><td>RB55</td><td>KM607002</td><td>168,896</td><td>259</td><td>272</td><td>8</td></tr><tr><td>RB59</td><td>KM607003</td><td>168,966</td><td>3,158</td><td>276</td><td>8</td></tr><tr><td>RB68</td><td>KM607004</td><td>168,401</td><td>3,187</td><td>276</td><td>9</td></tr></table>
21cdec7d7620d4b16970bbf079a5a8f8382126e92b7e2f19154c9a40af9a94b5.png
simple
<table><tr><td>Case</td><td>Constant Error (m/s)</td><td>Amplitude of White Noise </td></tr><tr><td>Case1</td><td>0</td><td>0</td></tr><tr><td>Case2</td><td>1</td><td>0</td></tr><tr><td>Case3</td><td>0</td><td>0.1</td></tr><tr><td>Case4</td><td>1</td><td>0.1</td></tr></table>
77cd1c5adc834d563169f60b306991aa9a51ce7a7a6bd5203941e8217b5e94c9.png
simple
<table><tr><td>Medium(dielectric constant)</td><td>Dipole Moment (D)</td></tr><tr><td>Gas</td><td>2.98</td></tr><tr><td>Water (78.3)</td><td>5.13</td></tr><tr><td>DMSO (46.8)</td><td>4.50</td></tr><tr><td>Acetonitrile (35.7)</td><td>4.53</td></tr><tr><td>n-Octanol (9.9)</td><td>4.54</td></tr><tr><td>Chloroform (4.7)</td><td>3.96</td></tr><tr><td>Carbon tetrachloride (2.2)</td><td>3.46</td></tr></table>
5bcbd58cc6622a5e0a7053dc43950f1633b4a34cb1dd0c253bee0c15bffe081a.png
simple
<table><tr><td>Tumor type</td><td>Site of sample collection <sup>a</sup></td><td>Metastatic disease </td><td>Ki67 index, %</td></tr><tr><td>Ileal carcinoid</td><td>Retro-peritoneal LN (m)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>Ileal carcinoid</td><td>Ileum (p)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>Ileal carcinoid</td><td>Ileum (p)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>Ileal carcinoid</td><td>Ileum (p)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>Ileal carcinoid</td><td>Ovary (m)</td><td>Yes</td><td>40</td></tr><tr><td>Ileal carcinoid</td><td>Retro-peritoneal LN (m)</td><td>Yes</td><td>5</td></tr><tr><td>Ileal carcinoid</td><td>Ileum (p)</td><td>No</td><td>&lt;2</td></tr><tr><td>Ileal carcinoid</td><td>Muscle (m)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>Ileal carcinoid</td><td>Ileum (p)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>Ileal carcinoid</td><td>Ileum (p)</td><td>No</td><td>&lt;2</td></tr><tr><td>Ileal carcinoid</td><td>Ileum (p)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>N-F pancreatic NET</td><td>Pancreas (p)</td><td>No</td><td>&lt;2</td></tr><tr><td>N-F pancreatic NET</td><td>Pancreas (p)</td><td>No</td><td>5</td></tr><tr><td>Functioning pancreatico-duodenal NETs</td><td></td><td></td><td></td></tr><tr><td><i>Gastrinoma</i></td><td>Retro-peritoneal LN (m)</td><td>Yes</td><td>5</td></tr><tr><td><i>Glucagonoma</i></td><td>Retro-peritoneal LN (m)</td><td>Yes</td><td>&lt;2</td></tr><tr><td><i>Glucagonoma</i></td><td>pancreas (p)</td><td>Yes</td><td>5</td></tr><tr><td><i>Glucagonoma</i></td><td>Pancreas (p)</td><td>Yes</td><td>50</td></tr><tr><td><i>Glucagonoma/Somatostatinoma</i></td><td>Pancreas (p)</td><td>No</td><td>&lt;2</td></tr><tr><td><i>Somatostatinoma</i></td><td>Pancreas (p)</td><td>Yes</td><td>&lt;2</td></tr><tr><td><i>Somatostatinoma</i></td><td>Papilla Vatery (p)</td><td>No</td><td>&lt;2</td></tr><tr><td>Pheochromocytoma</td><td>Adrenal medulla (p)</td><td>No</td><td>&lt;2</td></tr><tr><td>Pheochromocytoma</td><td>Adrenal medulla (p)</td><td></td><td>&lt;2</td></tr><tr><td>Pheochromocytoma</td><td>Adrenal medulla (m)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>Pheochromocytoma</td><td>Adrenal medulla (p)</td><td>No</td><td>10</td></tr><tr><td>Pheochromocytoma</td><td>Adrenal medulla (p)</td><td></td><td>&lt;2</td></tr><tr><td>Pheochromocytoma</td><td>Adrenal medulla (p)</td><td>Yes</td><td>5</td></tr><tr><td>Pheochromocytoma</td><td>Adrenal medulla (p)</td><td>No</td><td>&lt;2</td></tr><tr><td>Pheochromocytoma</td><td>Adrenal medulla (p)</td><td>No</td><td>25</td></tr><tr><td>Paraganglioma</td><td>Retroperitoneum (p)</td><td>No</td><td>&lt;2</td></tr><tr><td>NE colon carcinoma</td><td>Colon (p)</td><td>Yes</td><td>50</td></tr><tr><td>NE colon carcinoma</td><td>Colon (p)</td><td>Yes</td><td>85</td></tr><tr><td>NE colon carcinoma</td><td>Colon (p)</td><td>Yes</td><td>&lt;2</td></tr><tr><td>NE colon carcinoma</td><td>Liver (m)</td><td>Yes</td><td>5</td></tr><tr><td>Gastric NET, type 3</td><td>Corpus (p)</td><td>No</td><td>5</td></tr></table>
ab89f7acdfdaee7b9f2915f1b855d56e94666be471e4f618a740ea1a3dffdb9f.png
simple
<table><tr><td>Variable</td><td>Group</td><td>N</td><td>%</td></tr><tr><td>Aeitiology</td><td>HSV<sup>a</sup></td><td>38</td><td>18.18</td></tr><tr><td></td><td>ADEM<sup>b</sup></td><td>23</td><td>11</td></tr><tr><td></td><td>VZV<sup>c</sup></td><td>12</td><td>5.74</td></tr><tr><td></td><td>MTB<sup>d</sup></td><td>10</td><td>4.78</td></tr><tr><td></td><td>ANT<sup>e</sup></td><td>8</td><td>3.83</td></tr><tr><td></td><td>Other</td><td>34</td><td>16.27</td></tr><tr><td></td><td> Viral</td><td>22</td><td>10.53</td></tr><tr><td></td><td> Bacterial</td><td>12</td><td>5.74</td></tr><tr><td></td><td>Unknown</td><td>84</td><td>40.19</td></tr><tr><td>Gender</td><td>Male</td><td>114</td><td>54.54</td></tr><tr><td>Age: Categorical</td><td>Age &#8804; 10</td><td>55</td><td>26.32</td></tr><tr><td></td><td>10 &lt; Age &#8804;35</td><td>55</td><td>26.32</td></tr><tr><td></td><td>35 &lt; Age &#8804;55</td><td>42</td><td>20.1</td></tr><tr><td></td><td>Age &gt;55</td><td>50</td><td>23.92</td></tr><tr><td>Age: Continuous</td><td>33.29 &#177; 25.64 (0,87)*</td><td></td><td></td></tr><tr><td>Region</td><td>South West</td><td>17</td><td>8.13</td></tr><tr><td></td><td>London</td><td>86</td><td>41.15</td></tr><tr><td></td><td>North West</td><td>106</td><td>50.72</td></tr><tr><td>Duration of illness</td><td>58.88 &#177; 71.39 (3,535)*</td><td></td><td></td></tr><tr><td>Length of stay**</td><td>49.01 &#177; 67.01(2,521)*</td><td></td><td></td></tr></table>
259143eb3d3fd163f37f42f4f08f30ca826384db30792bef41b483246759c0b3.png
simple
<table><tr><td>Gene ID</td><td>Illumina sequencing</td><td>QRT-PCR</td><td>KO description</td></tr><tr><td>comp139796_c2</td><td>&#8722;53.83<sup>a</sup></td><td>&#8722;138.82</td><td>chalcone synthase</td></tr><tr><td>comp78650_c0</td><td>&#8722;26.86</td><td>&#8722;80.31</td><td>flavonol synthase</td></tr><tr><td>comp129681_c0</td><td>&#8722;3.78</td><td>&#8722;9.73</td><td>hydroxymethyl glutaryl CoA synthase</td></tr><tr><td>comp106407_c0</td><td>&#8722;10.00</td><td>&#8722;25.62</td><td>3-hydroxy-3-methylglutaryl-coenzyme A reductase</td></tr><tr><td>comp140511_c0</td><td>&#8722;3.30</td><td>&#8722;5.73</td><td>Dammarenediol-II synthase</td></tr><tr><td>comp126977_c0</td><td>&#8722;6.04</td><td>&#8722;4.79</td><td>glycosyltransferase</td></tr><tr><td>comp141084_c0</td><td>&#8722;2.13</td><td>&#8722;6.34</td><td>glycosyltransferase</td></tr><tr><td>comp140248_c0</td><td>6.98<sup>b</sup></td><td>19.41</td><td>glutathione S-transferase</td></tr><tr><td>comp117631_c0</td><td>8.19</td><td>25.85</td><td>glutathione S-transferase</td></tr><tr><td>comp128853_c0</td><td>2.05</td><td>63.56</td><td>myb proto-oncogene protein, plant</td></tr><tr><td>comp128641_c0</td><td>2.32</td><td>2.17</td><td>myb proto-oncogene protein, plant</td></tr><tr><td>comp66279_c0</td><td>3.55</td><td>2.63</td><td>myb proto-oncogene protein, plant</td></tr><tr><td>comp128496_c0</td><td>5.93</td><td>8.83</td><td>myb proto-oncogene protein, plant</td></tr><tr><td>comp77739_c0</td><td>8.52</td><td>8.26</td><td>myb proto-oncogene protein, plant</td></tr><tr><td>comp109390_c0</td><td>6.71</td><td>5.20</td><td>heat shock transcription factor, other eukaryote</td></tr><tr><td>comp141438_c1</td><td>5.22</td><td>9.27</td><td>heat shock 90 kDa protein</td></tr><tr><td>comp142366_c1</td><td>6.33</td><td>4.68</td><td>heat shock 70 kDa protein</td></tr><tr><td>comp141020_c0</td><td>7.02</td><td>21.39</td><td>heat shock 70 kDa protein</td></tr><tr><td>comp134360_c1</td><td>12.85</td><td>9.71</td><td>heat shock 70 kDa protein</td></tr><tr><td>comp134360_c0</td><td>13.58</td><td>20.37</td><td>heat shock 70 kDa protein</td></tr></table>
7a578efb0a61bb078147945ba42e28379c92e01531e74417cb6daf9d3296edd7.png
complex
<table><tr><td rowspan="2">Compound</td><td colspan="5">IC<sub>50</sub> (&#956;M)</td></tr><tr><td>HL-60</td><td>SMMC-7721</td><td>A-549</td><td>MCF-7</td><td>SW480</td></tr><tr><td>2</td><td>&gt;40</td><td>&gt;40</td><td>&gt;40</td><td>&gt;40</td><td>&gt;40</td></tr><tr><td>3</td><td>17.6</td><td>20.8</td><td>24.1</td><td>23.0</td><td>&gt;40</td></tr><tr><td>4</td><td>&gt;40</td><td>35.9</td><td>17.4</td><td>&gt;40</td><td>&gt;40</td></tr><tr><td>5</td><td>15.2</td><td>18.6</td><td>21.2</td><td>17.1</td><td>12.8</td></tr><tr><td>6</td><td>17.6</td><td>18.6</td><td>17.2</td><td>21.4</td><td>30.1</td></tr><tr><td>7</td><td>16.0</td><td>29.3</td><td>23.1</td><td>16.9</td><td>11.8</td></tr><tr><td>8</td><td>18.4</td><td>&gt;40</td><td>30.6</td><td>21.6</td><td>34.2</td></tr><tr><td>DDP <sup>a</sup></td><td>3.1</td><td>10.2</td><td>9.1</td><td>17.5</td><td>12.0</td></tr></table>
9ff1834a12a845521e4e2cd6065948fd5784b7057087de882eb68da434fb60d6.png
simple
<table><tr><td></td><td>arabinose</td><td>galactose</td><td>glucose</td><td>xylose</td><td>mannose</td><td>sucrose</td></tr><tr><td>sugar maple</td><td>not detected</td><td>not detected</td><td>1231</td><td>not detected</td><td>not detected</td><td>not detected</td></tr><tr><td>aspen</td><td>13.4</td><td>0.6</td><td>1.4</td><td>3.5</td><td>2.5</td><td>0.98</td></tr><tr><td>spalted aspen</td><td>not detected</td><td>3.3</td><td>10.1</td><td>15.8</td><td>12.6</td><td>12.1</td></tr><tr><td>tree of heaven</td><td>29.2</td><td>110</td><td>133.5</td><td>14.2</td><td>not detected</td><td>1.9</td></tr></table>
e775f9e63706db7f981282613177f0a1437ffb3abd1be9d42b4e1330ee30d214.png
simple
<table><tr><td>Site</td><td>Latitude</td><td>Longitude</td><td>Elevation(m)</td><td>Land Cover</td><td>Site Size</td></tr><tr><td>Dayekou</td><td>38.5337&#176;N</td><td>100.2502&#176;E</td><td>2835.2</td><td>Coniferous Forest</td><td>2 km &#215; 2 km</td></tr><tr><td>Yingke</td><td>38.8571&#176;N</td><td>100.4103&#176;E</td><td>1519.1</td><td>Cropland (corn)</td><td>2 km &#215; 2 km</td></tr><tr><td>Hulunber</td><td>49.3533&#176;N</td><td>120.1246&#176;E</td><td>650</td><td>Meadow steppe</td><td>3 km &#215; 3 km</td></tr><tr><td>Jingyuetan</td><td>44.1172&#176;N</td><td>125.3615&#176;E</td><td>190</td><td>Cropland (corn)</td><td>3 km &#215; 3 km</td></tr></table>
e32a9c962a3513bee7948e8279f344739030013db0d88ea23d31378130567a9d.png
simple
<table><tr><td><i>ROI</i></td><td><i>Cohen&#8217;s</i> d</td><td><i>s.e.</i></td><td>P<i>-value</i></td><td>I<sup><i>2</i></sup></td><td>N <i>voxels</i></td></tr><tr><td>Average FA</td><td>&#8722;0.42</td><td>0.042</td><td>4.5 &#215; 10<sup>&#8722;24</sup></td><td>34.65</td><td>112 889</td></tr><tr><td>ACR</td><td>&#8722;0.40</td><td>0.045</td><td>9.19 &#215; 10<sup>&#8722;19</sup></td><td>43.83</td><td>3129</td></tr><tr><td>CC</td><td>&#8722;0.40</td><td>0.045</td><td>8.36 &#215; 10<sup>&#8722;19</sup></td><td>42.51</td><td>7318</td></tr><tr><td>BCC</td><td>&#8722;0.39</td><td>0.045</td><td>2.51 &#215; 10<sup>&#8722;18</sup></td><td>43.24</td><td>3173</td></tr><tr><td>GCC</td><td>&#8722;0.37</td><td>0.042</td><td>1.24 &#215; 10<sup>&#8722;18</sup></td><td>35.22</td><td>1834</td></tr><tr><td>ALIC</td><td>&#8722;0.37</td><td>0.046</td><td>2.27 &#215; 10<sup>&#8722;15</sup></td><td>46.30</td><td>1510</td></tr><tr><td>CR</td><td>&#8722;0.33</td><td>0.040</td><td>3.16 &#215; 10<sup>&#8722;17</sup></td><td>27.89</td><td>7344</td></tr><tr><td>FXST</td><td>&#8722;0.32</td><td>0.042</td><td>8.28 &#215; 10<sup>&#8722;14</sup></td><td>36.39</td><td>706</td></tr><tr><td>FX</td><td>&#8722;0.31</td><td>0.045</td><td>6.76 &#215; 10<sup>&#8722;12</sup></td><td>43.25</td><td>222</td></tr><tr><td>PTR</td><td>&#8722;0.31</td><td>0.035</td><td>1.99 &#215; 10<sup>&#8722;18</sup></td><td>11.78</td><td>1987</td></tr><tr><td>SS</td><td>&#8722;0.30</td><td>0.040</td><td>4.91 &#215; 10<sup>&#8722;14</sup></td><td>30.34</td><td>1294</td></tr><tr><td>SFO</td><td>&#8722;0.29</td><td>0.054</td><td>3.96 &#215; 10<sup>&#8722;8</sup></td><td>59.68</td><td>193</td></tr><tr><td>CGC</td><td>&#8722;0.27</td><td>0.045</td><td>2.95 &#215; 10<sup>&#8722;9</sup></td><td>42.87</td><td>594</td></tr><tr><td>PCR</td><td>&#8722;0.25</td><td>0.036</td><td>2.39 &#215; 10<sup>&#8722;12</sup></td><td>15.76</td><td>1437</td></tr><tr><td>SCC</td><td>&#8722;0.22</td><td>0.048</td><td>4.39 &#215; 10<sup>&#8722;6</sup></td><td>50.94</td><td>2311</td></tr><tr><td>SLF</td><td>&#8722;0.22</td><td>0.040</td><td>5.61 &#215; 10<sup>&#8722;8</sup></td><td>29.17</td><td>3503</td></tr><tr><td>EC</td><td>&#8722;0.21</td><td>0.040</td><td>1.41 &#215; 10<sup>&#8722;7</sup></td><td>31.01</td><td>2896</td></tr><tr><td>IC</td><td>&#8722;0.18</td><td>0.042</td><td>1.80 &#215; 10<sup>&#8722;5</sup></td><td>36.25</td><td>4781</td></tr><tr><td>UNC</td><td>&#8722;0.16</td><td>0.033</td><td>8.78 &#215; 10<sup>&#8722;6</sup></td><td>4.18</td><td>125</td></tr><tr><td>SCR</td><td>&#8722;0.15</td><td>0.034</td><td>6.91 &#215; 10<sup>&#8722;6</sup></td><td>7.84</td><td>2778</td></tr><tr><td>RLIC</td><td>&#8722;0.13</td><td>0.041</td><td>0.0021</td><td>33.10</td><td>1496</td></tr><tr><td>IFO</td><td>&#8722;0.11</td><td>0.038</td><td>0.0035</td><td>22.70</td><td>88</td></tr><tr><td>CGH</td><td>&#8722;0.11</td><td>0.041</td><td>0.0082</td><td>33.73</td><td>524</td></tr><tr><td>CST</td><td>&#8722;0.04</td><td>0.038</td><td>0.24</td><td>24.20</td><td>167</td></tr><tr><td>PLIC</td><td>0.04</td><td>0.046</td><td>0.37</td><td>46.20</td><td>1775</td></tr></table>
cb87d8b8dd29947d784d4105e82f2e659e0f2cea22274822dd3c2ca953b816fe.png
complex
<table><tr><td rowspan="2"></td><td colspan="4">24-h group</td><td colspan="4">7-d group</td><td colspan="4">Re-exposure group</td></tr><tr><td>AMS<sup>+</sup><i>(n</i> = 190)</td><td>AMS<sup>-</sup><i>(n</i> = 71)</td><td><i>t</i></td><td><i>P</i></td><td>AMS<sup>+</sup> ( <i>n</i> = 26)</td><td>AMS<sup>-</sup>( <i>n</i> = 73)</td><td><i>t</i></td><td><i>P</i></td><td>AMS<sup>+</sup> ( <i>n</i> = 48)</td><td>AMS<sup>-</sup>( <i>n</i> = 46)</td><td><i>t</i></td><td><i>P</i></td></tr><tr><td>[Hb] (g/L)</td><td>145.77 &#177; 12.04</td><td>146.55 &#177; 15.24</td><td>-0.432</td><td>0.666</td><td>175.38 &#177; 10.82</td><td>169.33 &#177; 11.77</td><td>2.299</td><td>0.024<sup>*</sup></td><td>187.06 &#177; 12.69</td><td>183.46 &#177; 9.99</td><td>-1.527</td><td>0.130</td></tr><tr><td>RBC (10<sup>12</sup>)</td><td>4.57 &#177; 0.39</td><td>4.62 &#177; 0.40</td><td>-0.990</td><td>0.323</td><td>5.23 &#177; 0.35</td><td>5.12 &#177; 0.41</td><td>1.225</td><td>0.223</td><td>5.81 &#177; 0.72</td><td>5.62 &#177; 0.45</td><td>-1.519</td><td>0.132</td></tr><tr><td>HCT (L/L)</td><td>41.29 &#177; 3.08</td><td>41.48 &#177; 3.83</td><td>-0.398</td><td>0.691</td><td>47.91 &#177; 2.69</td><td>46.24 &#177; 3.15</td><td>2.419</td><td>0.017<sup>*</sup></td><td>54.34 &#177; 6.93</td><td>52.72 &#177; 4.36</td><td>-1.358</td><td>0.178</td></tr><tr><td>MCV (fl)</td><td>90.77 &#177; 5.48</td><td>89.58 &#177; 8.49</td><td>1.331</td><td>0.184</td><td>91.87 &#177; 2.81</td><td>90.71 &#177; 5.21</td><td>1.085</td><td>0.281</td><td>93.64 &#177; 4.30</td><td>93.86 &#177; 3.66</td><td>0.268</td><td>0.789</td></tr><tr><td>MCH (pg)</td><td>31.96 &#177; 2.19</td><td>31.70 &#177; 2.59</td><td>0.797</td><td>0.426</td><td>33.54 &#177; 1.23</td><td>33.16 &#177; 2.36</td><td>0.777</td><td>0.439</td><td>32.39 &#177; 2.66</td><td>32.69 &#177; 2.11</td><td>0.600</td><td>0.550</td></tr><tr><td>MCHC (g/L)</td><td>352.34 &#177; 7.60</td><td>352.51 &#177; 9.48</td><td>-0.144</td><td>0.886</td><td>365.50 &#177; 5.53</td><td>365.86 &#177; 10.79</td><td>-0.164</td><td>0.870</td><td>346.52 &#177; 25.32</td><td>348.78 &#177; 19.57</td><td>0.483</td><td>0.630</td></tr></table>
9535affd09077cbeb5bd826304b361a8284776624d84104e9f52a1c241331b9c.png
simple
<table><tr><td>Diagnosis</td><td>All patients (n)</td><td>RF+(n)</td><td>Patients with early disease (&lt;12 months) (n)</td><td>RF+(n)</td></tr><tr><td>Rheumatoid arthritis</td><td>160</td><td>129</td><td>52</td><td>39</td></tr><tr><td>Undifferentiated monoarhtritis</td><td>13</td><td>4/11<sup>a</sup></td><td>8<sup>b</sup></td><td>2/6<sup>a</sup></td></tr><tr><td>Undifferentiated oligoarthritis</td><td>9</td><td>2</td><td>4<sup>b</sup></td><td>1</td></tr><tr><td>Undifferentiated polyarthritis</td><td>7</td><td>2</td><td>5<sup>c</sup></td><td>1</td></tr><tr><td>Juvenile idiopathic arthritis</td><td>9</td><td>4</td><td>0</td><td>0</td></tr><tr><td>Adult Still's disease</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Undifferentiated spondylarthritis</td><td>4</td><td>0</td><td>2</td><td>0</td></tr><tr><td>Psoriatic arthritis</td><td>12</td><td>0</td><td>2</td><td>0</td></tr><tr><td>Ankylosing spondylitis</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Ulcerative colitis</td><td>2</td><td>0/1<sup>d</sup></td><td>1</td><td>0</td></tr><tr><td>Undifferentiated systemic inflammatory disease with arthritis</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Systemic lupus erythematosus</td><td>3</td><td>0</td><td>1</td><td>0</td></tr><tr><td>Cutaneous PAN with arthritis</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Osteoarthritis</td><td>4</td><td>4</td><td>1</td><td>1</td></tr><tr><td>Healthy individuals</td><td>10</td><td>ND</td><td>NA</td><td>NA</td></tr><tr><td>Sum</td><td>237</td><td>141</td><td>76</td><td>42</td></tr></table>
0d9eeed09c4a4dbccdc3cf6367031232eb85d410c1b11d18970a73f262835335.png
complex
<table><tr><td colspan="2">Bacterial Luciferase (Lux)</td><td colspan="2">Green Fluorescent Protein (GFP)</td></tr><tr><td><i>V. fischeri</i></td><td>[16]</td><td><i>E. coli</i></td><td>[17]</td></tr><tr><td>Various toxins</td><td></td><td>Various toxins</td><td></td></tr><tr><td>Bacteriophage</td><td>[18]</td><td><i>E. coli</i></td><td>[19]</td></tr><tr><td>Pathogenic Bacteria</td><td></td><td>L-arabinose</td><td></td></tr><tr><td><i>Saccharomyces cerevisiae</i></td><td>[20]</td><td>Yeast</td><td>[21]</td></tr><tr><td>Androgenic compounds</td><td></td><td>DNA damage</td><td></td></tr><tr><td><i>E. coli</i></td><td>[22]</td><td><i>E. coli</i></td><td>[23]</td></tr><tr><td>Nalidixic Acid</td><td></td><td>Arsenic</td><td></td></tr><tr><td><i>E. coli</i></td><td>[24]</td><td><i>Bacillus</i> sp.</td><td>[14]</td></tr><tr><td>Various stressors</td><td></td><td>Arsenic/Zinc</td><td></td></tr><tr><td>HEK293 mammalian cell line</td><td>[25]</td><td>Firefly Luciferase (Luc)</td><td></td></tr><tr><td>Whole animal imaging</td><td></td><td><i>E. coli</i></td><td>[26]</td></tr><tr><td></td><td></td><td>Gene expression</td><td></td></tr><tr><td><i>E. coli</i></td><td>[27]</td><td></td><td></td></tr><tr><td>Polycyclic aromatic hydrocarbons</td><td></td><td><i>E. coli</i></td><td>[28]</td></tr><tr><td></td><td></td><td>Benzene</td><td></td></tr><tr><td><i>Alcaligenes eutrophus</i></td><td>[29]</td><td></td><td></td></tr><tr><td>Heavy metals</td><td></td><td><i>E. coli</i></td><td>[30]</td></tr><tr><td></td><td></td><td>Various toxins</td><td></td></tr><tr><td><i>Pseudomonas putida</i></td><td>[31]</td><td></td><td></td></tr><tr><td>Microbial volatile organics</td><td></td><td>Aequorin</td><td></td></tr><tr><td></td><td></td><td><i>E. coli</i></td><td>[32]</td></tr><tr><td><i>Pseudomonas fluorescens</i></td><td>[33]</td><td>Calcium</td><td></td></tr><tr><td>Naphthalene/salicylate</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>B Cells</td><td>[34]</td></tr><tr><td><i>E. coli</i></td><td>[35]</td><td>Pathogenic Bacteria</td><td></td></tr><tr><td>DNA damaging agents</td><td></td><td></td><td></td></tr></table>
3bfe1830247c3df06a770cf2e5023bdc986530adf2c2f83e019f94686b9441cb.png
simple
<table><tr><td></td><td></td><td>Patient age</td><td></td><td>Total</td></tr><tr><td></td><td></td><td>Younger than 60 years</td><td>Older than 60 years</td><td></td></tr><tr><td></td><td>Low risk</td><td>12</td><td>41</td><td>53</td></tr><tr><td>Goasguen score</td><td>Intermediate risk</td><td>9</td><td>48</td><td>57</td></tr><tr><td>Total</td><td></td><td>21</td><td>89</td><td>110</td></tr></table>
002c7215e95cd4bfebffb13dc0db32ab229a6674f4f1add84518ae52b75ac0da.png
complex
<table><tr><td rowspan="3" colspan="2">Beneficiary-related features</td><td colspan="2">Men (<i>n</i> = 198)</td><td colspan="2">Women (<i>n</i> = 117)</td><td colspan="2">Total (<i>n</i> = 315)</td></tr><tr><td>Number</td><td>(%)</td><td>Number</td><td>(%)</td><td>Number</td><td>(%)</td></tr><tr><td colspan="8"><i>Aspects of life</i></td></tr><tr><td> </td><td>Working, attending school, or performing housework</td><td>159</td><td>(82.4%)</td><td>92</td><td>(81.4%)</td><td>251</td><td>(82.0%)</td></tr><tr><td> </td><td>Home care</td><td>28</td><td>(14.5%)</td><td>18</td><td>(15.9%)</td><td>46</td><td>(14.6%)</td></tr><tr><td> </td><td>Hospitalization or admission</td><td>6</td><td>(3.1%)</td><td>3</td><td>(2.7%)</td><td>9</td><td>(2.9%)</td></tr><tr><td> </td><td>Not known</td><td>5</td><td>&#8212;</td><td>4</td><td>&#8212;</td><td>9</td><td>&#8212;</td></tr><tr><td colspan="8"><i>Visit status</i></td></tr><tr><td> </td><td>Primarily inpatient</td><td>9</td><td>(4.7%)</td><td>1</td><td>(1.0%)</td><td>10</td><td>(3.4%)</td></tr><tr><td> </td><td>Half inpatient/half outpatient</td><td>12</td><td>(6.3%)</td><td>8</td><td>(7.6%)</td><td>20</td><td>(6.8%)</td></tr><tr><td> </td><td>Primarily outpatient</td><td>170</td><td>(89.0%)</td><td>96</td><td>(91.4%)</td><td>266</td><td>(89.9%)</td></tr><tr><td> </td><td>Other or not known</td><td>7</td><td>&#8212;</td><td>12</td><td>&#8212;</td><td>19</td><td>&#8212;</td></tr><tr><td colspan="8"><i>Physical-disability certification and grade</i></td></tr><tr><td> </td><td>Not certified</td><td>148</td><td>(75.1%)</td><td>92</td><td>(78.6%)</td><td>240</td><td>(76.4%)</td></tr><tr><td> </td><td>Grade 1</td><td>42</td><td>(21.3%)</td><td>17</td><td>(14.5%)</td><td>59</td><td>(18.8%)</td></tr><tr><td> </td><td>Grade 2&#8211;5</td><td>7</td><td>(3.6%)</td><td>8</td><td>(6.8%)</td><td>15</td><td>(4.8%)</td></tr><tr><td> </td><td>Not known</td><td>1</td><td>&#8212;</td><td>0</td><td>&#8212;</td><td>1</td><td>&#8212;</td></tr><tr><td colspan="8"><i>Care-requirement certification status</i></td></tr><tr><td> </td><td>Needing care or support</td><td>8</td><td>(4.1%)</td><td>7</td><td>(6.5%)</td><td>15</td><td>(5.0%)</td></tr><tr><td> </td><td>No need for care or support</td><td>185</td><td>(95.9%)</td><td>100</td><td>(93.5%)</td><td>285</td><td>(95.0%)</td></tr><tr><td> </td><td>Not known</td><td>5</td><td>&#8212;</td><td>10</td><td>&#8212;</td><td>15</td><td>&#8212;</td></tr><tr><td colspan="8"><i>Self-rated clinical course as compared with previous year</i></td></tr><tr><td> </td><td>Worse</td><td>52</td><td>(28.3%)</td><td>29</td><td>(27.4%)</td><td>81</td><td>(27.9%)</td></tr><tr><td> </td><td>Unchanged</td><td>109</td><td>(59.2%)</td><td>69</td><td>(65.1%)</td><td>178</td><td>(61.4%)</td></tr><tr><td> </td><td>Improved or cured</td><td>23</td><td>(12.5%)</td><td>8</td><td>(7.5%)</td><td>31</td><td>(10.7%)</td></tr><tr><td> </td><td>Other or not known</td><td>14</td><td>&#8212;</td><td>11</td><td>&#8212;</td><td>25</td><td>&#8212;</td></tr></table>
74a4c103684a52d28f05548ab24a844e3973f3a788643a54c43b029b9791e6b5.png
complex
<table><tr><td colspan="6">Cohorts</td></tr><tr><td>Parameter</td><td>All</td><td>LRC</td><td>BHS</td><td>ERA</td><td>LSADT</td></tr><tr><td><i>N</i></td><td>1156</td><td>620</td><td>271</td><td>185</td><td>80</td></tr><tr><td>Females %</td><td>44</td><td>33</td><td>66</td><td>33</td><td>70</td></tr><tr><td colspan="6">Age (years)</td></tr><tr><td> Baseline</td><td>38 &#177; 15</td><td>30 &#177; 1</td><td>31 &#177; 5</td><td>58 &#177; 10</td><td>75 &#177; 2</td></tr><tr><td> Follow-up</td><td>50 &#177; 14</td><td>43 &#177; 1</td><td>43 &#177; 4</td><td>68 &#177; 10</td><td>86 &#177; 2</td></tr><tr><td> Follow-up duration</td><td>12.1 &#177; 1.7</td><td>13.0 &#177; 0.8</td><td>12.4 &#177; 1.8</td><td>9.5 &#177; 0.5</td><td>10.8 &#177; 0.0</td></tr><tr><td colspan="6">LTL (kb)</td></tr><tr><td> Baseline</td><td>7.06 &#177; 0.81</td><td>7.34 &#177; 0.67</td><td>7.22 &#177; 0.73</td><td>6.45 &#177; 0.56</td><td>5.85 &#177; 0.60</td></tr><tr><td> Follow-up</td><td>6.73 &#177; 0.77</td><td>7.00 &#177; 0.63</td><td>6.83 &#177; 0.72</td><td>6.23 &#177; 0.54</td><td>5.51 &#177; 0.64</td></tr><tr><td> LTL attrition (bp/year)</td><td>27.3 &#177; 16.8</td><td>25.7 &#177; 14.8</td><td>32.2 &#177; 17.8</td><td>23.6 &#177; 15.6</td><td>31.2 &#177; 24</td></tr><tr><td colspan="6">BMI (Kg/m<sup>2</sup>)</td></tr><tr><td> Baseline</td><td>25.7 &#177; 4.8</td><td>24.8 &#177; 3.7</td><td>27.0 &#177; 6.7</td><td>26.5 &#177; 4.2</td><td>26.5 &#177; 4.1</td></tr><tr><td> Follow-up</td><td>27.6 &#177; 5.4</td><td>27.2 &#177; 4.6</td><td>29.8 &#177; 7.3</td><td>26.8 &#177; 4.3</td><td>24.9 &#177; 3.7</td></tr><tr><td> Difference</td><td>1.88 &#177; 3.14</td><td>2.36 &#177; 2.62</td><td>2.76 &#177; 3.73</td><td>0.33 &#177; 1.66</td><td>&#8722;1.60 &#177; 3.62</td></tr><tr><td colspan="6">Smoking (%)</td></tr><tr><td> Baseline</td><td>31</td><td>37</td><td>31</td><td>15</td><td>23</td></tr><tr><td> Follow-up</td><td>23</td><td>28</td><td>22</td><td>10</td><td>11</td></tr></table>
5f7da7dac69f43e9a12b0b1606e93e766068b1923716939c1ff067f53caeafa6.png
complex
<table><tr><td>Section</td><td>Global rating questions used</td><td>MID improvement</td><td>Specificity</td><td>Sensitivity</td><td>MID deterioration</td><td>Specificity</td><td>Sensitivity</td></tr><tr><td rowspan="3">Activity</td><td rowspan="3">Global health, Impairment, Walking</td><td>6</td><td>0.25&#8211;0.65</td><td>0.10&#8211;0.67</td><td>10</td><td>0.36&#8211;0.72</td><td>0.39&#8211;0.70</td></tr><tr><td><i>7</i></td><td>0.29&#8211;0.86</td><td>0.12&#8211;0.75</td><td><i>11</i></td><td>0.44&#8211;0.78</td><td>0.33&#8211;0.78</td></tr><tr><td>8</td><td>0.28&#8211;0.86</td><td>0.13&#8211;0.75</td><td>25</td><td>0.42&#8211;0.72</td><td>*</td></tr><tr><td rowspan="3">Participation</td><td rowspan="3">Global health, Impairment, Participation</td><td>16</td><td>0.47&#8211;0.90</td><td>0.50</td><td>15</td><td>0.44&#8211;0.9</td><td>0.22&#8211;0.78</td></tr><tr><td><i>17</i></td><td>0.45&#8211;0.88</td><td>0.67</td><td><i>17</i></td><td>0.43&#8211;0.91</td><td>0.40&#8211;0.80</td></tr><tr><td>20</td><td>0.45&#8211;0.89</td><td>0.50</td><td>22</td><td>*</td><td>*</td></tr><tr><td rowspan="3">Balance</td><td rowspan="3">Balance</td><td>1</td><td>0.46, 0.69</td><td>0.13, 0.15</td><td>2</td><td>0.42, 0.69</td><td>0.42, 0.42</td></tr><tr><td><i>2</i></td><td>0.48, 0.68</td><td>0.10, 0.21</td><td><i>3</i></td><td>0.49, 0.72</td><td>0.5, 0.67</td></tr><tr><td>3</td><td>0.49&#8211;0.71</td><td>0.13, 0.25</td><td>4</td><td>*</td><td>*</td></tr><tr><td rowspan="3">Total score</td><td rowspan="3">Global health, Participation Impairment</td><td>16</td><td>0.44&#8211;0.97</td><td>0.11&#8211;0.66</td><td>16</td><td>0.26&#8211;0.65</td><td>0.17&#8211;0.68</td></tr><tr><td><i>20</i></td><td>0.47&#8211;0.95</td><td>0.14&#8211;0.80</td><td><i>18</i></td><td>0.29&#8211;0.65</td><td>0.21&#8211;0.67</td></tr><tr><td>25</td><td>0.47&#8211;0.95</td><td>0.20&#8211;0.80</td><td>22</td><td>0.29&#8211;0.64</td><td>0.25&#8211;0.75</td></tr></table>
1ea172d0fab457681f47cab33336a49799a87555ff86fa92749b3eef53f8e439.png
complex
<table><tr><td>MiMix [21]</td><td>Minimum Information required for reporting a Molecular Interaction experiment</td></tr><tr><td colspan="2">It relies on PSI-MI [22] controlled vocabularies for terms, and its purpose is providing a checklist of the information to be supplied when describing experimental molecular interaction data. It is a module developed within the framework of the MIAPE guidelines.</td></tr><tr><td>MIAPE [23]</td><td>Minimum Information About a Proteomics Experiment</td></tr><tr><td colspan="2">It provides guidance modules for reporting the use of proteomics techniques such as gel electrophoresis and mass spectrometry, and has been developed and proposed to encourage collection and integration of these kinds of data.</td></tr><tr><td>MIAME [24]</td><td>Minimum Information About a Microarray Experiment</td></tr><tr><td colspan="2">It is used to submit fully compliant datasets, to enable the interpretation of the experimental results unambiguously and, potentially, to reproduce the study.</td></tr><tr><td>MIRIAM Registry [25]</td><td>Minimum Information Required in the Annotation of Models</td></tr><tr><td colspan="2">Created for defining the meta-information needed to ensure the re-usability of computational models of biological processes. It aims to maintain, unambiguously and perennially, the identifiers regarding the biomedical domain. The registry retrieves the identifiers in the form of URIs, and provides the http://www.Identifiers.org resolver online service, for their generation.</td></tr></table>
6333d1e1eecf3701e58f57284667a9bf39c11784732b2e6395efac0703dc7187.png
complex
<table><tr><td>Clinical Outcome Measure</td><td colspan="2">Natural course mean pp/y (95% CI) P-value</td><td colspan="2">Treatment course mean pp/y (95% CI) P-value</td><td colspan="2">Difference* mean pp/y (95% CI) P- value</td></tr><tr><td>MRC sumscore <i>Total study population (N = 69, M = 558)</i></td><td> </td><td> </td><td>1.4 (0.8 to 2.1)</td><td>&lt;0.001</td><td> </td><td> </td></tr><tr><td>MRC sumscore<i>Patients with pre-ERT + ERT follow-up (N = 49, M = 523)</i></td><td>&#8722;1.2 (&#8722;2.1 to &#8722;0.4)</td><td>0.006</td><td>2.1 (1.2 to 3.0)</td><td>&lt;0.001</td><td>3.3 (1.9 to 4.7)</td><td>&lt;0.001</td></tr><tr><td>HHD sumscore <i>Total study population (N = 64, M = 503)</i></td><td> </td><td> </td><td>4.0 (2.5 to 5.6)</td><td>&lt;0.001</td><td> </td><td> </td></tr><tr><td>HHD sumscore <i>Patients with pre-ERT + ERT follow-up (N = 42, M = 435)</i></td><td>&#8722;2.8 (&#8722;4.2 to &#8722;1.3)</td><td>&lt;0.001</td><td>5.1 (3.0 to 7.3)</td><td>&lt;0.001</td><td>7.9 (5.0 to 10.7)</td><td>&lt;0.001</td></tr><tr><td>QMFT score <i>Total study population (N = 69, M = 553)</i></td><td> </td><td> </td><td>0.7 (&#8722;0.2 to 1.7)</td><td>0.14</td><td> </td><td> </td></tr><tr><td>FVC in upright position <i>Total study population (N = 62, M = 475)</i></td><td> </td><td> </td><td>0.1 (&#8722;1.0 to 1.1)</td><td>0.92</td><td> </td><td> </td></tr><tr><td>FVC in upright position <i>Patients with pre-ERT + ERT follow-up (N = 46, M = 480)</i></td><td>&#8722;2.0 (&#8722;3.1 to &#8722;0.8)</td><td>0.001</td><td>&#8722;0.2 (&#8722;1.6 to 1.2)</td><td>0.76</td><td>1.8 (&#8722;0.2 to 3.7)</td><td>0.08</td></tr><tr><td>FVC in supine position <i>Total study population (N = 54, M = 411)</i></td><td> </td><td> </td><td>&#8722;1.1 (&#8722;2.1 to &#8722;0.1)</td><td>0.03</td><td> </td><td> </td></tr><tr><td>FVC in supine position <i>Patients with pre-ERT + ERT follow-up (N = 42, M = 436)</i></td><td>&#8722;1.8 (&#8722;2.9 to &#8722;0.7)</td><td>0.002</td><td>&#8722;1.0 (&#8722;2.3 to 0.3)</td><td>0.12</td><td>0.8 (&#8722;0.9 to 2.4)</td><td>0.38</td></tr></table>
1c93bfbd3e90f436d66ea8887c3dd03efe9fbaa0275da6f3d2f9333dbc759c12.png
complex
<table><tr><td rowspan="2">Variable, <i>n</i> (%)</td><td colspan="2">Fatal outcomes</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariable analysis</td></tr><tr><td>Yes (<i>n</i> = 69)</td><td>No (<i>n</i> = 117)</td><td>OR</td><td>95 % CI</td><td><i>P</i>-value</td><td>OR</td><td>95 % CI</td><td><i>P-</i>value</td></tr><tr><td>Demographics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Male gender</td><td>34(49.3)</td><td>49(41.9)</td><td>1.3</td><td>0.7&#8211;2.4</td><td>0.361</td><td></td><td></td><td></td></tr><tr><td> Mean age, years (range)</td><td>27.1(20.4&#8211;33.8)</td><td>26.9(21.6&#8211;32.3)</td><td></td><td></td><td>0.489</td><td></td><td></td><td></td></tr><tr><td> Newborns (0&#8211;28 days)</td><td>16(23.2)</td><td>10(8.5)</td><td>3.2</td><td>1.4&#8211;7.5</td><td>0.008</td><td>4.5</td><td>2.4&#8211;37.8</td><td>0.025</td></tr><tr><td>P remature babies</td><td>9(13.0)</td><td>5(4.3)</td><td>3.4</td><td>1.1&#8211;9.9</td><td>0.042</td><td></td><td></td><td></td></tr><tr><td> Children (1 month&#8211;17 years)</td><td>17(24.6)</td><td>54(46.1)</td><td>2.6</td><td>1.4&#8211;5.0</td><td>0.005</td><td></td><td></td><td></td></tr><tr><td> Adults (up to 17 years)</td><td>36(52.2)</td><td>53(45.3)</td><td>1.3</td><td>0.7&#8211;2.4</td><td>0.448</td><td></td><td></td><td></td></tr><tr><td>Comorbidity</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Sickle cell disease</td><td>6(8.7)</td><td>11(0.5)</td><td>0.5</td><td>0.3&#8211;2.5</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Malnutrition</td><td>4(5.8)</td><td>13(11.1)</td><td>0.5</td><td>0.5&#8211;1.5</td><td>0.296</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td> AIDS</td><td>3(4.3)</td><td>7(5.9)</td><td>0.7</td><td>0.2&#8211;2.6</td><td>0.747</td></tr><tr><td>Diagnostic at admission </td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Gastroenteritis</td><td>6(8.7)</td><td>19(16.2)</td><td>0.5</td><td>0.2&#8211;1.3</td><td>0.184</td><td></td><td></td><td></td></tr><tr><td> Respiratory disease</td><td>18(26.1)</td><td>17(14.5)</td><td>2.1</td><td>0.9&#8211;4.3</td><td>0.079</td><td></td><td></td><td></td></tr><tr><td> Meningitis</td><td>11(15.9)</td><td>4(3.4)</td><td>5.3</td><td>1.7&#8211;16.6</td><td>0.004</td><td>2.3</td><td>1.5&#8211;4.9</td><td>&lt;0.0001</td></tr><tr><td> Tuberculosis</td><td>2(2.8)</td><td>4(3.4)</td><td>0.8</td><td>0&#8211;4.1</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Cancer</td><td>12(20.3)</td><td>4(3.4)</td><td>5.9</td><td>1.9&#8211;18.3</td><td>0.002</td><td>2.7</td><td>1.6&#8211;6.6</td><td>0.001</td></tr><tr><td> Neurologic disorder</td><td>8(11.5)</td><td>24(20.5)</td><td>0.5</td><td>0.2&#8211;1.2</td><td>0.159</td><td></td><td></td><td></td></tr><tr><td>Invasive procedure</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Surgical intervention</td><td>15(21.7)</td><td>21(17.9)</td><td>1.3</td><td>0.6&#8211;2.6</td><td>0.567</td><td></td><td></td><td></td></tr><tr><td> Parenteral nutrition</td><td>15(21.7)</td><td>15(12.8)</td><td>1.9</td><td>0.9&#8211;4.1</td><td>0.148</td><td></td><td></td><td></td></tr><tr><td> Mechanical ventilation</td><td>28(40.5)</td><td>17(14.5)</td><td>3.9</td><td>1.9&#8211;7.9</td><td>0.0002</td><td>6.1</td><td>3.1&#8211;124.6</td><td>0.040</td></tr><tr><td> Central venous catheter</td><td>53(76.8)</td><td>66(56.4)</td><td>2.6</td><td>1.3&#8211;4.9</td><td>0.007</td><td></td><td></td><td></td></tr><tr><td> Urinary catheter</td><td>14(20.3)</td><td>36(30.8)</td><td>0.6</td><td>0.3&#8211;1.1</td><td>0.128</td><td></td><td></td><td></td></tr><tr><td> ESBL Production</td><td>52(75.4)</td><td>58(49.6)</td><td>3.1</td><td>1.6&#8211;5.9</td><td>&lt;0.0001</td><td>5.3</td><td>3.1&#8211;19.9</td><td>0.008</td></tr><tr><td>Type of infection</td><td></td><td></td><td></td><td></td><td></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td> Bloodstream infection</td><td>31(44.9)</td><td>38(32.5)</td><td>1.7</td><td>0.9&#8211;3.1</td><td>0.116</td></tr><tr><td> Urinary tract infection</td><td>18(26.1)</td><td>49(41.9)</td><td>0.5</td><td>0.2&#8211;0.9</td><td>0.039</td><td></td><td></td><td></td></tr><tr><td> Meningitidis</td><td>7(10.1)</td><td>2(1.7)</td><td>6.5</td><td>1.5&#8211;25.7</td><td>0.014</td><td></td><td></td><td></td></tr><tr><td> Surgical site infection</td><td>9(13.0)</td><td>15(12.8)</td><td>1.0</td><td>0.4&#8211;2.4</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Respiratory infection</td><td>4(6.8)</td><td>8(7.7)</td><td>0.8</td><td>0.2&#8211;2.7</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Inadequate antibiotherapy prescription</td><td>49(71.0)</td><td>62(52.9)</td><td>2.3</td><td>1.2&#8211;4.3</td><td>0.013</td><td></td><td></td><td></td></tr><tr><td> Mean time to infection, days, (95 % CI)</td><td>5.9(4.3&#8211;7.5)</td><td>7.3(5.4&#8211;9.3)</td><td></td><td></td><td>0.838</td><td></td><td></td><td></td></tr></table>
79633e7655bcc79ba9c7bfb6cf91ce6c00a914adfd9601e4bfe29e59bf542b0e.png
simple
<table><tr><td>Collection day</td><td>Total no. of females</td><td>No. of parous females</td><td>Daily parity rate</td></tr><tr><td>1</td><td>98</td><td>67</td><td>0.55</td></tr><tr><td>2</td><td>128</td><td>86</td><td>0.67</td></tr><tr><td>3</td><td>90</td><td>66</td><td>0.69</td></tr><tr><td>4</td><td>31</td><td>25</td><td>0.70</td></tr><tr><td>5</td><td>9</td><td>6</td><td>0.70</td></tr><tr><td>6</td><td>42</td><td>37</td><td>0.72</td></tr><tr><td>7</td><td>28</td><td>18</td><td>0.71</td></tr><tr><td>8</td><td>18</td><td>17</td><td>0.72</td></tr><tr><td>9</td><td>52</td><td>43</td><td>0.73</td></tr><tr><td>10</td><td>58</td><td>43</td><td>0.73</td></tr><tr><td>11</td><td>22</td><td>18</td><td>0.74</td></tr><tr><td>12</td><td>11</td><td>6</td><td>0.73</td></tr><tr><td>13</td><td>13</td><td>8</td><td>0.73</td></tr><tr><td>14</td><td>47</td><td>31</td><td>0.72</td></tr><tr><td>15</td><td>13</td><td>9</td><td>0.72</td></tr><tr><td>16</td><td>16</td><td>10</td><td>0.72</td></tr><tr><td>17</td><td>5</td><td>4</td><td>0.72</td></tr><tr><td>18</td><td>31</td><td>21</td><td>0.72</td></tr><tr><td>19</td><td>47</td><td>32</td><td>0.72</td></tr><tr><td>20</td><td>39</td><td>27</td><td>0.71</td></tr><tr><td>21</td><td>27</td><td>23</td><td>0.72</td></tr><tr><td>22</td><td>50</td><td>38</td><td>0.72</td></tr><tr><td>Totals</td><td>875</td><td>635</td><td>na</td></tr></table>
8f28c70c9929895b46b191726c1e4a41b51f25a5c0c89e70def51df720207044.png
simple
<table><tr><td> </td><td>Reduced transversal palatal diameter N (%)</td><td>Skeletal class II</td><td>Cross-byte</td><td>Atipic swallowing</td></tr><tr><td> </td><td> </td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td>Atopic SDB subjects</td><td>39/60 (65%)</td><td>24/60 (40%)</td><td>21/60 (35%)</td><td>54/60 ( 90%)</td></tr><tr><td>Non atopic SDB subjects</td><td>44/50 (88%)</td><td>24/50 (48%)</td><td>15/50 (30%)</td><td>47/50 (94%)</td></tr><tr><td>p</td><td>P&lt;0.05 (*)</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr></table>
e163599abfa8301348861294047e66b7d81503133ecf3eb5b8f83ad60812b3d4.png
complex
<table><tr><td>Axis</td><td> </td><td>Conditions</td><td>Mean</td><td>SD</td><td>SEM (95% CI)</td><td>ICC (95% CI)</td><td><i>P </i>value</td></tr><tr><td rowspan="3"><i>X</i></td><td rowspan="3">Anterior (+)/Posterior (&#8722;)</td><td>BL</td><td>0.9</td><td>1.3</td><td>0.07 (0.04 to 0.52)</td><td>0.994 (0.975 to 0.998)</td><td rowspan="3">0.01<sup>a</sup></td></tr><tr><td>ST</td><td>0.09</td><td>0.9</td><td>0.23 (0.04 to 0.86)</td><td>0.816 (0.259 to 0.954)</td></tr><tr><td>SR</td><td>2.3</td><td>2.2</td><td>0.05 (0.01 to 0.28)</td><td>0.999 (0.997 to 0.100)</td></tr><tr><td rowspan="3"><i>Y</i></td><td rowspan="3">Superior (+)/Inferior (&#8722;)</td><td>BL</td><td>0.7</td><td>1.7</td><td>0.02 (0.01 to 0.18)</td><td>0.100 (0.998 to 0.100)</td><td rowspan="3">0.048<sup>a</sup></td></tr><tr><td>ST</td><td>0.6</td><td>1.7</td><td>0.02 (0.01 to 0.07)</td><td>0.100 (0.999 to 0.100)</td></tr><tr><td>SR</td><td>&#8722;1.9</td><td>5.0</td><td>0.04 (0.01 to 0.31)</td><td>0.100 (0.999 to 0.100)</td></tr><tr><td rowspan="3"><i>Z</i></td><td rowspan="3">Lateral (&#8722;)/Medial (+)</td><td>BL</td><td>&#8722;2.5</td><td>1.9</td><td>0.04 (0.01 to 0.16)</td><td>0.100 (0.999 to 0.100)</td><td rowspan="3">0.001<sup>a</sup></td></tr><tr><td>ST</td><td>&#8722;2.6</td><td>2.1</td><td>0.02 (0.01 to 0.08)</td><td>0.100 (0.100 to 0.100)</td></tr><tr><td>SR</td><td>&#8722;5.4</td><td>1.2</td><td>0.03 (0.01 to 0.15)</td><td>0.999 (0.996 to 0.100)</td></tr></table>
7a19dbfdc33223e85fe5c39e04c39b34bc92478b618730c61faa43a007edadb0.png
simple
<table><tr><td>Days</td><td>Activities</td><td>Detail</td></tr><tr><td>Day 1</td><td>Orientation</td><td>Briefing on pharmacy operation and services</td></tr><tr><td></td><td></td><td>Discussion about the objective of the session</td></tr><tr><td></td><td></td><td>Daily work schedule, including learning clinical skills and responding to symptoms</td></tr><tr><td>Day 2</td><td>Observation</td><td>Pharmacy layout</td></tr><tr><td></td><td></td><td>Arrangement of drugs in pharmacy (outlet and store)</td></tr><tr><td></td><td></td><td>Types of medicines available</td></tr><tr><td></td><td></td><td>Requirements for medication storage</td></tr><tr><td>Day 3</td><td>Store management</td><td>Storage of drugs according to their volume of use</td></tr><tr><td></td><td></td><td>First-in/first-out method</td></tr><tr><td>Day 4 and day 5</td><td>Pharmaceutical care for the community</td><td>Management of chronic and long-term health problems though pharmacy</td></tr><tr><td></td><td></td><td>Responding to symptoms in community pharmacy</td></tr><tr><td></td><td></td><td>Dealing with special health issues</td></tr><tr><td></td><td></td><td>Proper information about family planning methods</td></tr><tr><td></td><td></td><td>Health screening</td></tr><tr><td>Day 6</td><td>Counselling skills</td><td>Basic counselling skills</td></tr><tr><td></td><td></td><td>Counselling for stigmatized patients</td></tr><tr><td></td><td></td><td>Use of pharmacological and non-pharmacological approaches during counselling</td></tr><tr><td>Day 7</td><td>Practical skills</td><td>Use of medical devices</td></tr><tr><td></td><td></td><td>Applying methods of physical examination</td></tr><tr><td>Day 8</td><td>Business plan</td><td>Drug selection criteria and drug procurement activities</td></tr><tr><td></td><td></td><td>Inventory management</td></tr><tr><td></td><td></td><td>Break-even point analysis</td></tr><tr><td></td><td></td><td>Legal procedure for establishing a community pharmacy</td></tr><tr><td>Day 9</td><td>Waste management</td><td>Handling of damaged and expired drugs</td></tr><tr><td></td><td></td><td>Disposal of wastage</td></tr><tr><td>Day 10</td><td>Medicine information source</td><td>Use of available information sources in pharmacy</td></tr><tr><td></td><td></td><td>Development of informational material by the pharmacy such as leaflets, booklets, and other materials for educational purposes</td></tr><tr><td>Day 11</td><td>ADR reporting and pharmacovigilance</td><td>Determination of ADR by various assessment scales</td></tr><tr><td></td><td></td><td>Reporting of ADR to regional pharmacovigilance center</td></tr><tr><td>Day 12</td><td>Future prospects</td><td>Potential for community pharmacy-managed services in the Nepalese context</td></tr></table>
b9546ecead494fb685801906fbb8790c7c87486b0daadcdea1883b68d39cc6ef.png
simple
<table><tr><td>Variable</td><td>Diabetes Patients (n=218)</td><td>Non-Diabetes (n=734)</td><td><i>P </i>value</td></tr><tr><td>Operative time (min) (mean&#177;SD)</td><td>434&#177;81</td><td>422&#177;76</td><td>0.014</td></tr><tr><td>Aortic cross clamp time (min) (mean&#177;SD)</td><td>82&#177;25</td><td>83&#177;30</td><td>0.351</td></tr><tr><td>No. of coronary grafts (%)</td><td></td><td></td><td>0.143</td></tr><tr><td>One</td><td>3.7</td><td>4.1</td><td></td></tr><tr><td>Two</td><td>16.5</td><td>19.6</td><td></td></tr><tr><td>Three</td><td>79.8</td><td>75.5</td><td></td></tr><tr><td>&#8805;Four </td><td>0</td><td>0.8</td><td></td></tr></table>
4b152bf915e9f3ce24957fe46e48c9f1e7f2f888ac25e1f42a4aeefc88572271.png
simple
<table><tr><td>Predictor Variables</td><td>B</td><td>&#946;</td><td>sr<sup>2</sup></td><td>t</td><td>p</td></tr><tr><td>Age</td><td>.02</td><td>.01</td><td>.00</td><td>.36</td><td>.72</td></tr><tr><td>Income</td><td>-.36</td><td>-.05</td><td>-.11</td><td>-2.06</td><td>.04*</td></tr><tr><td>Education</td><td>-.26</td><td>-.02</td><td>-.03</td><td>-.85</td><td>.39</td></tr><tr><td>History of Depression</td><td>-.02</td><td>-.01</td><td>-.00</td><td>-.23</td><td>.82</td></tr><tr><td>History of Abuse</td><td>.26</td><td>.06</td><td>.00</td><td>2.22</td><td>.03*</td></tr><tr><td>History of Miscarriage/Abortion</td><td>-.46</td><td>-.03</td><td>-.05</td><td>-1.03</td><td>.34</td></tr><tr><td>Antenatal Anxiety</td><td>2.15</td><td>.32</td><td>.06</td><td>9.46</td><td>.00***</td></tr><tr><td>Major Life Events</td><td>.97</td><td>.07</td><td>.00</td><td>2.55</td><td>.01*</td></tr><tr><td>Negative Cognitive Style</td><td>.04</td><td>.11</td><td>.00</td><td>2.68</td><td>.00**</td></tr><tr><td>Self-Esteem</td><td>-.43</td><td>-.34</td><td>-.33</td><td>-6.46</td><td>.00***</td></tr><tr><td>Social Support</td><td>-1.86</td><td>-.18</td><td>-.19</td><td>-3.71</td><td>.00***</td></tr><tr><td>R = .88</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>R<sup>2 </sup>= .78***</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Adjusted R<sup>2 </sup>= .77</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Standard Error = 4.30</td><td></td><td></td><td></td><td></td><td></td></tr></table>
26117248d390866809ac020322082e5812565699752fa8fbc79711ea74c687e7.png
complex
<table><tr><td rowspan="2">Security Level</td><td colspan="3">NISTP192-SHA256</td><td colspan="3">NISTP224-SHA256</td><td colspan="3">NISTP224-SHA224</td><td colspan="3">NISTP384-SHA256</td><td colspan="3">NISTP384-SHA384</td></tr><tr><td>CB</td><td>Xn</td><td>i7</td><td>CB</td><td>Xn</td><td>i7</td><td>CB</td><td>Xn</td><td>i7</td><td>CB</td><td>Xn</td><td>i7</td><td>CB</td><td>Xn</td><td>i7</td></tr><tr><td>Sign w/o Certificate <sup>a</sup></td><td>1.39</td><td>0.19</td><td>0.06</td><td>1.77</td><td>0.26</td><td>0.12</td><td>1.76</td><td>0.26</td><td>0.16</td><td>6.32</td><td>0.85</td><td>0.36</td><td>6.21</td><td>0.85</td><td>0.39</td></tr><tr><td>Sign with Certificate <sup>a</sup></td><td>1.44</td><td>0.20</td><td>0.07</td><td>1.83</td><td>0.27</td><td>0.08</td><td>1.81</td><td>0.27</td><td>0.09</td><td>6.39</td><td>0.86</td><td>0.42</td><td>6.31</td><td>0.86</td><td>0.38</td></tr><tr><td>Encrypt w/o Certificate <sup>b</sup></td><td>6.57</td><td>0.92</td><td>0.29</td><td>8.58</td><td>1.28</td><td>0.42</td><td>8.65</td><td>1.27</td><td>0.40</td><td>42.88</td><td>5.25</td><td>1.79</td><td>42.82</td><td>5.29</td><td>1.79</td></tr><tr><td>Encrypt with Certificate <sup>b</sup></td><td>6.58</td><td>0.93</td><td>0.30</td><td>8.62</td><td>1.29</td><td>0.40</td><td>8.68</td><td>1.28</td><td>1.18</td><td>42.93</td><td>5.29</td><td>1.78</td><td>42.87</td><td>5.30</td><td>1.92</td></tr><tr><td>Sign &amp; Encrypt w/o Certificate <sup>c</sup></td><td>8.01</td><td>1.13</td><td>0.38</td><td>10.42</td><td>1.54</td><td>0.51</td><td>10.47</td><td>1.54</td><td>0.60</td><td>49.35</td><td>6.12</td><td>2.10</td><td>49.21</td><td>6.12</td><td>2.21</td></tr><tr><td>Sign &amp; Encrypt with Certificate <sup>c</sup></td><td>8.06</td><td>1.14</td><td>0.39</td><td>10.55</td><td>1.56</td><td>0.78</td><td>10.54</td><td>1.55</td><td>0.53</td><td>49.43</td><td>6.17</td><td>2.11</td><td>49.29</td><td>6.14</td><td>2.12</td></tr></table>
6791823e29a0dc470e6fbc409eb8f9bb7ea2acf0e95889b49337cfdb12846b4e.png
simple
<table><tr><td>Region</td><td>Ergot limit in cereal grains for humans (ppm)</td><td>Ergot limit in animal feed (ppm)</td><td>Other comments</td></tr><tr><td>Australia and New Zealand</td><td>0.05</td><td>N/A</td><td>0&#8211;0.1% (T)</td></tr><tr><td>Canada</td><td>0&#8211;0.05</td><td>0.10&#8211;0.33</td><td>Varies with grade of wheat</td></tr><tr><td>European Union</td><td>0.05</td><td>0.10</td><td>&#8211;</td></tr><tr><td>Switzerland</td><td>0.02</td><td>N/A</td><td>0.05 limit on cereals destined for milling</td></tr><tr><td>Japan</td><td>0.04</td><td>N/A</td><td>&#8211;</td></tr><tr><td>United Kingdom</td><td>Zero tolerance</td><td>0.001</td><td>&#8211;</td></tr><tr><td>United States</td><td>0.3 (W, R)</td><td>0.3 (W, R)</td><td>0.1% (B, O, T)</td></tr></table>
6d280178e17bdf362004338414e86006ac986f6fc2bbb8caf45426ab50f588c1.png
complex
<table><tr><td></td><td colspan="2">First story (Aladdin&#8217;s Lamp)</td><td colspan="2">Second story (The Three Little Pigs)</td><td colspan="2">Third story (Adopting a Star)</td></tr><tr><td></td><td>Moral</td><td>No moral</td><td>Moral</td><td>No moral</td><td>Moral</td><td>No moral</td></tr><tr><td>TB</td><td>37</td><td>13</td><td>24</td><td>26</td><td>32</td><td>18</td></tr><tr><td>PC-NoIA</td><td>16</td><td>34</td><td>31</td><td>19</td><td>21</td><td>29</td></tr><tr><td>PC-IA</td><td>20</td><td>30</td><td>8</td><td>42</td><td>11</td><td>39</td></tr><tr><td></td><td colspan="2">&#967;<sup>2</sup> = 19.51</td><td colspan="2">&#967;<sup>2</sup> = 22.82</td><td colspan="2">&#967;<sup>2</sup> = 18.04</td></tr><tr><td></td><td colspan="2"><i>p</i> &lt; 0.001</td><td colspan="2"><i>p</i> &lt; 0.001</td><td colspan="2"><i>p</i> &lt; 0.001</td></tr></table>
56fd31730c8292e20cec2e590e8dbcd5a986377361f6ade8c48cdb392e7cf73a.png
simple
<table><tr><td>Participant Patients</td><td>Age</td><td>Gender</td><td>Lesion location</td><td>Hemi-paretic side</td><td>Etio-logy</td><td>Time since lesion (days)</td><td>ARAT (max = 57)</td><td>Max. grip force (kg) affected\non-affected</td><td>% max. grip force (%)</td><td>Moberg Pick-Up Test (s) affected\non-affected</td><td>Mono-filaments (g) affected\non-affected</td></tr><tr><td>1</td><td>76</td><td>F</td><td>Right precentral gyrus and right lenticular nucleus</td><td>left</td><td>H</td><td>36</td><td>57</td><td>12\16</td><td>75</td><td>16\12</td><td>0.4\0.4</td></tr><tr><td>2</td><td>49</td><td>M</td><td>Left parieto-occipital cortex, intra-ventricular and corpus callosum</td><td>right</td><td>H</td><td>120</td><td>57</td><td>42\39</td><td>100</td><td>25\13</td><td>0.4\0.07</td></tr><tr><td>3</td><td>25</td><td>M</td><td>Right temporo-parietal cortex</td><td>left</td><td>H</td><td>330</td><td>32</td><td>15/44</td><td>34</td><td>60\13</td><td>0.07\0.07</td></tr><tr><td>4</td><td>68</td><td>F</td><td>Left fronto-parietal cortex</td><td>right</td><td>I</td><td>19</td><td>57</td><td>11/15</td><td>73</td><td>19\14</td><td>0.07\0.4</td></tr><tr><td>5</td><td>46</td><td>M</td><td>Right sylvian and subdural hematoma</td><td>left</td><td>I</td><td>165</td><td>51</td><td>12/26</td><td>46</td><td>50\30</td><td>0.4\0.4</td></tr><tr><td>6</td><td>68</td><td>M</td><td>Left sylvian</td><td>right</td><td>I</td><td>315</td><td>40</td><td>18/37</td><td>49</td><td>60\22</td><td>0.07\0.4</td></tr><tr><td>7</td><td>40</td><td>M</td><td>Left thalamus</td><td>right</td><td>H</td><td>75</td><td>40</td><td>6/43</td><td>14</td><td>51\21</td><td>0.07\0.4</td></tr><tr><td>8</td><td>64</td><td>M</td><td>Left pons</td><td>right</td><td>I</td><td>40</td><td>57</td><td>38/30</td><td>100</td><td>32\24</td><td>0.4\0.4</td></tr><tr><td>9</td><td>50</td><td>F</td><td>Left precentral cortex and left semi-oval center</td><td>right</td><td>I</td><td>210</td><td>56</td><td>19/24</td><td>79</td><td>13\12</td><td>0.4\0.4</td></tr><tr><td>10</td><td>65</td><td>M</td><td>Left pons</td><td>right</td><td>I</td><td>180</td><td>57</td><td>17/39</td><td>43</td><td>26\17</td><td>0.4\0.4</td></tr><tr><td>Patients</td><td>55.1 (&#177;15.7)</td><td>3 F/7M</td><td></td><td></td><td></td><td>149 (&#177;112)</td><td>50.4 (&#177;9.4)</td><td>31.3 (&#177;10.7)</td><td>61.3 (&#177;28.5)</td><td>35.2 (&#177;18.3)</td><td>0.33 (&#177;0.14)</td></tr><tr><td>Mean (&#177;SD)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>\19.0 (&#177;11.7)</td><td></td><td>\17.8 (&#177;6.2)</td><td>\0.27 (&#177;0.18)</td></tr><tr><td>Controls Mean (&#177;SD)</td><td>52.9 (&#177;17.4)</td><td>4 F/6 M</td><td></td><td></td><td></td><td></td><td></td><td>35.1 (&#177;11.4)</td><td></td><td>14.3 (&#177;1.9)</td><td>0.14 (&#177;0.14)</td></tr></table>
a74a45f80685abb0c2f735aeb5de895a0d0d982483200046a37ecb3635259f77.png
simple
<table><tr><td>Treatment (<i>n</i> = 5)</td><td>Dose (mg/kg)</td><td>Onset of sleep (min)</td><td>Duration of sleep (min)</td></tr><tr><td>Control</td><td>&#8211;</td><td>32.80 &#177; 7.03</td><td>128.20 &#177; 19.79</td></tr><tr><td><i>Hibiscus tiliaceus</i> leaves</td><td>500</td><td>16.40 &#177; 1.03*</td><td>133.40 &#177; 13.87*</td></tr><tr><td><i>Hibiscus tiliaceus</i> barks</td><td>500</td><td>13.80 &#177; 2.08*</td><td>101.40 &#177; 12.54*</td></tr></table>
05846dc6ef7c824e0b1da9fdd582778d2f6b51f8eea809f45feddd064a1be18b.png
simple
<table><tr><td>Category</td><td>Survey question</td></tr><tr><td>Awareness items</td><td>Do you know what colorectal cancer is?</td></tr><tr><td></td><td>Do you know what a colon polyp is?</td></tr><tr><td></td><td>Do you know what a cancer screening test is?</td></tr><tr><td></td><td>Do you know the different types of screening tests available for colorectal cancer?</td></tr><tr><td></td><td>Do you know what the following tests are:</td></tr><tr><td></td><td>Fecal Occult Blood Test (FOBT)/ Stool Blood Test?</td></tr><tr><td></td><td>Colonoscopy?</td></tr><tr><td></td><td>Sigmoidoscopy?</td></tr><tr><td></td><td>Do you know where you can obtain screening tests for colorectal cancer?</td></tr><tr><td>Knowledge items</td><td>Do you think a diet low in fat and high in fiber helps decrease the risk for developing colorectal cancer?</td></tr><tr><td></td><td>Do you think physical activity decreases the risk of developing colorectal cancer?</td></tr><tr><td></td><td>Do you think the risks for developing colorectal cancer increases after the age of 50?</td></tr><tr><td></td><td>Do you think most patients survive colorectal cancer if it is found early and removed?</td></tr><tr><td></td><td>Do you think you ONLY need colorectal cancer screening if you are having any symptoms?</td></tr><tr><td>Behavioral intention to obtain colorectal cancer screening</td><td>Do you plan on talking to your doctor about cancer of the colon and rectum in the future?</td></tr><tr><td></td><td>Do you plan on getting screened for cancer of the colon and rectum in the future?</td></tr><tr><td>Behavioral intentions to promote colorectal cancer education</td><td>How likely are you to talk about colorectal cancer with your:</td></tr><tr><td></td><td>Parents</td></tr><tr><td></td><td>Grandparents</td></tr><tr><td></td><td>Relatives (aunts, uncles, cousins)</td></tr><tr><td></td><td>Peers (friends, colleagues, etc.)</td></tr><tr><td></td><td>Community members</td></tr><tr><td></td><td>Individuals at risk (50+ years of age, family history, etc.)</td></tr></table>
5c028737ae62090f2a17f2d58755f6b291a85990b615f505358fc61c24e1865a.png
simple
<table><tr><td>Characteristics</td><td>Preoperative with plasmapheresis group (PPG) <i>N</i> (33)</td><td>Preoperative without plasmapheresis group (NPPG) <i>N</i> (53)</td><td><i>P</i> value</td></tr><tr><td>Male, <i>n</i> (%)</td><td>8 (24.2)</td><td>17 (32.1)</td><td>0.475</td></tr><tr><td>Age (years), (mean &#177; SD)</td><td>44.2 &#177; 11.6</td><td>44.0 &#177; 15.3</td><td>0.933</td></tr><tr><td>Underlying disease (DM or HT or dyslipidemia)</td><td>17 (51.5)</td><td>30 (56.6)</td><td>0.663</td></tr><tr><td>Osserman classification</td><td> </td><td> </td><td>0.611</td></tr><tr><td> I</td><td>2 (6.1)</td><td>5 (9.4)</td><td>0.703</td></tr><tr><td> IIA</td><td>6 (18.2)</td><td>14 (26.4)</td><td>0.440</td></tr><tr><td> IIB</td><td>21 (63.6)</td><td>31 (58.5)</td><td>0.658</td></tr><tr><td> III</td><td>4 (12.1)</td><td>3 (5.7)</td><td>0.421</td></tr><tr><td>History of myasthenic crisis at any time </td><td>16 (48.5)</td><td>12 (22.6)</td><td>0.018</td></tr><tr><td>History of myasthenic crisis within one month before surgery</td><td>7 (21.2)</td><td>1 (1.9)</td><td>0.005</td></tr><tr><td>History of plasmapheresis within one month before surgery</td><td>11 (33.3)</td><td>5 (9.4)</td><td>0.009</td></tr><tr><td>Ocular involvement</td><td>15 (45.5)</td><td>25 (47.2)</td><td>1.000</td></tr><tr><td>Neck muscle motor power (mean &#177; SD)</td><td>4.5 &#177; 0.7 </td><td>4.8 &#177; 0.4</td><td>0.025</td></tr><tr><td>Upper extremities motor power (mean &#177; SD)</td><td>4.4 &#177; 0.7</td><td>4.7 &#177; 0.5</td><td>0.009</td></tr><tr><td>lower extremities motor power (mean &#177; SD)</td><td>4.3 &#177; 0.8</td><td>4.7 &#177; 0.5</td><td>0.004</td></tr><tr><td>Respiratory involvement</td><td>6 (18.2)</td><td>1 (1.9)</td><td>0.012</td></tr><tr><td>Bulbar involvement</td><td>13 (39.4)</td><td>6 (11.3)</td><td>0.003</td></tr><tr><td>Mestinon use </td><td>33 (100)</td><td>47 (88.7)</td><td>0.078</td></tr><tr><td>Dose of mestinon (mg/day) (mean &#177; SD)</td><td>238.2 &#177; 132.0</td><td>204.9 &#177; 88.1</td><td>0.179</td></tr><tr><td>Prednisolone use </td><td>30 (91.0)</td><td>48 (91.0)</td><td>1.000</td></tr><tr><td> Dose of prednisolone (mg/day) (mean &#177; SD)</td><td>36.0 &#177; 19.8</td><td>29.3 &#177; 14.9</td><td>0.094</td></tr><tr><td>Azathioprine use</td><td>16 (48.5)</td><td>21 (39.6)</td><td>0.503</td></tr><tr><td>Dose of Azathioprine (mg/day) (mean &#177; SD)</td><td>65.6 &#177; 22.1</td><td>73.8 &#177; 28.0</td><td>0.342</td></tr><tr><td>FVC (mean &#177; SD)</td><td>1503.3 &#177; 304.7</td><td>2552.9 &#177; 221.5</td><td>0.019</td></tr><tr><td>Probability of receiving treatment (propensity score)*</td><td>0.53 &#177; 0.32</td><td>0.26 &#177; 0.15</td><td>&lt;0.001</td></tr></table>
2e855884c02f7b136c123c1357f3831a0236e5779b18ee69f372953256ee888a.png
simple
<table><tr><td>Gene symbol</td><td>Gene name &amp; function</td><td>Fold change</td><td>p-value</td></tr><tr><td><i>ompC</i></td><td>Outer membrane protein C porin - permeability</td><td>0.97</td><td>NS</td></tr><tr><td><i>ompF</i></td><td>Outer membrane protein F porin - permeability</td><td>0.14</td><td>&lt; .001</td></tr><tr><td><i>micF</i></td><td>Anti-sense RNA - negative regulation of OmpF translation</td><td>2.27</td><td>&lt; .001</td></tr><tr><td><i>marA</i></td><td>Multiple antibiotic resistance (mar) protein A - transcription activator of mar regulon</td><td>2.01</td><td>&lt; .001</td></tr><tr><td><i>marB</i></td><td>mar protein B</td><td>2.22</td><td>&lt; .001</td></tr><tr><td><i>marR</i></td><td>mar operon repressor</td><td>1.80</td><td>.003</td></tr><tr><td><i>soxS</i></td><td>Regulatory protein SoxS - superoxide response regulon</td><td>0.37</td><td>&lt; .001</td></tr><tr><td><i>acrA</i></td><td>Acriflavine resistance protein A - antibiotic and bile resistance</td><td>1.89</td><td>&lt; .001</td></tr><tr><td><i>acrB</i></td><td>Acriflavine resistance protein B - antibiotic and bile resistance</td><td>2.21</td><td>&lt; .001</td></tr><tr><td><i>acrR</i></td><td>Acriflavine resistance protein R &#8211;transcription regulator</td><td>2.83</td><td>&lt; .001</td></tr><tr><td><i>yceE</i></td><td>Multidrug resistance protein - antibiotic and bile resistance</td><td>2.04</td><td>.002</td></tr><tr><td><i>yojI</i></td><td>Drug (microcin) efflux pump</td><td>2.49</td><td>&lt; .001</td></tr></table>
3571852c90b19db343af8d11c36cc961cec92ad928013c5d41a263b5eca154cd.png
complex
<table><tr><td rowspan="2">Multiplex PCR assay</td><td colspan="2">Biochemical test</td><td rowspan="2">TOTAL</td></tr><tr><td>Nitrate positive</td><td>Nitrate negative</td></tr><tr><td>Nitrate positive</td><td>133</td><td>5</td><td>138</td></tr><tr><td>Nitrate negative</td><td>5</td><td>205</td><td>210</td></tr><tr><td>Total</td><td>138</td><td>210</td><td>348</td></tr></table>
2812304e0a27c2af49fa8e5afd27500510ba1d7dd4bc67569ed329de8f5c2d1e.png
simple
<table><tr><td>Characteristic variables</td><td>Number</td><td>Weighting %</td><td>(95% CI)</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>958</td><td>48.4</td><td>(47.4&#8211;49.4)</td></tr><tr><td>Female</td><td>6355</td><td>51.6</td><td>(50.6&#8211;52.6)</td></tr><tr><td>Age (years)</td><td> </td><td> </td><td> </td></tr><tr><td>&lt;17</td><td>3649</td><td>29.3</td><td>(25.7&#8211;33.2)</td></tr><tr><td>17&#8211;18</td><td>6695</td><td>55.4</td><td>(51.0&#8211;59.6)</td></tr><tr><td>&gt;18</td><td>1969</td><td>15.3</td><td>(12.4&#8211;18.7)</td></tr><tr><td>Hometown</td><td> </td><td> </td><td> </td></tr><tr><td>Shanghai</td><td>6290</td><td>49.8</td><td>(46.8&#8211;52.9)</td></tr><tr><td>Sanming</td><td>3027</td><td>24.3</td><td>(21.4&#8211;27.5)</td></tr><tr><td>Beihai</td><td>2996</td><td>25.9</td><td>(23.2&#8211;28.7)</td></tr><tr><td>School type</td><td> </td><td> </td><td> </td></tr><tr><td>Model senior high school</td><td>2371</td><td>19.0</td><td>(16.0&#8211;22.5)</td></tr><tr><td>Common senior high school</td><td>8053</td><td>64.0</td><td>(60.5&#8211;67.4)</td></tr><tr><td>Vocational high school</td><td>1889</td><td>16.9</td><td>(14.6&#8211;19.6)</td></tr><tr><td>Average monthly income per person (CNY*)</td><td> </td><td> </td><td> </td></tr><tr><td>&lt;1500</td><td>3982</td><td>32.7</td><td>(31.3&#8211;34.1)</td></tr><tr><td>1500-2500</td><td>5281</td><td>42.5</td><td>(41.4&#8211;43.6)</td></tr><tr><td>&gt;2500</td><td>3050</td><td>24.8</td><td>(23.7&#8211;25.9)</td></tr><tr><td>Experience of premarital sex</td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>552</td><td>4.5</td><td>(4.1&#8211;5.5)</td></tr><tr><td>No</td><td>11761</td><td>95.4</td><td>(95.0&#8211;95.9)</td></tr><tr><td>Condom use in sexual debut</td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>132</td><td>25.0</td><td>(21.2&#8211;29.1)</td></tr><tr><td>No</td><td>420</td><td>75.0</td><td>(70.9&#8211;78.8)</td></tr><tr><td>Consistent condom use</td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>65</td><td>11.6</td><td>(9.1&#8211;14.7)</td></tr><tr><td>No</td><td>487</td><td>89.5</td><td>(85.0&#8211;90.3)</td></tr></table>
73904dcd932e4b543a6eda4aeb5746ec7c87354b490f32793b839a9956e7ef26.png
simple
<table><tr><td>Group</td><td>N</td><td>WBC (&#215;10<sup>9</sup>/L)</td><td>PMN (%)</td></tr><tr><td>control</td><td>14</td><td>6.38&#177;1.23</td><td>24.22&#177;5.11</td></tr><tr><td>model</td><td>11</td><td>13.52&#177;2.86**</td><td>56.24&#177;6.37**</td></tr><tr><td>DSQ</td><td>13</td><td>8.60&#177;2.86<sup>##</sup></td><td>37.25&#177;4.22<sup>##</sup></td></tr><tr><td>LVX</td><td>13</td><td>9.29&#177;1.80<sup>##</sup></td><td>35.44&#177;6.42<sup>##</sup></td></tr></table>
9f709bae94faec4c191eb841fcaa6e171c580f32d5d26d1abba916ea7c49dd9c.png
simple
<table><tr><td>Categories</td><td>Search terms</td></tr><tr><td>Participants</td><td>(child OR children OR adolescent* OR pediatric*OR paediatric*) AND</td></tr><tr><td>Disease</td><td>(sleeplessness OR &#8216;chronic insomnia&#8217; ORinsomniac OR insomnia OR insomni* OR &#8216;sleep initiation andmaintenance disorders&#8217;) AND</td></tr><tr><td>Interventions</td><td>(CBT OR &#8216;cognitive behavioural therapy&#8217; OR&#8216;cognitive behavioral therapy&#8217; OR &#8216;cognitive behaviortherapy&#8217; OR &#8216;cognitive behavioural therapies&#8217; OR &#8216;cognitivebehavioral therapies&#8217; OR &#8216;cognitive behavior therapies&#8217; OR&#8216;cognitive analytic therapy&#8217; OR &#8216;sleep hygiene&#8217; OR &#8216;stimuluscontrol&#8217; OR &#8216;relaxation&#8217; OR &#8216;relaxation therapy&#8217; OR&#8216;relaxation techniques&#8217; OR &#8216;behavior modification&#8217; OR&#8216;behavior therapy&#8217; OR &#8216;cognitive therapy&#8217; OR &#8216;imagery&#8217; OR&#8216;biofeedback&#8217; OR &#8216;counseling&#8217; OR &#8216;family therapy&#8217; OR&#8216;psychoanalytic therapy&#8217; OR &#8216;psychotherapy&#8217;)</td></tr></table>
604ccf8036cbd5165cfede2bb7e1c1a6601278fe236bed64d0f5c9a1e0e9a6f6.png
simple
<table><tr><td>Categories of neuropsychiatric services</td><td>Total cost AED (%)</td><td>Average cost per visit paid by patient AED (US $) (%)</td><td>Average cost per visit paid by insurance AED (US $) (%)</td><td>Average cost per visit AED (US $) (%)</td></tr><tr><td>Psychiatry</td><td>12,337,182 (44 %)</td><td>151 ($41) (34 %)</td><td>300 ($82) (66 %)</td><td>451 ($123) (100 %)</td></tr><tr><td>Neurology</td><td>7908,970 (28 %)</td><td>75 ($20) (14 %)</td><td>458 ($132) (86 %)</td><td>533 ($145) (100 %)</td></tr><tr><td>Psychotherapy</td><td>7810,044 (28 %)</td><td>335 ($91) (67 %)</td><td>165 ($45) (33 %)</td><td>500 ($136) (100 %)</td></tr><tr><td>Total</td><td>28,056,196 (100 %)</td><td>181 ($49) (37 %)</td><td>304 ($83) (63 %)</td><td>485 ($132) (100 %)</td></tr></table>
d6cd9c10871b9e59d843241badb094f82a1c0533118ee67f6ab07b5b2f5262f4.png
complex
<table><tr><td>Primer name</td><td>Sequence</td><td>Used to generate data for figure:</td></tr><tr><td>IAP-F [8]</td><td>5<sup>&#8242;</sup>-ATAATCTGCGCATGAGCCAAGG-3<sup>&#8242;</sup></td><td>1</td></tr><tr><td>IAP-R [8]</td><td>5<sup>&#8242;</sup>-AGGAAGAACACCACAGACCAGA-3<sup>&#8242;</sup></td><td>1</td></tr><tr><td>Tagln F</td><td>5<sup>&#8242;</sup>-GCATAAGAGGGAGTTCACAGACA-3<sup>&#8242;</sup></td><td>3, 4, S11</td></tr><tr><td>Tagln R</td><td>5<sup>&#8242;</sup>-GCCTTCCCTTTCTAACTGATGATC-3<sup>&#8242;</sup></td><td>3, 4, S11</td></tr><tr><td>Myh11 F</td><td>5<sup>&#8242;</sup>-CAGTTGGACACTATGTCAGGGAAA-3<sup>&#8242;</sup></td><td>3, 4, S11</td></tr><tr><td>Myh11 R</td><td>5<sup>&#8242;</sup>-ATGGAGACAAATGCTAATCAGCC-3<sup>&#8242;</sup></td><td>3, 4, S11</td></tr><tr><td>1F [33]</td><td>5<sup>&#8242;</sup>-GCGCCAGTCATCCGATAGACT-3<sup>&#8242;</sup></td><td>S2</td></tr><tr><td>K1R [33]</td><td>5<sup>&#8242;</sup>-AAGGCTTTATTGGGAACACG-3<sup>&#8242;</sup></td><td>S2</td></tr><tr><td>MoA 5 bbone</td><td>5<sup>&#8242;</sup>-GCGCCAGTCCTCCGATTGAC-3<sup>&#8242;</sup></td><td>S13</td></tr><tr><td>XMRV adapt MoA</td><td>5<sup>&#8242;</sup> -TGAGAACGCTGGACTTTCCATC</td><td rowspan="2">S13</td></tr><tr><td>5bbone R</td><td>GATGTTAGGCCATTAAGGAG-3<sup>&#8242;</sup></td></tr><tr><td>XMRV adapt MoA</td><td>5<sup>&#8242;</sup>-AACTCCTCCGGCCGGAACAGC</td><td rowspan="2">S13</td></tr><tr><td>env F</td><td>ATGAGACAGCGGACCCGGACT-3<sup>&#8242;</sup></td></tr><tr><td>MoA adapt XMRV</td><td>5<sup>&#8242;</sup>-GAAACTGAATAAAATCTTTTAT</td><td rowspan="2">S13</td></tr><tr><td>env R</td><td>GGCTCGTACTCTATAGGCTT-3<sup>&#8242;</sup></td></tr><tr><td>MoA adapt XMRV</td><td>5<sup>&#8242;</sup>-GAAGAAGTGGAATCACGTGA</td><td rowspan="2">S13</td></tr><tr><td>3bbone F</td><td>ATAGATAAAATAAAAGATTTTA-3<sup>&#8242;</sup></td></tr><tr><td rowspan="2">MoA 3bbone R</td><td>5<sup>&#8242;</sup>-TGCAACTGCAAG</td><td rowspan="2">S13</td></tr><tr><td>AGGGTTTATTGG-3<sup>&#8242;</sup></td></tr><tr><td>XMRV 5bbone F</td><td>5<sup>&#8242;</sup>-GCGCCAGTCCTCCGATTGAC-3<sup>&#8242;</sup></td><td>S14</td></tr><tr><td>MoA adapt XMRV</td><td>5<sup>&#8242;</sup>-CTCCTTAATGGCCTAACATCG</td><td rowspan="2">S14</td></tr><tr><td>env F</td><td>ATGGAAAGTCCAGCGTTCTCA-3<sup>&#8242;</sup></td></tr><tr><td>MoA adapt XMRV</td><td>5<sup>&#8242;</sup>-GAAACTGAATAAAATCTTTTA</td><td rowspan="2">S14</td></tr><tr><td>env R</td><td>TGGCTCGTACTCTATAGGCTT-3<sup>&#8242;</sup></td></tr><tr><td>XMRV adapt MoA</td><td>5<sup>&#8242;</sup>-TAAAATCTTTTATTTTATCTA</td><td rowspan="2">S14</td></tr><tr><td>env R</td><td>TTCACGTGATTCCACTTCTTC-3<sup>&#8242;</sup></td></tr><tr><td rowspan="2">XMRV 3bbone F</td><td>5<sup>&#8242;</sup>-AAGCCTATAGAGTACGAGCCA</td><td rowspan="2">S14</td></tr><tr><td>TAAAAGATTTTATTCAGTTTC-3<sup>&#8242;</sup></td></tr><tr><td>XMRV 3bbone R</td><td>5<sup>&#8242;</sup>-TTGCAAACAGCAAAAGGCTTT-3<sup>&#8242;</sup></td><td>S14</td></tr><tr><td>XPR1 F [35]</td><td>5<sup>&#8242;</sup>- TAATTCAGAAGAATCAGGAATT-3<sup>&#8242;</sup></td><td>S16</td></tr><tr><td>XPR1 R [35]</td><td>5<sup>&#8242;</sup>-CGAGTGACCTCGTTCTTTG-3<sup>&#8242;</sup></td><td>S16</td></tr></table>
2187c7e700a1bbe1d469980d70a35f2dc24464457022d44e6fae08be35782ead.png
simple
<table><tr><td>Health Unit</td><td>Health Region Peer Group<sup>a</sup></td><td>Land area (km<sup>2</sup>)</td><td>Population density (persons/km<sup>2</sup>)(Census, 2011)</td><td>Populationage 65+ (% of total)(Census, 2011)</td><td>Visible minorities (% of population)(NHS, 2011)</td></tr><tr><td>North Bay Parry Sound District</td><td>Sparsely populated urban-rural mix</td><td>16,801</td><td>7.4</td><td>19%</td><td>1.7%</td></tr><tr><td>Simcoe Muskoka District</td><td>Moderately populated urban centres</td><td>8736</td><td>58</td><td>16%</td><td>4%</td></tr><tr><td>York Region</td><td>Highly populated urban centres</td><td>1762</td><td>586.0</td><td>12%</td><td>43%</td></tr></table>
a8adeb477fd7546ab7ff029405331fac86a3e77ef33e62dfe5865b2c04a19bb3.png
simple
<table><tr><td>Initial pH</td><td>pH range</td><td>&#916;pH</td></tr><tr><td>5.1</td><td>5.1&#8211;3.7</td><td>1.4</td></tr><tr><td>6.0</td><td>6.0 &#8211;3.8</td><td>2.2</td></tr><tr><td>7.0</td><td>7.0 &#8211;3.9</td><td>3.1</td></tr><tr><td>7.9</td><td>7.9&#8211;4.0</td><td>3.9</td></tr></table>
62e4eb13ddadc3ebabb729741ffa836d8283573f94eb5bf21875753a6d363a69.png
complex
<table><tr><td rowspan="2">Performance Parameter</td><td colspan="2">Mean (SD)</td><td rowspan="2">Z statistic</td><td rowspan="2">&#961; &#8211; value</td></tr><tr><td>Group A (<i>n</i> = 6)</td><td>Group B (<i>n</i> = 10)</td></tr><tr><td>P1</td><td>8.2 (0.85)</td><td>9.4 (0.14)</td><td>&#8722;0.617</td><td>0.077*</td></tr><tr><td>P2</td><td>8.1 (1.07)</td><td>9.3 (0.99)</td><td>&#8722;4.934</td><td>0.035*</td></tr><tr><td>P3</td><td>14.0 (5.06)</td><td>7.0 (1.25)</td><td>&#8722;4.904</td><td>0.015*</td></tr><tr><td>P4</td><td>5.8 (2.13)</td><td>4.2 (0.85)</td><td>&#8722;3.047</td><td>0.042*</td></tr><tr><td>P5</td><td>1.0 (0.49)</td><td>0.7 (0.05)</td><td>&#8722;3.297</td><td>0.021*</td></tr><tr><td>P6</td><td>549.6 (35.06)</td><td>436.2 (14.25)</td><td>&#8722;5.751</td><td>0.028*</td></tr></table>
b0c911420c20d34605aaf5c41a9912ff215d0b9b7dbc9e1e2fe24b126e614113.png
complex
<table><tr><td> </td><td colspan="5">KNH (%)</td><td colspan="5">AKUH (%)</td></tr><tr><td>Attitude statements</td><td>SA</td><td>A</td><td>U</td><td>D</td><td>SD</td><td>SA</td><td>A</td><td>U</td><td>D</td><td>SD</td></tr><tr><td>A computer increases costs by increasing the nurses workload</td><td>5.2</td><td>11</td><td>4.5</td><td>35.5</td><td>43.9</td><td>16.3</td><td>Nil</td><td>2.3</td><td>23.3</td><td>55.8</td></tr><tr><td>Costs of health care are likely to increase because of computers</td><td>8.4</td><td>18.8</td><td>4.6</td><td>34.4</td><td>33.8</td><td>18.2</td><td>4.6</td><td>29.6</td><td>34.1</td><td>2.3</td></tr><tr><td>The time spent using a computer is out of proportion to the benefits</td><td>5.9</td><td>9.2</td><td>9.9</td><td>32.2</td><td>42.8</td><td>7.3</td><td>2.4</td><td>36.6</td><td>41.5</td><td>13.6</td></tr><tr><td>Computers represent a violation of patient privacy</td><td>6.7</td><td>17.3</td><td>8</td><td>31.3</td><td>36.7</td><td>17.1</td><td>14.6</td><td>22</td><td>34.2</td><td>12.2</td></tr><tr><td>Only one person at a time can use a computer terminal and, therefore, staff efficiency is inhibited.</td><td>16.2</td><td>27.9</td><td>10.4</td><td>26.6</td><td>18.2</td><td>27.3</td><td>9.1</td><td>15.9</td><td>20.5</td><td>12.2</td></tr><tr><td>Computerization of nursing data offers nurses a remarkable opportunity to improve patient care</td><td>49.7</td><td>35.5</td><td>2.6</td><td>5.2</td><td>6.5</td><td>40.9</td><td>29.6</td><td>22.7</td><td>6.8</td><td>27.3</td></tr><tr><td>Computers contain too much personal data to be used in an area as open as a nursing station</td><td>14.7</td><td>27.6</td><td>5.1</td><td>30.1</td><td>22.4</td><td>11.6</td><td>20.9</td><td>4.7</td><td>44.2</td><td>18.6</td></tr><tr><td>Computers can cause nurses to give less time to quality nursing care</td><td>8.3</td><td>11.5</td><td>6.4</td><td>35.3</td><td>38.5</td><td>14</td><td>14</td><td>4.7</td><td>14</td><td>53.5</td></tr><tr><td>If I had my way, nurses would never have to use computers</td><td>4</td><td>4.6</td><td>4</td><td>15.1</td><td>72.4</td><td>4.7</td><td>4.7</td><td>2.3</td><td>16.3</td><td>72.1</td></tr><tr><td>Computers should only be used in the financial department</td><td>4.6</td><td>0.7</td><td>2.6</td><td>17.7</td><td>73.9</td><td>4.9</td><td>2.4</td><td>2.4</td><td>9.8</td><td>80.5</td></tr><tr><td>Computers make nurses jobs easier</td><td>51.7</td><td>31.1</td><td>6</td><td>7.3</td><td>4</td><td>60.5</td><td>25.6</td><td>7</td><td>4.7</td><td>2.3</td></tr><tr><td>Paperwork for nurses can be reduced greatly by the use of computers</td><td>69.9</td><td>20.9</td><td>5.2</td><td>1.3</td><td>2.6</td><td>56.8</td><td>29.6</td><td>2.3</td><td>9.1</td><td>2.3</td></tr><tr><td>Orientation for new employees takes longer because of computers</td><td>7.1</td><td>8.4</td><td>11.7</td><td>38.3</td><td>34.4</td><td>4.7</td><td>11.6</td><td>9.3</td><td>37.2</td><td>37.2</td></tr><tr><td>Nursing data cannot be manipulated using computers</td><td>13.6</td><td>23.9</td><td>9.7</td><td>27.1</td><td>25.8</td><td>12.2</td><td>26.8</td><td>4.9</td><td>36.6</td><td>19.5</td></tr><tr><td>Computers save steps and allow the nursing staff to become more efficient</td><td>43.5</td><td>35.7</td><td>6.5</td><td>10.4</td><td>3.9</td><td>47.7</td><td>29.6</td><td>2.3</td><td>13.6</td><td>6.8</td></tr><tr><td>The more computers in an institution, the less number of jobs for employees</td><td>21.8</td><td>25</td><td>10.9</td><td>24.4</td><td>18</td><td>29.6</td><td>22.7</td><td>6.8</td><td>20.5</td><td>20.5</td></tr><tr><td>Increased computer use will allow nurses more time to give patient care</td><td>45.3</td><td>26</td><td>9.3</td><td>14</td><td>5.3</td><td>37.8</td><td>29.7</td><td>8.1</td><td>16.2</td><td>8.1</td></tr><tr><td>Because of computers, nurses will face more law suits</td><td>9.5</td><td>15.5</td><td>12.2</td><td>29.1</td><td>33.8</td><td>3</td><td>15.2</td><td>9.1</td><td>36.4</td><td>36.4</td></tr><tr><td>Computers can cause a decrease in communication between hospital departments</td><td>7.3</td><td>11.3</td><td>6.7</td><td>28.7</td><td>46</td><td>16.7</td><td>16.7</td><td>Nil</td><td>30.6</td><td>36.1</td></tr><tr><td>Confidentiality will be sacrificed by patient records being computerized</td><td>14</td><td>17.3</td><td>6</td><td>33.3</td><td>29.3</td><td>32.4</td><td>27</td><td>2.7</td><td>18.9</td><td>18.9</td></tr></table>
d476fefd2ac6212869824f84b70a7df561e5c0d5c4e6e6381baf2de106da2959.png
simple
<table><tr><td>Fungicide concentration (kg ha<sup>&#8722;1</sup>)</td><td>Tebuconazole</td><td>Copper hydroxide</td></tr><tr><td>0.0</td><td>260 &#177; 2.47f (100)</td><td>260 &#177; 1.85f (100)</td></tr><tr><td>1.0</td><td>410 &#177; 0.68d (157)</td><td>420 &#177; 2.68e (161)</td></tr><tr><td>2.5</td><td>750 &#177; 2.81c (288)</td><td>650 &#177; 2.31c (250)</td></tr><tr><td>5.0</td><td>920 &#177; 2.46a (353)</td><td>800 &#177; 0.82a (307)</td></tr><tr><td>7.5</td><td>820 &#177; 2.46b (315)</td><td>740 &#177; 0.97b (284)</td></tr><tr><td>10.0</td><td>380 &#177; 1.48e (146)</td><td>350 &#177; 0.62d (134)</td></tr></table>
ade00a83622c68be5946792b1997baceab3a10de89725eac7e452e9a2eb084c2.png
simple
<table><tr><td>Epitope</td><td>Start position</td><td>Combined score</td></tr><tr><td>FIEYCNHCY</td><td>64</td><td>2.4978</td></tr><tr><td>FRYEFTAPF</td><td>56</td><td>2.0697</td></tr><tr><td>RYEFTAPFI</td><td>57</td><td>1.6395</td></tr><tr><td>ESLLHQASW</td><td>19</td><td>1.2675</td></tr><tr><td>SFVTDLEKY</td><td>44</td><td>1.1582</td></tr></table>
e5ea1d9f9d2c9e1c7c4c63af62e789a36fd7f2537bda15332add29ac57772002.png
complex
<table><tr><td rowspan="2">Cellulase</td><td colspan="2">Percentage of mass/area remove</td><td rowspan="2">Film swelling</td></tr><tr><td>RT</td><td>Topt</td></tr><tr><td>Cel9A</td><td>5</td><td>11</td><td>No</td></tr><tr><td>Cel9A-CBM</td><td>12</td><td>32</td><td>Yes</td></tr><tr><td>Cel5A</td><td>1</td><td>4</td><td>No</td></tr><tr><td>Cel5A-CBM</td><td>16</td><td>35</td><td>Yes</td></tr></table>
3467c3de3883e7116ef7c4430ea71318e61977837a9f97456b4d764494d0ad6d.png
simple
<table><tr><td>SNP reference</td><td>Chromosome</td><td>Genotype association <i>&#967;</i><sup>2 </sup><i>P </i>value</td><td>Permutation test <i>P </i>value</td></tr><tr><td>rs17163819</td><td>2</td><td>2.587 * 10<sup>-150</sup></td><td>0.0042</td></tr><tr><td>rs10894818</td><td>12</td><td>1.751 * 10<sup>-120</sup></td><td>0.0046</td></tr><tr><td>rs582397</td><td>3</td><td>1.089 * 10<sup>-82</sup></td><td>0.0022</td></tr><tr><td>rs7596121</td><td>3</td><td>5.212 * 10<sup>-60</sup></td><td>0.0022</td></tr><tr><td>rs16898558</td><td>6</td><td>1.718 * 10<sup>-52</sup></td><td>0.0046</td></tr><tr><td>rs996877</td><td>13</td><td>1.566 * 10<sup>-44</sup></td><td>0.0036</td></tr><tr><td>rs9387380</td><td>7</td><td>2.315 * 10<sup>-34</sup></td><td>0.011</td></tr><tr><td>rs940153</td><td>9</td><td>1.032 * 10<sup>-33</sup></td><td>0.0040</td></tr><tr><td>rs1456222</td><td>4</td><td>1.544 * 10<sup>-33</sup></td><td>0.0048</td></tr><tr><td>rs1572075</td><td>5</td><td>1.474 * 10<sup>-23</sup></td><td>0.0040</td></tr><tr><td>rs7192563</td><td>17</td><td>2.862 * 10<sup>-18</sup></td><td>0.0030</td></tr><tr><td>rs17765376</td><td>15</td><td>3.277 * 10<sup>-18</sup></td><td>0.0058</td></tr><tr><td>rs9532645</td><td>14</td><td>1.26 * 10<sup>-16</sup></td><td>0.0028</td></tr><tr><td>rs10751815</td><td>11</td><td>1.036 * 10<sup>-15</sup></td><td>0.0014</td></tr><tr><td>rs6975106</td><td>8</td><td>3.207 * 10<sup>-13</sup></td><td>0.0028</td></tr></table>
75e54e349b33a187b737a32c7ea3cfa9ce3bd22dc8db24cdb3128c56524105fd.png
simple
<table><tr><td>OPINIONS ABOUT USE OF MORPHINE</td><td>GP AGREEMENT (%)</td><td>HP AGREEMENT (%)</td><td>% DIFFERENCE GP - HP</td><td>P-Value</td></tr><tr><td>It means that it is serious (GP n = 171; HP n = 399)</td><td>96 (56,1)</td><td>37 (9,3)</td><td>46,8</td><td>0,000*</td></tr><tr><td>There is a risk to develop dependency (GP n = 171; HP n = 405)</td><td>70 (41.0)</td><td>6 (1,5)</td><td>39,5</td><td>0,000*</td></tr><tr><td>There is a risk of delirium or euphoria (GP n = 171; HP n = 405)</td><td>68 (39.8)</td><td>18 (4,4)</td><td>35,4</td><td>0,000*</td></tr><tr><td>It does diminish the surviving period (GP n = 171; HP n = 407)</td><td>61 (35,7)</td><td>13 (3,2)</td><td>32,5</td><td>0,002*</td></tr><tr><td>There is a risk of somnolence or sedation (PG n = 170; PS n = 403)</td><td>74 (43,5)</td><td>123 (30,5)</td><td>13,0</td><td>0,000*</td></tr><tr><td>It can lead to increasing doses (GP n = 170; HP n = 403)</td><td>85 (50,0)</td><td>105 (26,1)</td><td>23,9</td><td>0,000*</td></tr><tr><td>It is a sign of limited life expectancy (GP n = 171 - HP n = 409)</td><td>47 (27,5)</td><td>4 (1,0)</td><td>26,5</td><td>0,000*</td></tr><tr><td>It increases legal risks in relation to other medication (GP n = 171; HP n = 407)</td><td>85 (49,7)</td><td>229 (56,3)</td><td>-6,6</td><td>0,149</td></tr><tr><td>There is a risk of discrimination (PG n = 169; PS n = 397)</td><td>33 (19,5)</td><td>10 (2,5)</td><td>17,0</td><td>0,000*</td></tr></table>
eaf235ca20a721e0d89fa47d98e4dfcd90589e028c1ab2ef6730786245012c1a.png
complex
<table><tr><td></td><td colspan="3">Genotypes</td><td></td></tr><tr><td></td><td>GG</td><td>GA</td><td>AA</td><td>P</td></tr><tr><td>N = 141</td><td>32</td><td>78</td><td>31</td><td></td></tr><tr><td>New coronary lesion (mean)</td><td>0.34 &#177; 0.48</td><td>0.38 &#177; 0.49</td><td>0.26 &#177; 0.45</td><td>0.462</td></tr><tr><td>Subjects with new coronary lesions (%)</td><td>11 (34.3)</td><td>30 (38.4)</td><td>8 (25.8)</td><td>0.265</td></tr><tr><td>New coronary occlusions (mean)</td><td>0.03 &#177; 0.18</td><td>0.08 &#177; 0.27</td><td>0.06 &#177; 0.25</td><td>0.678</td></tr><tr><td>Subjects with new coronary occlusions (%)</td><td>1 (3.1)</td><td>6 (7.7)</td><td>2 (6.5)</td><td>0.209</td></tr><tr><td>Average final MLD (mm)</td><td>1.54 &#177; 0.40</td><td>1.62 &#177; 0.41</td><td>1.59 &#177; 0.39</td><td>0.657</td></tr><tr><td>Change in MLD (mm)</td><td>-0.09 &#177; 0.25</td><td>-0.11 &#177; 0.23</td><td>-0.11 &#177; 0.25</td><td>0.928</td></tr></table>
0ec3d023ebc3ca9c6aee855fde4b68ba23a4382c3b3a74c2cf6c7cd82f28ad58.png
simple
<table><tr><td></td><td>Website (<i>n</i> = 24)</td><td>JawboneTM/UP app (<i>n</i> = 23)</td><td>F2F (group) (<i>n</i> = 19)</td><td>F2F (1-2-1) (<i>n</i> = 22)</td><td>Facebook group (<i>n</i> = 24)</td><td>Food &amp; nutrient report (<i>n</i> = 24)</td><td>GymstickTM (<i>n</i> = 23)</td><td>TEMPlateTM dinner disc (<i>n</i> = 16)</td></tr><tr><td>Provided me with useful information about healthy eating</td><td>4.0 &#177; 0.6</td><td>3.2 &#177; 1.0</td><td>4.1 &#177; 0.6</td><td>4.5 &#177; 0.7</td><td>3.8 &#177; 0.8</td><td>4.4 &#177; 0.9</td><td>NA</td><td>3.9 &#177; 0.9</td></tr><tr><td>Provided me with useful information about exercise</td><td>4.2 &#177; 0.6</td><td>3.9 &#177; 0.9</td><td>4.2 &#177; 0.9</td><td>4.2 &#177; 0.8</td><td>3.7 &#177; 0.8</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Provided me with useful information about stress</td><td>3.7 &#177; 0.7</td><td>3.0 &#177; 0.9</td><td>3.6 &#177; 0.8</td><td>4.0 &#177; 0.9</td><td>3.5 &#177; 0.8</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Helped me to attain my goals</td><td>3.6 &#177; 0.8</td><td>3.8 &#177; 0.9</td><td>3.9 &#177; 1.0</td><td>4.0 &#177; 0.9</td><td>3.7 &#177; 0.9</td><td>4.1 &#177; 1.0</td><td>3.7 &#177; 1.0</td><td>3.3 &#177; 0.9</td></tr><tr><td>Motivated me</td><td>3.5 &#177; 0.9</td><td>4.1 &#177; 0.7</td><td>4.3 &#177; 0.7</td><td>4.0 &#177; 0.8</td><td>3.6 &#177; 0.8</td><td>4.0 &#177; 0.9</td><td>3.5 &#177; 1.0</td><td>3.3 &#177; 1.1</td></tr><tr><td>Made me feel accountable</td><td>3.3 &#177; 0.9</td><td>4.0 &#177; 1.0</td><td>3.8 &#177; 0.9</td><td>4.1 &#177; 0.8</td><td>3.5 &#177; 1.0</td><td>4.2 &#177; 0.9</td><td>3.6 &#177; 1.0</td><td>3.2 &#177; 0.9</td></tr><tr><td>Was easy to use/navigate</td><td>4.3 &#177; 0.6</td><td>4.0 &#177; 0.9</td><td>NA</td><td>NA</td><td>4.2 &#177; 0.8</td><td>NA</td><td>3.8 &#177; 1.0</td><td>3.5 &#177; 1.2</td></tr><tr><td>Content was easy to understand</td><td>4.3 &#177; 0.4</td><td>4.1 &#177; 0.7</td><td>4.4 &#177; 0.6</td><td>4.4 &#177; 0.6</td><td>4.2 &#177; 0.8</td><td>4.1 &#177; 0.9</td><td>NA</td><td>NA</td></tr><tr><td>Was visually appealing</td><td>4.0 &#177; 0.7</td><td>4.0 &#177; 0.9</td><td>NA</td><td>NA</td><td>3.8 &#177; 0.8</td><td>3.9 &#177; 0.9</td><td>NA</td><td>3.4 &#177; 0.9</td></tr><tr><td>Was supportive in answering any queries/questions</td><td>NA</td><td>NA</td><td>4.5 &#177; 0.7</td><td>4.5 &#177; 0.6</td><td>3.7 &#177; 0.8</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Satisfaction</td><td>4.0 &#177; 0.6</td><td>4.2 &#177; 1.1</td><td>4.1 &#177; 0.8</td><td>4.3 &#177; 0.8</td><td>Not asked</td><td>4.2 &#177; 0.8</td><td>4.0 &#177; 0.9</td><td>3.0 &#177; 0.9</td></tr></table>
dcbcf693667eb69890d39fbb8f7398def572c2d099758a8a0ea72b4de145ec2d.png
complex
<table><tr><td></td><td colspan="3">Prevalence %</td></tr><tr><td></td><td>Beijing urban (1)</td><td>Beijing rural (2)<sup>b</sup></td><td>Hong Kong (3)<sup>b</sup></td></tr><tr><td>Male</td><td></td><td></td><td></td></tr><tr><td> 65&#8211;74</td><td>108 (8.88 %)</td><td>4 (1.29 %)<sup>1</sup></td><td>99 (7.36 %)<sup>2</sup></td></tr><tr><td> 75&#8211;84</td><td>202 (18.33 %)</td><td>6 (7.19 %)<sup>1</sup></td><td>90 (15.80 %)<sup>2</sup></td></tr><tr><td> 85+</td><td>22 (19.30 %)</td><td>0 (0 %)</td><td>9 (21.40 %)</td></tr><tr><td>Female</td><td></td><td></td><td></td></tr><tr><td> 65&#8211;74</td><td>342 (14.89 %)</td><td>24 (6.59 %)<sup>1</sup></td><td>223 (17.61 %)<sup>1,2</sup></td></tr><tr><td> 75&#8211;84</td><td>362 (24.69 %)</td><td>16 (12.62 %)<sup>1</sup></td><td>164 (27.12 %)<sup>2</sup></td></tr><tr><td> 85+</td><td>41 (32.80 %)</td><td>1 (33.33 %)</td><td>20 (34.39 %)</td></tr><tr><td>Total</td><td></td><td></td><td></td></tr><tr><td> 65&#8211;74</td><td>450 (12.81 %)</td><td>28 (4.53 %)<sup>1</sup></td><td>322 (12.91 %)<sup>2</sup></td></tr><tr><td> 75&#8211;84</td><td>564 (21.96 %)</td><td>22 (10.05 %)<sup>1</sup></td><td>254 (20.94 %)<sup>2</sup></td></tr><tr><td> 85+</td><td>63 (26.36 %)</td><td>1 (13.84 %)</td><td>29 (26.69 %)</td></tr></table>
15d39a64b562f6f69ff1ccfd8005223d152a7fb17c86e40d917de1e52c4b38cc.png
simple
<table><tr><td>City</td><td>As</td><td>Cr</td><td>Ni</td><td>Cd</td><td>Co</td><td>Reference</td></tr><tr><td>Hezhang, China</td><td>4.9 &#215; 10<sup>&#8722;4</sup></td><td>3.1 &#215; 10<sup>&#8722;6</sup></td><td>2.2 &#215; 10<sup>&#8722;7</sup></td><td>1.8 &#215; 10<sup>&#8722;9</sup></td><td>4.6 &#215; 10<sup>&#8722;8</sup></td><td>This study</td></tr><tr><td>Zhuzhou, China</td><td>1.1 &#215; 10<sup>&#8722;6</sup></td><td>3.2 &#215; 10<sup>&#8722;8</sup></td><td>6.9 &#215; 10<sup>&#8722;9</sup></td><td>8.5 &#215; 10<sup>&#8722;8</sup></td><td>3.2 &#215; 10<sup>&#8722;8</sup></td><td>[58]</td></tr><tr><td>Huludao, China</td><td></td><td></td><td></td><td>2.4 &#215; 10<sup>&#8722;8</sup></td><td></td><td>[7]</td></tr><tr><td>Beijing, China</td><td>2.4 &#215; 10<sup>&#8722;8</sup></td><td>2.0 &#215; 10<sup>&#8722;7</sup></td><td>2.1 &#215; 10<sup>&#8722;9</sup></td><td>9.5 &#215; 10<sup>&#8722;10</sup></td><td>5.6 &#215; 10<sup>&#8722;9</sup></td><td>[31]</td></tr><tr><td>Nanjing, China</td><td></td><td>3.9 &#215; 10<sup>&#8722;8</sup></td><td>7.2 &#215; 10<sup>&#8722;10</sup></td><td>3.1 &#215; 10<sup>&#8722;10</sup></td><td>2.3 &#215; 10<sup>&#8722;9</sup></td><td>[21]</td></tr><tr><td>Shiraz, Iran</td><td></td><td>1.1 &#215; 10<sup>&#8722;8</sup></td><td>8.3 &#215; 10<sup>&#8722;8</sup></td><td></td><td></td><td>[30]</td></tr><tr><td>Luanda, Angola</td><td>7.7 &#215; 10<sup>&#8722;6</sup></td><td>5.7 &#215; 10<sup>&#8722;8</sup></td><td>4.6 &#215; 10<sup>&#8722;10</sup></td><td>3.9 &#215; 10<sup>&#8722;10</sup></td><td>1.5 &#215; 10<sup>&#8722;9</sup></td><td>[32]</td></tr></table>
ae57e843f249b3fb65a6af1e0de2697851c6028120b720583517f165677df162.png
complex
<table><tr><td>Database</td><td></td><td>Search strategy</td></tr><tr><td rowspan="3">Embase</td><td>#1</td><td>&#8216;headache*&#8217;:ti,ab OR &#8216;cephalgia*&#8217;:ti,ab OR &#8216;cephalalgia*&#8217;:ti,ab OR &#8216;cranialgia*&#8217;:ti,ab OR &#8216;head ache*&#8217;:ti,ab OR &#8216;cephalodynia*&#8217;:ti,ab OR &#8216;cephalea*&#8217;:ti,ab OR &#8216;cerebral pain&#8217;:ti,ab OR &#8216;head pain&#8217;:ti,ab OR &#8216;eye pain&#8217;:ti,ab</td></tr><tr><td>#2</td><td>&#8216;neuroimaging&#8217;:ti,ab OR &#8216;brain imaging&#8217;:ti,ab OR &#8216;tomography&#8217;:ti,ab OR &#8216;mri&#8217;:ti,ab OR &#8216;magnetic resonance imaging&#8217;:ti,ab OR &#8216;mr imaging&#8217;:ti,ab OR &#8216;nmr imaging&#8217;:ti,ab</td></tr><tr><td>#3</td><td>#1AND #2</td></tr><tr><td>Restrict to humans</td><td>#4</td><td>#3 AND &#8216;human&#8217;/de</td></tr><tr><td>Filter by type of study</td><td>#5</td><td>#4 AND (&#8216;clinical study&#8217;/de OR &#8216;clinical trial&#8217;/de OR &#8216;cohort analysis&#8217;/de OR &#8216;comparative study&#8217;/de OR &#8216;controlled clinical trial&#8217;/de OR &#8216;controlled study&#8217;/de OR &#8216;family study&#8217;/de OR &#8216;major clinical study&#8217;/de OR &#8216;medical record review&#8217;/de OR &#8216;observational study&#8217;/de OR &#8216;prospective study&#8217;/de OR &#8216;randomized controlled trial&#8217;/de OR &#8216;retrospective study&#8217;/de OR &#8216;systematic review&#8217;/de)</td></tr></table>
804af72f007fe5f2932be15dab0e3922a8d5723d00b6507303f7de425861c769.png
complex
<table><tr><td>Antibiotic name</td><td>MSO(central government</td><td>MCD</td><td>CG1</td><td>CG2</td><td>CPA(Delhi state government)</td></tr><tr><td>Azithromycin cap/tab</td><td>No rate available</td><td>6.31</td><td>No rate available</td><td>9.45</td><td>No rate available</td></tr><tr><td>Ceftriaxone injection</td><td>14.99</td><td>18.28</td><td>16.46</td><td>15.50</td><td>8.50</td></tr><tr><td>Erythromycin Stearate</td><td rowspan="2">1.43</td><td rowspan="2">1.32</td><td rowspan="2">2.04</td><td rowspan="2">1.68</td><td rowspan="2">0.85</td></tr><tr><td>cap/tab</td></tr><tr><td>Gentamicin eye drops</td><td>No rate available</td><td>0.61</td><td>0.81</td><td>1.21</td><td>0.58</td></tr><tr><td>Gentamicin injection</td><td>No rate available</td><td>1.40</td><td>1.53</td><td>2.49</td><td>1.52</td></tr><tr><td>Roxithromycin cap/tab</td><td>1.04</td><td>1.29</td><td>No rate available</td><td>No rate available</td><td>0.74</td></tr></table>